Piperidinylamino-thieno[2,3-d] pyrimidine compounds

专利摘要:

公开号:AU2005287898A1
申请号:U2005287898
申请日:2005-09-23
公开日:2006-03-30
发明作者:Sekar Reddy Alla；Shay Bar-Haim；Oren Becker；Dongli Chen；Srinivasa Rao Cheruku；Dale S. Dhanoa；Alexander Heifetz；Boaz Inbal；Venkitasamy Kesavan；Yael Marantz；Rosa E. Melendez；Silvia Noiman；Sharon Shacham；Anurag Sharadendu
申请人:Epix Delaware Inc；
IPC主号:C07D495-04

专利说明:
WO 2006/034511 PCT/US2005/034862 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS FIELD OF THE INVENTION The invention generally relates to the field of serotonin (5-hydroxytryptamine, or 5 HT) receptor modulators, e.g., antagonists, and more particularly to new piperidinylamino 5 thieno [2,3-d] pyrimidine compounds which are also 5-HT modulators, and use of these compounds, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with serotonin action, such as in treating vascular disorders, e.g., angina, migraine, pulmonary hypertension and systemic hypertension. 10 BACKGROUND OF THE INVENTION The serotonergic neural system of the brain has been shown to influence a variety of physiologic functions which manifest themselves in a variety of disorders such as eating disorders, schizophrenia, neuralgia, and addiction disorders; depression, obsessive compulsive disorders, panic disorders, anxiety, sexual dysfunctions caused by the central 15 nervous system and disturbances in sleep and the absorption of food, alcoholism, pain, memory deficits, unipolar depression, dysthymia, bipolar depression, treatment-resistant depression, depression in the medically ill, panic disorder, obsessive-compulsive disorder, eating disorders, social phobia, premenstrual dysphoric disorder, pulmonary hypertension and systemic hypertension. 20 5-HT receptor modulators e.g., antagonists, partial agonists or agonists, and/or selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, paroxetine, fluvoxamine, sertraline, lorazepam, imipramine, citalopram, and nortriptyline, may be used for the treatment of the above conditions, as well as for vasodilation, smooth muscle contraction, bronchoconstriction, brain disorders such as vascular disorders such as angina and migraine; 25 and neuropathological disorders including Parkinson's disease and Alzheimer's disease. These compounds are also suitable for the modulation of the cardiovascular system and pulmonary disorders including pulmonary hypertension and pulmonary fibrosis. They also -1 - WO 2006/034511 PCT/US2005/034862 intervene in the regulation of the cerebral circulation and thus represent effective agents for controlling migraine. They are also suitable for the prophylaxis and control of the effects of occurrences of cerebral infarct (Apoplexia cerebri) such as stroke or cerebral ischemia. They are also suitable for the control of disorders of the intestinal tract which are characterized by 5 disturbances of the serotoninergic system and also by disturbances of the carbohydrate metabolism. Trazodone controls 5-HT actions, and fluoxetine and fluvoxamine facilitate serotoninergic neurotransmission via potent and selective inhibition of serotonin reuptake into presynaptic neurons. 3-chloroimipramine inhibits both 5-HT and norepinephrine reuptake. 10 Other compounds of current interest for use as antidepressants include zimeldine, bupropion and nomifensine. Type 2 serotonin inhibitors (5-HT 2 ) mediate the action of several drugs used in treating, e.g., schizophrenia, feeding disorders, perception, depression, migraines, hypertension, anxiety, hallucinations, and gastrointestinal dysfunctions. The 5-HT 2 A, B or c 15 receptor subtypes show considerable homology at genetic, structural and functional levels, and all are G-protein coupled receptors (GPCRs.) 5-HT2A receptors have been found in high density in the cerebral cortex and in interneuronal regions, as well as, in lower density, in the hippocampus, striatum, other cerebral regions, platelets, and vascular and uterine smooth muscle. 20 5-HT2B receptors are widely distributed in mammalian peripheral tissue, e.g., heart, skeletal and vascular muscle, adipose tissue, intestine, ovary, uterus, testis, liver, lung, pancreas, trachea, spleen, thymus, thyroid, prostate and salivary gland, as well as in the CNS, e.g., in the cerebral cortex and the whole brain. Serotonin binds to the receptor with an affinity of 2-10 nM (Rothman et al. 2000; Kursar et al. 1994). 5-HT2B receptors are present 25 in many vascular beds and have been localized to both vascular smooth muscle and vascular endothelial cells in humans (Ullmer et al. 1995; Marcos et al. 2004). The receptor was characterized initially in the rat gastric (fundus) smooth muscle cells (SMC) as the receptor responsible mediating serotonin (5-HT)-induced contraction in this tissue (Kursar et al. 1994). -2- WO 2006/034511 PCT/US2005/034862 SUMMARY OF THE INVENTION The present invention relates to the discovery of new compounds which are 5-HT modulators, e.g., antagonists, partial agonists, or agonists, that can be used for treating, 5 preventing or curing 5-HT-related conditions, such as in treating vascular disorders, e.g., angina, migraine, pulmonary hypertension and systemic hypertension. In particular, it has been found that certain piperidinylamino-thieno[2,3-d] pyrimidine compounds are effective 5 HT receptor modulators. In an embodiment, such compounds include those having the formula R5 4)&nR6 R4,'N
R
2 R 10 S N R 3 (1) wherein
R
1 and R 2 may independently be hydrogen; lower alkyl, e.g., straight or branched C 1 ,
C
2 , C 3 , C 4 or C 5 alkyl; C 1
-C
6 cycloalkyl or cycloheteroalkyl; halogens including F, Cl, Br, I, halo-substituted alkyls such as CF 3 , CF 2
CF
3 , CH 2
CF
3 ; COOH; CN; NH 2 ; NO 2 ; OH; 15 substituted or unsubstituted aryl or heteroaryl; R 7 ; COOR 7 ; CONHR 7 ; CON(R 7
)
2 ; OR 7 ;
NHR
7 ; N(R 7
)
2 ; R 7 -alkoxy; and R 7 -haloalkyl; R 7 -haloalkoxy; wherein R 7 is substituted or unsubstituted (C 1
-C
6 ) alkyl or a (C 3
-C
6 ) cycloalkyl or cycloheteroalkyl; or conjugated substituted or unsubstituted alicyclic, e.g., cycloalkyl, or
R
1 and R 2 , taken together with their bonded carbons, form a substituted or 20 unsubstituted C 4
-C
7 cycloalkyl ring (e.g., cyclohexyl) or cycloheteroalkyl ring; wherein a heteroatom in the C 4
-C
7 cycloheteroalkyl ring comprises at least one of 0, N and S, and the substituted C 4
-C
7 cycloalkyl or cycloheteroalkyl ring comprises at least one substitutent selected from hydrogen, halogen, COOH; CN; NH 2 ; NO 2 ; OH; lower alkyl; substituted lower alkyl; substituted or unsubstituted C 1
-C
6 cycloalkyl or cycloheteroalkyl; substituted or -3- WO 2006/034511 PCT/US2005/034862 unsubstituted aryl or heteroaryl; R 7 ; COOR 7 ; CONHR 7 ; CON(R 7
)
2 ; OR 7 ; NHR 7 ; N(R 7
)
2 ; R 7 alkoxy; R 7 -haloalkyl; R 7 -haloalkoxy; and
R
3 may be H; halogen; CN; NH 2 ; lower alkyl; R 7 ; OR 7 ; NHR 7 ; N(R 7
)
2 ; or substituted or unsubstituted aryl or heteroaryl; 5 R 4 may be H, R 7 , or substituted or unsubstituted aryl or heteroaryl; * HN HN R R8 * Q is any one of , , * ,,wherein R may be hydrogen, halogen, or a substituted or unsubstituted lower alkyl, e.g., CN or CF 3 ;
R
5 and R 6 are independently selected from hydrogen, halogen, COOH; CN; NH 2 ;
NO
2 ; OH; lower alkyl; substituted lower alkyl; substituted or unsubstituted aryl or heteroaryl; 10 R 7 ; COOR7; CONHR 7 ; CON(R 7
)
2 ; OR 7 ; NHR 7 ; N(R 7
)
2 ; R 7 -alkoxy; and R 7 -haloalkyl; R 7 haloalkoxy; or
R
5 and R 6 , taken together with their bonded carbons, form a substituted or unsubstituted unsaturated 5- or 6- membered carbocyclic ring or a substituted or unsubstituted saturated 5-, 6-, or 7-membered carbocyclic ring, wherein the carbocyclic ring may be a fused 15 biaryl ring or a heterocarbocyclic ring comprising at least one hetero atom chosen from 0, N, S and P; and the substituted ring comprises at least one hydrogen, halogen, COOH; CN; NH 2 ;
NO
2 ; OH; lower alkyl; substituted lower alkyl; substituted or unsubstituted aryl or heteroaryl;
R
7 ; COOR 7 ; CONHR 7 ; CON(R 7
)
2 ; OR 7 ; NHR 7 ; N(R 7
)
2 ; R 7 -alkoxy; and R 7 -haloalkyl; R 7 haloalkoxy or optionally other radicals; and R 5 and R 6 , taken together with their bonded 20 carbons, is desirably an aromatic ring structure, e.g., phenyl, naphthyl, diphenylmethyl, biaryl; and optionally substitutions on the adjacent carbon atoms may form 5 or 6 membered unsaturated or saturated cyclic rings such as 0 N= N= N==aa S N O5 O and -4- WO 2006/034511 PCT/US2005/034862
R
7 is substituted or unsubstituted (C 1
-C
6 ) alkyl or a (C 3
-C
6 ) cycloalkyl or cycloheteroalkyl; n is 0, 1, 2, 3, 4 or 5, and is straight or is branched. In various desired compounds, n is 2, 3, 4 or 5. Also provided in the invention are any one or more pharmaceutically 5 acceptable salts and/or esters of the formula I compound. In one embodiment, R, may desirably be H, -CH 3 , -CH(CH 3
)
2 , or Cl. In another embodiment, R 2 may desirably be H, Cl, lower alkyl, e.g., straight or branched C 1 , C 2 , C 3 (e.g., iso- or tert-butyl), C 4 or C 5 alkyl, or aryl, e.g., phenyl or fluorophenyl. R 1 and R 2 may also, taken together with the bonded carbons from the thieno, desirably form a cyclohexyl 10 ring. The Q group is preferably an N-substituted alkyl or cycloalkyl. The linking group denoted by () may be substituted or unsubstituted, straight or branched, and may be a single bond, or made up of 1, 2, 3, 4 or 5 carbons or more. In another embodiment, compounds of the invention further include those of the formula n NH NH n(R1) NH 15 S N ( , wherein R 1 may be halo, lower alkyl, cyano, or trihalomethyl; each R 2 may independently be hydrogen, halo, cyano, trihalomethyl, lower alkoxy, carboxylate, an amide, or a sulfonyl group, and n is 1 or 2, provided that when n is 1, R 2 is not hydrogen, and when n 20 is 2, both R 2 groups are not hydrogen. Examples of amides include amido, N-methylamido -5- WO 2006/034511 PCT/US2005/034862 and dimethylamido groups; examples of sulfonyl groups include trifluoromethylsulfonyl, sulfonyl, and methylsulfonyl groups. This embodiment encompasses pharmaceutically acceptable salts of the formula II compounds, including maleate, hydrochloride, and fumarate salts. 5 In another embodiment, compounds of the invention further include those of the formula (RA)n N NH / ~N (III), wherein X is halo; R 3 may be hydrogen, halo, cyano, or trihalomethyl, and n is 1 or 2, 10 provided that when n is 1, R 3 is not hydrogen, and when n is 2, both R 3 groups are not hydrogen. This embodiment encompasses pharmaceutically acceptable salts of the formula II compounds, including maleate, hydrochloride, and fumarate salts. In another embodiment compounds of the invention include those having the formula
R
6 1 Cy
R
6 P N R N-R 4 R2 15 S N R 3 (IV) -6- WO 2006/034511 PCT/US2005/034862 wherein R 1 through R 4 are as defined for Formula I. Cy is preferably phenyl, but may be a substituted or unsubstituted, saturated or unsaturated 4-, 5-, 6- or 7- membered cycloalkyl or aryl ring. A cycloalkyl or aryl ring may include, e.g., mono-, di-, or tri-substituted phenyl, naphthyl, or biphenyl with lower alkyl, e.g., methyl, ethyl, propyl, allyl, n-butyl, n-pentyl, n 5 hexyl; alkoxy or aryloxy, e.g., methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, cyclopropoxy, cyclopentyloxy; halo, e.g., fluoro, chloro, bromo, and iodo; amino, dimethylamino, nitro, cyano, carboxy, carboxy esters, carboxamides, N-alkylcarboxamide, N.N-dialkylcarboxamide, trifluoromethyl, trifluoromethoxy, tetrazolo, sulphonyl, thiomethyl, thioethyl, phenylthio, 2,3-methylenedioxy, and 3,4-methylenedioxy. Substituents on Cy are 10 designated R 5 , which may be hydrogen; halogen, halo-substituted alkyl, lower alkyl, CN, COOH, COOR 7 , OR 7 , CONH 2 , CONHR 7 , CON(R 7
)
2 , halo-substituted or unsubstituted NR 7 , halo-substituted or unsubstituted SOOR 7 , aryl, halo-substituted aryl or heteroaryl, C 1
-C
6 cycloalkyl, or C 3
-C
6 cycloheteroalkyl, wherein n is 0, 1, 2, 3, 4 or 5, and R 7 is a substituted or unsubstituted lower alkyl. The linker group may be branched or unbranched, and p may be 0, 15 1, 2, 3, 4, 5, 6 or more. Where the linker group is branched, p is 1 or higher, and R 6 and R 6 ' are independently H, halogen, CN or R 7 , wherein R 7 is a substituted or unsubstituted, branched or unbranched lower alkyl. Pharmaceutically acceptable salts and/or esters of Formula II compounds are also provided. In various embodiments, R 1 may desirably be H, -CH 3 , -CH(CH 3
)
2 , or Cl. In another 20 embodiment, R 2 may desirably be H, Cl, lower alkyl, e.g., straight or branched C 1 , C 2 , C 3 (e.g., iso- or tert-butyl), C 4 or C 5 alkyl, or aryl, e.g., phenyl or fluorophenyl. R 1 and R2 may also, taken together with the bonded carbons from the thieno, desirably form a cyclohexyl ring. R3 and R 4 are independently H, halogen or R 7 , wherein H is preferred. -7- WO 2006/034511 PCT/US2005/034862 Specific compounds having the formula R Cy ,
R
3 N (R4) NH R2 / S N (V) are included in the invention, wherein
R
1 and R 2 independently are one or more of hydrogen; halogen, halo-substituted alkyl, 5 lower alkyl, C1-C 6 cycloalkyl, C 3
-C
6 cycloheteroalkyl, aryl, halo-substituted aryl or heteroaryl; or R 1 and R 2 , taken together, form a C 5
-C
7 cycloalkyl or cycloheteroalkyl ring; R3 and R3' are independently H, halogen, CN or R 5 ; Cy is a single or conjugated substituted or unsubstituted cycloalkyl, cycloheteroalkyl, aryl or heteroaryl; and 10 R 4 is hydrogen; halogen, halo-substituted alkyl, lower alkyl, CN, COOH, COOR 5 ,
OR
5 , CONH 2 , CONHR 5 , CON(Rs) 2 , halo-substituted or unsubstituted NR 5 , halo-substituted or unsubstituted SOOR 5 , aryl, halo-substituted aryl or heteroaryl, C 1
-C
6 cycloalkyl, or C3-C6 cycloheteroalkyl; wherein R5 is a substituted or unsubstituted lower alkyl; and n is 1, 2, 3, 4 or 5. 15 Pharmaceutically acceptable salts and/or esters of Formula V compounds are also provided. Compounds of the invention are desirably 5-HT receptor antagonists, e.g., 5-HT 2 receptor antagonists including 5-HT2A, B or c receptors, and desirably 5-HT2B receptor antagonists. In another embodiment compounds of the invention may also be 5-HT receptor partial 20 agonists, e.g., 5-HT 2 receptor partial agonists including 5-HT2A, B or c receptors, and desirably 5-HT2B receptor partial agonists. -8- WO 2006/034511 PCT/US2005/034862 In another embodiment compounds of the invention may also be 5-HT receptor agonists, e.g., 5-HT 2 receptor agonists including 5-HT2A, B or c receptors, and desirably 5-HT2B receptor agonists. Another aspect of the invention is a pharmaceutical composition comprising an 5 effective amount of a compound according to Formula I, II, III, IV or V to treat depression in a mammal suffering therefrom, and a pharmaceutically acceptable carrier. Another aspect of the invention is a method for treating depression in a mammal such as a human comprising administering a therapeutically effective amount of a compound according to Formula I, II, III, IV or V. 10 Another aspect of the invention is a composition comprising an effective amount of a compound according to Formula I, II, m, IV or V to treat diseases of the central nervous system in a mammal suffering therefrom, and a pharmaceutically acceptable carrier. Another aspect of the invention is a method for treating diseases of the central nervous system in a mammal such as a human comprising administering a therapeutically effective 15 amount of a compound according to Formula I, II, III, IV or V. Another aspect of the invention is a composition comprising an effective amount of a compound according to Formula I, II, III, IV or V to treat erectile dysfunction in a mammal suffering therefrom, and a pharmaceutically acceptable carrier. Another aspect of the invention is a method for treating erectile dysfunction in a 20 mammal such as a human comprising administering a therapeutically effective amount of a compound according to Formula 1, 11, III, IV or V. Another aspect of the invention is a composition comprising an effective amount of a compound according to Formula I, II, III, IV or V to treat systemic hypertension in a mammal suffering therefrom, and a pharmaceutically acceptable carrier. 25 Another aspect of the invention is a method for treating systemic hypertension in a mammal such as a human comprising administering a therapeutically effective amount of a compound according to Formula I, II, III, IV or V. -9- WO 2006/034511 PCT/US2005/034862 Another aspect of the invention is a composition comprising an effective amount of a compound according to Formula I, II, IH, IV or V to treat pulmonary hypertension in a mammal suffering therefrom, and a pharmaceutically acceptable carrier. Another aspect of the invention is a method for treating pulmonary hypertension in a 5 mammal such as a human comprising administering a therapeutically effective amount of a compound according to Formula I, II, EI, IV or V. Another aspect of the invention is a composition comprising an effective amount of a compound according to Formula I, 11, 11, IV or V to treat conditions associated with vascular disorders, e.g., angina, migraine, pulmonary hypertension and systemic hypertension. 10 Also provided are various compound according to Formula I, I, I1, IV or V and administering those compounds to a subject in need thereof to treat a disease state that is alleviated by treatment with a 5-HT2B antagonist. Disease states that are alleviated by treatment with a 5-HT2B antagonist include, but are not limited to, e.g., pulmonary arterial hypertension, migraine, hypertension, disorders of the gastrointestinal tract, restenosis, 15 asthma, obstructive airway disease, prostatic hyperplasia, erectile dysfunction, priapism, inflammatory pain, neuropathic pain, cancer pain, acute pain or chronic pain; allergic asthma, irritable bowel syndrome, hypertonic lower esophageal sphincter, motility disorders, benign prostatic hyperplasia, depression, anxiety, attention deficit hyperactivity disorder, obesity, sleeping disorder, Alzheimer's disease, Parkinson disease or vascular disorders, e.g., angina, 20 migraine, pulmonary hypertension and systemic hypertension. Processes for preparing the compounds and novel intermediates are also included in the invention. The invention is also drawn to methods of treating associated with serotonergic hypofunction or hyperfunction. As explained above, compounds of the invention can have 25 antagonistic activity at 5-HT2B receptors, which will counteract the negative feedback mechanism induced by the inhibition of serotonin reuptake; this is thereby expected to improve the effect of the serotonin reuptake inhibiting activity of the compounds of the invention. -10- WO 2006/034511 PCT/US2005/034862 DETAILED DESCRIPTION OF THE INVENTION The features and other details of the invention will now be more particularly described with reference to the accompanying drawings and pointed out in the claims. It will be 5 understood that particular embodiments described herein are shown by way of illustration and not as limitations of the invention. The principal features of this invention can be employed in various embodiments without departing from the scope of the invention. All parts and percentages are by weight unless otherwise specified. Definitions 10 For convenience, certain terms used in the specification, examples, and appended claims are collected here. "5-HT receptor modulator" or "5-HT modulator" includes compounds having effect at the 5-HT 1 , 5-HT 2 , 5-HT 3 , 5-HT 4 , 5-HT 5 , 5-HT 6 or 5-HT 7 receptors, including the subtypes of each receptor type, such as 5-HT1A, B, C, D, E orF; 5-HT2A, B orc; and 5-HT5A orB. 5-HT 15 modulators may be agonists, partial agonists or antagonists. "Treating", includes any effect, e.g., lessening, reducing, modulating, or eliminating, that results in the improvement of the condition, disease, disorder, etc. "Alkyl" includes saturated aliphatic groups, including straight-chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl), branched-chain 20 alkyl groups (e.g., isopropyl, tert-butyl, isobutyl, isoamyl), cycloalkyl (e.g., alicyclic) groups (e.g., cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. "Alkyl" further includes alkyl groups which have oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more hydrocarbon backbone carbon atoms. In certain embodiments, a straight chain or branched 25 chain alkyl has six or fewer carbon atoms in its backbone (e.g., C 1
-C
6 for straight chain, C 3 C 6 for branched chain), and more preferably four or fewer. Likewise, preferred cycloalkyls have from three to eight carbon atoms in their ring structure, and more preferably have five or -11- WO 2006/034511 PCT/US2005/034862 six carbons in the ring structure. "CI-C 6 " includes alkyl groups containing one to six carbon atoms. The term "alkyl" also includes both "unsubstituted alkyls" and "substituted alkyls", the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or 5 more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkenyl, alkoxyl, alkoxycarbonyl, alkoxycarbonyloxy, alkyl, alkynyl, alkylcarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylsulfinyl, alkylthio, alkylthiocarbonyl, thiocarboxylate, arylthio, arylcarbonyl, arylcarbonyloxy, aryloxycarbonyloxy, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and 10 alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, azido, carboxylate, cyano, halogen, haloalkyl, haloalkoxy, cycloalkoxyl, acetamide, alkylacetamide, cycloalkylacetamide, amine, cycloamine, heterocyclyl, hydroxyl, nitro, phosphate, phosphonato, phosphinato, sulfates, sulfonato, sulfamoyl, sulfhydryl, sulfonamido, trifluoromethyl, alkylaryl, or an aromatic or 15 heteroaromatic moiety, or any other substituent or its equivalent disclosed herein. Cycloalkyls can be further substituted, e.g., with the substituents described herein and or their equivalents known in the art. An "alkylaryl" or an "aralkyl" moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (benzyl)). "Alkyl" also includes the side chains of natural and unnatural amino acids. 20 A "substituted" moiety is non-limiting as to the type of substituent. As used herein, a substitutent includes any one or more chemical moieties disclosed herein, or any equivalent known in the art. "Aryl" includes groups with aromaticity, including 5- and 6-membered "unconjugated", or single-ring, aromatic groups that may include from zero to four 25 heteroatoms, as well as "conjugated", or multicyclic, systems with at least one aromatic ring. Examples of aryl groups include benzene, phenyl, benzoxazole, benzthiazole, benzo[d][1,3]dioxole, naphthyl, quinolinyl, pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isooxazole, pyridine, pyridinyl, pyrazine, pyridazine, and pyrimidine, and the like. Furthermore, the term "aryl" includes multicyclic -12- WO 2006/034511 PCT/US2005/034862 aryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, napthridine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine. Those aryl groups having heteroatoms in the ring structure may also be referred to as "aryl 5 heterocycles", "heterocycles," "heteroaryls" or "heteroaromatics". The aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, 10 alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, 15 heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety, or any other substituent disclosed herein or its equivalent. Aryl groups can also be fused or bridged with alicyclic or heterocyclic rings which are not aromatic so as to form a multicyclic system (e.g., tetralin, methylenedioxyphenyl). "Alkenyl" includes unsaturated aliphatic groups analogous in length and possible 20 substitution to the alkyls described above, but that contain at least one double bond. For example, the term "alkenyl" includes straight-chain alkenyl groups (e.g., ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl), branched-chain alkenyl groups, cycloalkenyl (e.g., alicyclic) groups (e.g., cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, 25 and cycloalkyl or cycloalkenyl substituted alkenyl groups. The term "alkenyl" further includes alkenyl groups which include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more hydrocarbon backbone carbons. In certain embodiments, a straight chain or branched chain alkenyl group has six or fewer carbon atoms in its backbone (e.g.,
C
2
-C
6 for straight chain, C 3
-C
6 for branched chain.) Likewise, cycloalkenyl groups may have 30 from three to eight carbon atoms in their ring structure, and more preferably have five or six -13- WO 2006/034511 PCT/US2005/034862 carbons in the ring structure. The term "C 2
-C
6 " includes alkenyl groups containing two to six carbon atoms. The term "alkenyl" also includes both "unsubstituted alkenyls" and "substituted alkenyls", the latter of which refers to alkenyl moieties having substituents replacing a 5 hydrogen on one or more hydrocarbon backbone carbon atoms. Such substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including 10 alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. 15 "Alkynyl" includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond. For example, "alkynyl" includes straight-chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl), branched-chain alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups. The term "alkynyl" further includes 20 alkynyl groups having oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more hydrocarbon backbone carbons. In certain embodiments, a straight chain or branched chain alkynyl group has six or fewer carbon atoms in its backbone (e.g., C 2
-C
6 for straight chain,
C
3
-C
6 for branched chain). The term "C 2
-C
6 " includes alkynyl groups containing two to six carbon atoms. 25 The term "alkynyl" also includes both "unsubstituted alkynyls" and "substituted alkynyls", the latter of which refers to alkynyl moieties having substituents replacing a hydrogen on one or more hydrocarbon backbone carbon atoms. Such substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, -14- WO 2006/034511 PCT/US2005/034862 arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, 5 alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Unless the number of carbons is otherwise specified, "lower alkyl" includes an alkyl group, as defined above, but having from one to ten, more preferably from one to six, carbon 10 atoms in its backbone structure. "Lower alkenyl" and "lower alkynyl" have chain lengths of, for example, 2-5 carbon atoms. "Acyl" includes compounds and moieties which contain the acyl radical (CH 3 CO-) or a carbonyl group. "Substituted acyl" includes acyl groups where one or more of the hydrogen atoms are replaced by for example, alkyl groups, alkynyl groups, halogens, hydroxyl, 15 alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), 20 amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. "Acylamino" includes moieties wherein an acyl moiety is bonded to an amino group. For example, the term includes alkylcarbonylamino, arylcarbonylamino, carbamoyl and 25 ureido groups. "Aroyl" includes compounds and moieties with an aryl or heteroaromatic moiety bound to a carbonyl group. Examples of aroyl groups include phenylcarboxy, naphthyl carboxy, etc. -15- WO 2006/034511 PCT/US2005/034862 "Alkoxyalkyl", "alkylaminoalkyl" and "thioalkoxyalkyl" include alkyl groups, as described above, which further include oxygen, nitrogen or sulfur atoms replacing one or more hydrocarbon backbone carbon atoms, e.g., oxygen, nitrogen or sulfur atoms. The term "alkoxy" includes substituted and unsubstituted alkyl, alkenyl, and alkynyl 5 groups covalently linked to an oxygen atom. Examples of alkoxy groups include methoxy, ethoxy, isopropyloxy, propoxy, butoxy, and pentoxy groups. Examples of substituted alkoxy groups include halogenated alkoxy groups. The alkoxy groups can be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, 10 alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, 15 nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moieties. Examples of halogen substituted alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, and trichloromethoxy. The terms "heterocyclyl" or "heterocyclic group" include closed ring structures, e.g., 20 3- to 10-, or 4- to 7-membered rings, which include one or more heteroatoms. Heterocyclyl groups can be saturated or unsaturated and include pyrrolidine, oxolane, thiolane, piperidine, piperizine, morpholine, lactones, lactams such as azetidinones and pyrrolidinones, sultams, sultones, and the like. The heterocyclic ring can be substituted at one or more positions with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, 25 arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, -16- WO 2006/034511 PCT/US2005/034862 sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, or an aromatic or heteroaromatic moiety. The term "thiocarbonyl" or "thiocarboxy" includes compounds and moieties which contain a carbon connected with a double bond to a sulfur atom. 5 The term "ether" includes compounds or moieties which contain an oxygen bonded to two different carbon atoms or heteroatoms. For example, the term includes "alkoxyalkyl" which refers to an alkyl, alkenyl, or alkynyl group covalently bonded to an oxygen atom which is covalently bonded to another alkyl group. The term "ester" includes compounds and moieties which contain a carbon or a 10 heteroatom bound to an oxygen atom which is bonded to the carbon of a carbonyl group. The term "ester" includes alkoxycarboxy groups such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, etc. The alkyl, alkenyl, or alkynyl groups are as defined above. The term "thioether" includes compounds and moieties which contain a sulfur atom 15 bonded to two different carbon or heteroatoms. Examples of thioethers include, but are not limited to alkthioalkyls, alkthioalkenyls, and alkthioalkynyls. The term "alkthioalkyls" include compounds with an alkyl, alkenyl, or alkynyl group bonded to a sulfur atom which is bonded to an alkyl group. Similarly, the term "alkthioalkenyls" and alkthioalkynyls" refer to compounds or moieties wherein an alkyl, alkenyl, or alkynyl group is bonded to a sulfur atom 20 which is covalently bonded to an alkynyl group. The term "hydroxy" or "hydroxyl" includes groups with an -OH or -0. The term "halogen" includes fluorine, bromine, chlorine, iodine, etc. The term "perhalogenated" generally refers to a moiety wherein all hydrogens are replaced by halogen atoms. 25 "Polycyclyl" or "polycyclic radical" refers to two or more cyclic rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings. Rings that are joined through non-adjacent atoms are termed "bridged" rings. Each of the rings of the polycycle can be substituted with -17- WO 2006/034511 PCT/US2005/034862 such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, aminocarbonyl, 5 alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkyl, alkylaryl, or an aromatic or 10 heteroaromatic moiety. "Heteroatom" includes atoms of any element other than carbon or hydrogen. Examples of heteroatoms include nitrogen, oxygen, sulfur and phosphorus. It will be noted that the structure of some of the compounds of the invention includes asymmetric carbon atoms. It is to be understood accordingly that the isomers arising from 15 such asymmetry (e.g., all enantiomers and diastereomers) are included within the scope of the invention, unless indicated otherwise. Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis. Furthermore, the structures and other compounds and moieties discussed in this application also include all tautomers thereof. Alkenes can include either the E- or Z-geometry, where 20 appropriate. Combination therapy" (or "co-therapy") includes the administration of a 5-HT modulator of the invention and at least a second agent as part of a specific treatment regimen intended to provide the beneficial effect from the co-action of these therapeutic agents. The beneficial effect of the combination includes, but is not limited to, pharmacokinetic or 25 pharmacodynamic co-action resulting from the combination of therapeutic agents. Administration of these therapeutic agents in combination typically is carried out over a defined time period (usually minutes, hours, days or weeks depending upon the combination selected). "Combination therapy" may, but generally is not, intended to encompass the administration of two or more of these therapeutic agents as part of separate monotherapy -18- WO 2006/034511 PCT/US2005/034862 regimens that incidentally and arbitrarily result in the combinations of the present invention. "Combination therapy" is intended to embrace administration of these therapeutic agents in a sequential manner, that is, wherein each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents, or at least two of the therapeutic agents, 5 in a substantially simultaneous manner. Substantially simultaneous administration can be accomplished, for example, by administering to the subject a single capsule having a fixed ratio of each therapeutic agent or in multiple, single capsules for each of the therapeutic agents. Sequential or substantially simultaneous administration of each therapeutic agent can be effected by any appropriate route including, but not limited to, oral routes, intravenous 10 routes, intramuscular routes, and direct absorption through mucous membrane tissues. The therapeutic agents can be administered by the same route or by different routes. For example, a first therapeutic agent of the combination selected may be administered by intravenous injection while the other therapeutic agents of the combination may be administered orally. Alternatively, for example, all therapeutic agents may be administered orally or all therapeutic 15 agents may be administered by intravenous injection. The sequence in which the therapeutic agents are administered is not narrowly critical. "Combination therapy" also can embrace the administration of the therapeutic agents as described above in further combination with other biologically active ingredients and non-drug therapies (e.g., surgery or radiation treatment.) Where the combination therapy further comprises a non-drug treatment, the non-drug 20 treatment may be conducted at any suitable time so long as a beneficial effect from the co action of the combination of the therapeutic agents and non-drug treatment is achieved. For example, in appropriate cases, the beneficial effect is still achieved when the non-drug treatment is temporally removed from the administration of the therapeutic agents, perhaps by days or even weeks. 25 One suitable combination therapy would include treating PAH by administration of one or more compounds of the invention, e.g., compounds of formula III, with other vasodilators such as the prostacyclin epoprostenol (FLOLAN); bosentan (TRACLEER); isosorbide dinitrate (DILATRATE-SR, ISO-BID, ISONATE, ISORBID, ISORDIL, ISOTRATE, SORBITRATE); isorbide mononitrate (IMDUR); hydralazine (APRESOLIE); -19- WO 2006/034511 PCT/US2005/034862 treprostinil (REMODULIN); phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil; and calcium channel blockers, in appropriate dosage regimes. An "anionic group," as used herein, refers to a group that is negatively charged at physiological pH. Preferred anionic groups include carboxylate, sulfate, sulfonate, sulfinate, 5 sulfamate, tetrazolyl, phosphate, phosphonate, phosphinate, or phosphorothioate or functional equivalents thereof. "Functional equivalents" of anionic groups are intended to include bioisosteres, e.g., bioisosteres of a carboxylate group. Bioisosteres encompass both classical bioisosteric equivalents and non-classical bioisosteric equivalents. Classical and non-classical bioisosteres are known in the art (see, e.g., Silverman, R. B. The Organic Chemistry of Drug 10 Design and Drug Action, Academic Press, Inc.: San Diego, Calif., 1992, pp.19-23). A particularly preferred anionic group is a carboxylate. The term "heterocyclic group" is intended to include closed ring structures in which one or more of the atoms in the ring is an element other than carbon, for example, nitrogen, or oxygen or sulfur. Heterocyclic groups can be saturated or unsaturated and heterocyclic 15 groups such as pyrrole and furan can have aromatic character. They include fused ring structures such as quinoline and isoquinoline. Other examples of heterocyclic groups include pyridine and purine. Heterocyclic groups can also be substituted at one or more constituent atoms with, for example, a halogen, a lower alkyl, a lower alkenyl, a lower alkoxy, a lower alkylthio, a lower alkylamino, a lower alkylcarboxyl, a nitro, a hydroxyl, -CF 3 , -CN, or the 20 like. The present invention relates to the discovery of new compounds which are 5-HT modulators, e.g., antagonists, and/or SSRIs, that can be used for treating, preventing or curing 5-HT-related conditions. In particular, it has been found that certain piperidinylamino thieno[2,3-d] pyrimidine compounds are effective 5-HT receptor modulators and/or SSRIs. 25 In an embodiment, such compounds include those having the formula -20- WO 2006/034511 PCT/US2005/034862 R5 Q§R6
R
4 1. IQ RR, R N S N R 3 are provided, wherein: a) R 1 and R2 are selected from i) R 1 and R2 independently may be hydrogen; lower alkyl, e.g., straight or branched 5 C 1 , C 2 , C 3 , C 4 or Cs alkyl; C 1
-C
6 cycloalkyl or cycloheteroalkyl; halogens including F, Cl, Br, I, halo-substituted alkyls such as CF 3 , CF 2
CF
3 , CH 2
CF
3 ; COOH; CN; NH 2 ; NO 2 ; OH; substituted or unsubstituted aryl or heteroaryl; R 7 ; COOR 7 ; CONHR 7 ; CON(R 7
)
2 ; OR 7 ;
NHR
7 ; N(R 7
)
2 ; R 7 -alkoxy; and R 7 -haloalkyl; R 7 -haloalkoxy; wherein R 7 is substituted or unsubstituted (CI-C 6 ) alkyl or a (C 3
-C
6 ) cycloalkyl or cycloheteroalkyl; or conjugated 10 substituted or unsubstituted alicyclic, e.g., cycloalkyl, or ii) R 1 and R2, taken together with their bonded carbons, form a substituted or unsubstituted C 4
-C
7 cycloalkyl ring (e.g., cyclohexyl) or cycloheteroalkyl ring; wherein a heteroatom in the C 4
-C
7 cycloheteroalkyl ring comprises at least one of 0, N and S, and the substituted C 4
-C
7 cycloalkyl or cycloheteroalkyl ring comprises at least one substitutent 15 selected from hydrogen, halogen, COOH; CN; NH 2 ; NO 2 ; OH; lower alkyl; substituted lower alkyl; substituted or unsubstituted C 1
-C
6 cycloalkyl or cycloheteroalkyl; substituted or unsubstituted aryl or heteroaryl; R7; COOR 7 ; CONIHR 7 ; CON(R 7
)
2 ; OR7; NHR 7 ; N(R 7
)
2 ; R7 alkoxy; R 7 -haloalkyl; R 7 -haloalkoxy; and b) R3 may be H; halogen; CF 3 ; CN; NH 2 ; lower alkyl; R7; OR7; NHR 7 ; N(R 7
)
2 ; or substituted 20 or unsubstituted aryl or heteroaryl; c) R 4 may be H, R7, or substituted or unsubstituted aryl or heteroaryl; -21- WO 2006/034511 PCT/US2005/034862 i i I I ii N N N N HN HN
R
8
R
8 N* R* d) Qisanyoneof * , , * , , * ,and ,whereinR8may be hydrogen, halogen, or a substituted or unsubstituted lower alkyl, e.g., CN or CF 3 , wherein * indicates the bonds that connect the structure with the rest of the backbone; e) R5 and R6 are variously: 5 i) R5 and R 6 are independently selected from hydrogen, halogen, COOH; CN; NH 2 ;
NO
2 ; OH; lower alkyl; substituted lower alkyl; substituted or unsubstituted aryl or heteroaryl; R7; COOR 7 ; CONHR 7 ; CON(R 7
)
2 ; OR 7 ; NIHR 7 ; N(R 7
)
2 ; R 7 -alkoxy; and R 7 -haloalkyl;
R
7 -haloalkoxy; or ii) R5 and R6, taken together with their bonded carbons, form a substituted or 10 unsubstituted unsaturated 5- or 6- membered carbocyclic ring or a substituted or unsubstituted saturated 5-, 6-, or 7-membered carbocyclic ring, wherein the carbocyclic ring may be a fused biaryl ring or a heterocarbocyclic ring comprising at least one hetero atom chosen from 0, N, S and P; and the substituted ring comprises at least one hydrogen, halogen, COOH; CN; NH 2 ;
NO
2 ; OH; lower alkyl; substituted lower alkyl; substituted or unsubstituted aryl or heteroaryl; 15 R 7 ; COOR 7 ; CONHR 7 ; CON(R 7
)
2 ; OR 7 ; NHR 7 ; N(R 7
)
2 ; R 7 -alkoxy; and R 7 -haloalkyl;
R
7 -haloalkoxy or optionally other radicals; and R 5 and R 6 , taken together with their bonded carbons, is desirably an aromatic ring structure, e.g., phenyl, naphthyl, diphenylmethyl, biaryl; and optionally substitutions on the adjacent carbon atoms may form 5 or 6 membered unsaturated or saturated cyclic rings such as 0 0 S N O 0 20 and f) R7 is substituted or unsubstituted (C-C 6 ) alkyl or a (C 3
-C
6 ) cycloalkyl or cycloheteroalkyl; - 22 - WO 2006/034511 PCT/US2005/034862 g) n is 0, 1, 2, 3, 4, 5 or 6, and is straight or is branched. In various desirable compounds n is 2, 3, 4 or 5. Also provided in the invention are any one or more pharmaceutically acceptable salts and/or esters of the formula I compound. An alternative depiction of Q, which is defined above, is sometimes shown by the 5 formula below, namely N wherein m is 0, 1 or 2. Where m=2, -()m -is meant to depict the carbons at the 2, 3 positions of the piperidine; m = 1, -( )m -is meant to depict one carbon to yield pyrrolidine, and where m=0, the -( )m - moiety is absent, and only the open chain alkylamine is meant 10 to be depicted, i.e., a straight chain alkylamine. In one embodiment, R 1 may desirably be H, -CH 3 , -CH(CH 3
)
2 , or Cl. In another embodiment, R 2 may desirably be H, Cl, lower alkyl, e.g., straight or branched C 1 , C 2 , C 3 (e.g., iso- or tert-butyl), C 4 or C 5 alkyl, or aryl, e.g., phenyl or fluorophenyl. R 1 and R 2 may also, taken together with the bonded carbons from the thieno, desirably form a cyclohexyl 15 ring. The Q group is preferably an N-substituted alkyl or cycloalkyl. The linking group denoted by (), may be a substituted or unsubstituted, straight or branched, and may be a single bond, or made up of 1, 2, 3, 4 or 5 carbons or more. In another embodiment compounds of the invention include those having the formula R CyIR5)n
R
6 ! K N R, N-R 4 R2 RN S N R 3 (V 20 -23- WO 2006/034511 PCT/US2005/034862 wherein R 1 through R 4 are as defined for Formula I. Cy is preferably phenyl, but may be a substituted or unsubstituted, saturated or unsaturated 4-, 5-, 6- or 7- membered cycloalkyl or aryl ring. A cycloalkyl or aryl ring may include, e.g., mono-, di-, or tri-substituted phenyl, naphthyl, or biphenyl with lower alkyl, e.g., methyl, ethyl, propyl, allyl, n-butyl, n-pentyl, n 5 hexyl; alkoxy or aryloxy, e.g., methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, cyclopropoxy, cyclopentyloxy; halo, e.g., fluoro, chloro, bromo, and iodo; amino, dimethylamino, nitro, cyano, carboxy, carboxy esters, carboxamides, N-alkylcarboxamide, N.N-dialkylcarboxamide, trifluoromethyl, trifluoromethoxy, tetrazolo, sulphonyl, thiomethyl, thioethyl, phenylthio, 2,3-methylenedioxy, and 3,4-methylenedioxy. Substituents on Cy are 10 designated R 5 , which may be hydrogen; halogen, halo-substituted alkyl, lower alkyl, CN, COOH, COOR 7 , OR 7 , CONH 2 , CONHR 7 , CON(R 7
)
2 , halo-substituted or unsubstituted NR 7 , halo-substituted or unsubstituted SOOR 7 , aryl, halo-substituted aryl or heteroaryl, C 1
-C
6 cycloalkyl, or C 3
-C
6 cycloheteroalkyl, wherein n is 0, 1, 2, 3, 4 or 5, and R 7 is a substituted or unsubstituted lower alkyl. The linker group may be branched or unbranched, and p may be 0, 15 1, 2, 3, 4, 5, 6 or more. Where the linker group is branched, p is 1 or higher, and R 6 and R 6 ' are independently H, halogen, CN or R 7 , wherein R 7 is a substituted or unsubstituted, branched or unbranched lower alkyl. Pharmaceutically acceptable salts and/or esters of Formula II compounds are also provided. In various embodiments, R 1 may desirably be H, -CH 3 , -CH(CH 3
)
2 , or Cl. In another 20 embodiment, R 2 may desirably be H, lower alkyl, e.g., straight or branched C 1 , C 2 , C 3 (e.g., iso- or tert-butyl), C 4 or C 5 alkyl, or aryl, e.g., phenyl or fluorophenyl. R 1 and R 2 may also, taken together with the bonded carbons from the thieno, desirably form a cyclohexyl ring. R3 and R 4 are independently H, halogen or R 7 , wherein H is preferred. Specific compounds having the formula -24 - WO 2006/034511 PCT/US2005/034862
R
3 ' Cy"
R
3 N R4)" R1 NH R2 S N (V) wherein
R
1 and R 2 independently are one or more of hydrogen; halogen, halo-substituted alkyl, lower alkyl, C 1
-C
6 cycloalkyl, C 3
-C
6 cycloheteroalkyl, aryl, halo-substituted aryl or 5 heteroaryl; or R 1 and R 2 , taken together, form a Cs-C 7 cycloalkyl or cycloheteroalkyl ring;
R
3 and R 3 ' are independently H, halogen, CN or Rs; Cy is a single or conjugated substituted or unsubstituted cycloalkyl, cycloheteroalkyl, aryl or heteroaryl; and
R
4 is hydrogen; halogen, halo-substituted alkyl, lower alkyl, CN, COOH, COOR 5 , 10 OR 5 , CONH 2 , CONHR 5 , CON(Rs) 2 , halo-substituted or unsubstituted NR 5 , halo-substituted or unsubstituted SOOR 5 , aryl, halo-substituted aryl or heteroaryl, C1-C 6 cycloalkyl, or C3-C6 cycloheteroalkyl; wherein R 5 is a substituted or unsubstituted lower alkyl; and n is 1, 2, 3, 4 or 5. Pharmaceutically acceptable salts and/or esters of Formula III compounds are also provided. 15 Compounds of the invention may also be 5-HT receptor antagonists, e.g., 5-HT 2 receptor antagonists including 5-HT 2 A, B or c receptors, and desirably 5-HT2B receptor antagonists. In a particular embodiment; the invention includes those compounds having the formula (Ia) -25- WO 2006/034511 PCT/US2005/034862
R
5 Q-§R6 R4'N'Q R2/ S N R 3 (1a) wherein:
R
1 and R2 are - independently hydrogen; halogen such as Cl, F, Br, I; CN; NO 2 ; NH 2 ; lower 5 alkyl such as Me, Et, n-Pr, i-Pr, n-Bu, i-Bu, t-Bu, n-pentyl, i-amyl, n-hexyl; substituted or unsubstituted phenyl, thiophenyl, furyl, pyridinyl, triazolyl, tetrazolyl, COOH, COO(C 1
-C
6 ) alkyl, COO(C 3
-C
6 ) cycloalkyl, CONH(CI-C 6 ) alkyl, CONH(C 3
-C
6 ) cycloalkyl, CON(C 1
-C
6
)
2 alkyl, CON(C 3
-C
6
)
2 cycloalkyl, 0-( CI-C 6 )alkyl, 0-( C 3
-C
6 ) cycloalkyl, C 3
-C
6 cycloalkyl or cycloheteroalkyl; 10 mono, di or tri halo-substituted (C 1
-C
6 ) alkyl; or - Ri and R2 together with the carbon atoms to which they are bonded form a C 4 C 7 cycloalkyl or cycloheteroalkyl ring containing hetero atoms such as 0, N or S in place of CH 2 and which is optionally substituted by 1, 2 or 3 identical or different groups, these groups being halogen, OH, Cyano, NO 2 , NH 2 , NH(Ci 15 C 6 ) alkyl, NH(C 3
-C
6 ) cycloalkyl, N(C 1
-C
6
)
2 alkyl, N(C 3
-C
6
)
2 cycloalkyl, (C 1 C 4 )- alkyl, C 3
-C
6 cycloalkyl or cycloheteroalkyl, (C 1
-C
4 )- alkoxy, ( C 3
-C
6 ) cycloalkoxy, (C 1
-C
4 )-haloalkyl, (CI-C 4 )- haloalkoxy, COOH, COO(C 1
-C
6 ) alkyl, COO(C 3
-C
6 ) cycloalkyl, CONH(C 1
-C
6 ) alkyl, CONH(C 3
-C
6 ) cycloalkyl,
CON(C
1
-C
6
)
2 alkyl, CON(C 3
-C
6
)
2 cycloalkyl, mono, di or tri halo-substituted 20 (CI-C 6 ) alkyl; or - R 1 and R2 together with the carbon atoms to which they are bonded form an unsaturated 5- or 6- membered carbocyclic ring, which can contain a hetero atom such as 0, S or N in place of CH 2 and which 5- or 6- membered ring is optionally substituted by 1, 2 or 3 identical or different groups, these groups -26- WO 2006/034511 PCT/US2005/034862 being halogen, OH, Cyano, NO 2 , NH 2 , NH(C I-C 6 ) alkyl, NH(C 3
-C
6 ) cycloalkyl, N(C 1
-C
6
)
2 alkyl, N(C 3
-C
6
)
2 cycloalkyl, (C 1
-C
4 )- alkyl, C 3
-C
6 cycloalkyl or cycloheteroalkyl, (C 1
-C
4 )- alkoxy, (C 3
-C
6 ) cycloalkoxy, (C 1 C4)-haloalkyl, (C 1
-C
4 )- haloalkoxy, COOH, COO(C 1
-C
6 ) alkyl, COO(C 3
-C
6 ) 5 cycloalkyl, CONH(CI-C 6 ) alkyl, CONH(C 3
-C
6 ) cycloalkyl, CON(C 1
-C
6
)
2 alkyl, CON(C 3
-C
6
)
2 cycloalkyl, mono, di or tri halo-substituted (C 1
-C
6 ) alkyl; = R 3 is selected from the group consisting of H, F, CF 3 , Cl, Br, I, CN, NH 2 , C 1
-C
6 alkyl, 0-( C 1
-C
6 )alkoxy, C 3
-C
6 cycloalkyl, C 3
-C
6 cycloalkoxy, NH(C 1
-C
6 ) alkyl, NH(C 3
-C
6 ) cycloalkyl, N(C 1
-C
6
)
2 alkyl, N(C 3
-C
6
)
2 cycloalkyl, unsubstituted or substituted phenyl, 10 naphthyl, pyridinyl, pyrimidinyl, pyrrolyl, CH 2 aryl, CH 2 hetero aryl; = R 4 is H, CI-C 6 alkyl, C 3
-C
6 cycloalkyl, substituted or unsubstituted phenyl, pyridinyl, pyrimidinyl, pyrrolyl, CH 2 aryl, CH 2 hetero aryl; Sn is an integer from 0, 1, 2, 3, 4, 5 or 6; = R 5 and R 6 are 15 - independently selected from the group consisting of substituted or unsubstituted aryl, arylalkyl, aryloxy groups where in aryl group represents groups like phenyl, naphthyl, thiophenyl, furyl, pyridinyl, quinolinyl, triazolyl, tetrazolyl, hydrogen; halogen such as Cl, F, Br, I; CN; NO 2 ; NH 2 ; lower alkyl such as Me, Et, n-Pr, i-Pr, n-Bu, i-Bu, t-Bu, n-pentyl, i-amyl, n-hexyl etc., or 20 - R 5 and R 6 together with the carbon atoms to which they are bonded form an unsaturated 5- or 6- membered carbocyclic ring which can contain hetero atoms such as 0, S, and N in place of CH 2 and in which 5- or 6- membered ring is optionally substituted by 1-5 identical or different radicals, these radicals being halogen, OH, Cyano, NO 2 , NH 2 , NH(C 1
-C
6 ) alkyl, NH(C 3
-C
6 ) 25 cycloalkyl, N(Ci-C 6
)
2 alkyl, N(C 3
-C
6
)
2 cycloalkyl, (Cl-C4)- alkyl, C 3
-C
6 cycloalkyl or cycloheteroalkyl, (C 1
-C
4 )- alkoxy, (C 3
-C
6 ) cycloalkoxy, (C 1
-C
4
)
haloalkyl, (C 1
-C
4 )- haloalkoxy, COOH, COO(C 1
-C
6 ) alkyl, COO(C 3
-C
6 ) cycloalkyl, CONH(C 1
-C
6 ) alkyl, CONH(C 3
-C
6 ) cycloalkyl, CON(C 1
-C
6
)
2 -27- WO 2006/034511 PCT/US2005/034862 alkyl, CON(C 3
-C
6 ) 2 cycloalkyl, , mono, di or tri halo-substituted (C 1
-C
6 ) alkyl etc., or - R 5 and R 6 together with the carbon atoms to which they are bonded form an unsaturated 5- or 6- membered carbocyclic ring which can contain hetero 5 atoms such as 0, S, and N in place of CH 2 and in which 5- or 6- membered ring is optionally substituted by 1-5 identical or different radicals, in which substitutions on the adjacent carbon atoms may form 5 or 6 membered unsaturated or saturated cyclic rings such as 0 0 S N O O 10 - R 5 and R 6 together with the carbon atoms to which they are bonded form a saturated 5-, 6-, 7-membered carbocyclic ring which can contain 0, S, N, in place of CH 2 and which is optionally substituted by 1, 2 or 3 (CI-C 6 ) alkyl groups, OH, NH 2 , etc., iiI I iS i N N N N HN HN
R
8 f) Q is any one of * , * * * , * ,and * ,wherein R 8 15 may be hydrogen, halogen, or a substituted or unsubstituted lower alkyl, and its pharmaceutical compositions, prodrugs and all stereoisomers. Included in the invention is the use of the compounds disclosed herein for the manufacture of a medicament for treatment of a disease state that can be alleviated by treatment with a 5-HT 2 B antagonist. In one embodiment the disease state is selected from the 20 diseases pulmonary arterial hypertension, migraine, hypertension, disorders of the gastrointestinal tract, restenosis, asthma, obstructive airway disease, prostatic hyperplasia and priapism. In a related embodiment the disease state comprises inflammatory pain, neuropathic pain, cancer pain, acute pain or chronic pain. In a variant embodiment the -28- WO 2006/034511 PCT/US2005/034862 disease state comprises allergic asthma, irritable bowel syndrome, hypertonic lower esophageal sphincter, motility disorders or benign prostatic hyperplasia. In a further embodiment, the disease state comprises depression, anxiety, attention deficit hyperactivity disorder, obesity, sleeping disorder, Alzheimer's disease, or Parkinson disease. 5 In various embodiments the compound is a 5-HT receptor antagonist, and may be a 5
HT
2 receptor antagonist, including, e.g., a 5-HT2A, B or c receptor antagonist. A preferred compound is a 5-HT2B receptor antagonist. In a specific embodiment, R 3 is selected from a group consisting of H, NH 2 or CF3. In another embodiment R 4 is either H or methyl. Preferably R 1 and R 2 are independently 10 selected from the group consisting of H, CH 3 , Et, n-Pr, i-Pr, i- Bu, Cl, CF 3 , Br, F. When R 1 and R 2 join together, they may form a cyclic ring such as cyclohexane, cyclopentane, cycloheptane or cyclooctane. Compounds are also provided wherein R5 and R 6 are independently selected from a group consisting of H, Me, CF 3 , Et, n-pr, i-Pr, n-bu, i-Bu, Ph, 3-fluorophenyl, 3-chlorophenyl, 3-cyanophenyl, 3-cyano-4-fluorophenyl, phenylcarbonyl, 15 pyridinyl, pyrimidinyl or pyrrolyl. In another embodiment compounds of the invention include those having the formula Cy 6 Rs)y N R, N-R 4 R2 N 2 N R 3 (Ila) wherein R 1 through R 4 are as defined for Formula I. Cy is preferably phenyl, but may be a 20 substituted or unsubstituted, saturated or unsaturated 4-, 5-, 6- or 7- membered cycloalkyl or aryl ring. A cycloalkyl or aryl ring may include, e.g., mono-, di-, or tri-substituted phenyl, naphthyl, or biphenyl with lower alkyl, e.g., methyl, ethyl, propyl, allyl, n-butyl, n-pentyl, n hexyl; alkoxy or aryloxy, e.g., methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, -29- WO 2006/034511 PCT/US2005/034862 cyclopropoxy, cyclopentyloxy; halo, e.g., fluoro, chloro, bromo, and iodo; amino, dimethylamino, nitro, cyano, carboxy, carboxy esters, carboxamides, N-alkylcarboxamide, N.N-dialkylcarboxamide, trifluoromethyl, trifluoromethoxy, tetrazolo, sulphonyl, thiomethyl, thioethyl, phenylthio, 2,3-methylenedioxy, and 3,4-methylenedioxy. Substituents on Cy are 5 designated R 5 , which may be hydrogen; halogen, halo-substituted alkyl, lower alkyl, CN, COOH, COOR 7 , OR 7 , CONHI 2 , CONHR 7 , CON(R 7
)
2 , halo-substituted or unsubstituted NR 7 , halo-substituted or unsubstituted SOOR 7 , aryl, halo-substituted aryl or heteroaryl, C 1
-C
6 cycloalkyl, or C 3
-C
6 cycloheteroalkyl, wherein n is 0, 1, 2, 3, 4 or 5, and R7 is a substituted or unsubstituted lower alkyl. The linker group may be branched or unbranched, and p may be 0, 10 1, 2, 3, 4, 5, 6 or more. Where the linker group is branched, p is 1 or higher, and R 6 and R6' are independently H, halogen, CN or R 7 , wherein R 7 is a substituted or unsubstituted, branched or unbranched lower alkyl. Pharmaceutically acceptable salts and/or esters of Formula II compounds are also provided. Compounds of the invention are useful in the treatment of hypoxia, pulmonary arterial 15 hypertension (PAH) and other hypoxia-induced PAH syndromes caused by chronic obstructive pulmonary disease, mountain sickness, and cardiac valve disease. (Other conditions include congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), scleroderma, valvular heart disease, cor pulmonale, chronic hypoxic lung conditions, sickle cell anemia, portal hypertension, altitude sickness, congenital heart 20 abnormalities, and respiratory distress syndrome.) Several studies have suggested a role for 5-HT in the etiology of PAH. Furthermore, circulating 5-HT levels are increased (10-30X) in both primary PAH and PAH secondary to anorexigen intake. Recently, it has been demonstrated that 5-HT is not only a potent pulmonary vasoconstrictor, but also a growth amplification factor that possibly plays a crucial role in proliferation of pulmonary vascular 25 smooth muscle cells. It has been shown that isolated smooth muscle and endothelial cells from pulmonary arteries express mRNAs for several 5-HT receptors. Thus, by activating its cognate receptors, 5-HT has a dual effect on the pulmonary vascular beds contributing to both vasoconstriction and vascular remodeling that are associated with PAH. -30- WO 2006/034511 PCT/US2005/034862 5-HT2B receptors are found in pulmonary arteries in rats and humans and are up regulated in PAH patients. Moreover, metabolites of anorexigens such as Redux or Fen Phen, have been associated with an increased risk of primary PAH and are potent 5-HT2B receptor agonists. In a recent pivotal study using the chronic-hypoxic-mouse model of 5 pulmonary hypertension, Lanuay and colleagues (2002) showed that 5-HT2B antagonists can prevent arterial hypertrophy in hypoxia-induced PAH in mice by blocking smooth muscle cell proliferation. Mice with genetically inactive 5-HT 2 B receptors did not demonstrate the hypoxia-dependent increase in pulmonary blood pressure and lung remodeling that was observed in the wild type mice. In addition, Teoh et al. (2005) recently demonstrated that 5 10 HT 2 B receptor protein expression is increased in arteries taken from rats exposed to hypoxic conditions for 16-48 hours, suggesting that 5-HT 2 B receptors play a crucial role in hypoxia induced PAH. Overall, these findings suggest that 5-HT 2 5 antagonists can potentially induce selective and sustained pulmonary vasodilatation in patients with hypoxic or primary pulmonary hypertension without having a marked effect on systemic arterial pressure and 15 therefore afford both acute and chronic treatment for PAH. The new compounds of the invention, such as those of formula III, are highly selective. For example, 5-((4-(6-Chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1 yl)methyl)-2-fluoro benzonitrile ("compound A") is a highly selective and potent (Ki = 1.8 nM) 5-HT2B receptor antagonist with more than 500-fold differences in receptor affinities for 20 compared with all other 5-HT receptor subtypes, except for the 5-HTIA (Ki = 100nM) receptor. This compound has almost no affinity (Ki> 1 pM) for more than 51 receptors tested including GPCRs, ion channels and receptor tyrosine kinases; and is active on the dopamine D4.4 receptor (Ki = 5.4 nM) and displays moderate activity for the dopamine D3 receptor (Ki ~ 310 nM). However, blocking of the dopamine D3 and D4 receptors is not 25 associated with extrapyramidal side effects. Compound A appears to be a weak dopamine D2 receptor (IC 50 = 0.67 iM) antagonist and did not show any dopamine D1 and D5 receptor activity (Ki > 5 RM). Compound A displayed moderate binding to the al and a2 receptors (Ki = 100 nM and 110 nM, respectively). However, in functional assays the compound demonstrated very weak agonist activity for a receptors (EC50 ~ 10 pM). -31- WO 2006/034511 PCT/US2005/034862 In in vitro functionality assays, compound A potently inhibits the 5-HT-induced inositol phosphate formation, with an IC 50 = 0.79 nM, without affecting basal inositol levels (indicating that the compound does not possess any inverse agonist activity). In the rat stomach fundus assay, the compound inhibited the 5-HT-induced contractile response with a 5 calculated IC 50 of -27 nM. In a series of in vitro studies designed to test the effect of compound A on the 5-HT-induced vascular muscularization, the compound inhibited the 5 HT-induced mitogen-activated protein kinase (MAPK) activation (IC 50 ~ 12nM) and markedly reduced thymidine incorporation (IC 5 0 ~ 3nM) in Chinese Hamster Ovary (CHO) cells expressing the human 5-HT2B receptor. These studies confirm that 5-HT2B receptor 10 inhibitors have the potential to block the 5-HT-mediated mitogenic activity through this receptor and therefore indicate that compounds of the invention can be effective inhibitors of 5-HT2B receptor-mediated pulmonary vascular remodeling. Compound A was also able to inhibit 5-HT-induced contraction in endothelial denuded pulmonary arterial rings from normoxic and hypoxic rats, with IC 5 os of ~ 5nM and a maximal inhibition of 60-70% of the 15 5-HT-induced contraction. The vasodilatory effect of compound A was confirmed by measuring the right ventricular systolic pressure (RVSP) in the chronic-hypoxic-mouse model of pulmonary hypertension following administration of PRX-08066 (50 mg/kg i.p.). Administration of the compound (60 minutes pre-measurement) produced an acute decrease of the RVSP (human equivalent dose 4-5mg/kg or = 300mg), similar to that measured 20 following administration of 5-HT 2 B receptor antagonist RS-127445 (Roche/Syntex; 20 mg/kg i.p.). The compound also showed 41.87% inhibition of the hERG channel at I LM (estimated IC50 = 1.4gM), which compares favorably with other serotonergic agents (e.g., hERG IC50s for ondansetron, citalopram, and fluoxetine are 0.81 [LM (Kuryshev et al. 2000), 3.97 M and 1.50VM (Witchel et al. 2002), respectively. 25 Together, these findings suggest that compounds of the invention such as those of formula III may be used for treating patients with PAH with a rapid effect on exercise tolerance (quality of life) due to its direct and selective vasodilatory action on pulmonary smooth muscle cells (PSMC) and a disease modifying agent by means of inhibiting the disease progression as a result of blocking the 5-HT-mediated detrimental mitogenic effect on 30 pulmonary arterial SMC. -32- WO 2006/034511 PCT/US2005/034862 Congestive heart failure (CHF) is significant area of medical need. Heart failure is most commonly a chronic condition that is often associated with remodeling of the heart, leading to enlargement of the myocardium (hypertrophy.) These maladaptive changes lead to increased morbidity and mortality, so there is a need for new treatments in this area. Cardiac 5 remodeling (ventricular hypertrophy and dilation) is a prelude to heart failure, and a characteristic of established heart failure. Myocardium remodeling is associated with myocyte growth, dysregulation of myocyte function and mocyte apoptosis. Pathological hypertrophy is often mediated by up-regulation of systemic and/or local mediators wuch as angiotensin II and endothelin. These mediators activate Gq-coupled receptors which are 10 thought to play a major role in the cardiac hypertrophic response. Sustained or excessive activation of the Gq signaling pathway has been noted to result in myocyte hypertrophy and apoptosis. Studies by Nebigil et al. have noted the role of the 5-HT2B receptor in cardiac development. Inactivation of the gene leads to embryonic and neonatal death caused by heart 15 defects. Surviving newborns display a severe ventricular hypoplasia caused by impaired proliferative capacity of myocytes and adult mice consistently exhibited myocyte disarray and ventricular dilation. Ablation of the Gq-coupled receptors in mice leads to cardiomyopathy with left ventricular dysfunction, dilation and an abnormal tissue structure, consistent with that of dilated cardiomyopathy, but no morphological signs of hypertrophy or hypertrophy 20 related gene expression were found. Overexpression of the 5-HT2B receptor in mice hearts was found to lead to cardiac hypertrophy, accompanied by mitochondrial proliferation and enzyme activity. Overexpression of Gq-coupled receptors including 5-HT23 or their signaling molecules, GQ, phospholipase C, or p39 MAPK, is believed to trigger a hypertrophic response (optionally including extensive hypertrophy) that leads to cardiac hypertrophy. A 25 study by Rothman et al. implies that activation of 5-HT2B receptors can produce valvular heart disease, but serotonergic compounds that are not 5-HT2B receptor-specific are unlikely to produce valvular heart disease. Myotonia is induced by any of a number of factors or a combination thereof, for example, cervico-omo-brachial syndromes accompanying stiffness or pain in the neck, -33- WO 2006/034511 PCT/US2005/034862 shoulder, arm, lumbar and dorsal skeletal muscles due to abnormal posture, fatigue, changes in the backbone with aging etc., shoulder periarthritis accompanying inflammation in the tissues constituting the shoulder joint due to changes in the shoulder joint caused by trauma, and the like, and spastic paralysis wherein accelerated limb muscle tonus hinders voluntary 5 movements. In particular, spastic paralysis is a disease which accompanies limb muscle tonus, stiffening, walking difficulty, etc., and thus seriously restrains daily life. These conditions have been treatable with central or peripheral muscle relaxants, e.g., central muscle relaxants like Tolperisone hydrochloride, Baclofen, Tizanidine hydrochloride, Chlorzoxazone, and Diazepam; and peripheral muscle relaxants such as suxamethonium 10 chloride, Pancuronium bromide, and dantrolene sodium. Central muscle relaxants act selectively on the central nervous system so as to relax muscles. Therefore, it is expected that those action on the upper center would exhibit a more potent muscle relaxant effect. However, there arise at the same time some problems including extrapyramidal symptoms and neurologic manifestations such as sleepiness, 15 sluggishness, and atony. It is believed that the compounds of the invention, e.g., those of formula II, may be used as a muscle relaxant and avoid the above problems. Another aspect of the invention is a pharmaceutical composition comprising an amount of a compound according to Formula I effective in treating conditions associated with vascular disorders, e.g., angina, migraine, pulmonary hypertension and systemic hypertension. 20 Another aspect of the invention is a method of treating conditions associated with vascular disorders, e.g., angina, migraine, pulmonary hypertension and systemic hypertension. The compounds of the invention are valuable for treating a wide variety of clinical conditions which are characterized by serotonin excess or absence, e.g., serotonergic hypofunction or hyperfunction. Such conditions include schizophrenia and other psychotic 25 disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic disorders and psychotic disorders with delusions or hallucinations; gastrointestinal disorders like Crohn's disease, eating disorders, neuralgia, and addiction disorders; obsessive compulsive disorders, panic disorders, sexual dysfunctions caused by the central nervous system and disturbances in sleep and the - 34 - WO 2006/034511 PCT/US2005/034862 absorption of food, alcoholism, pain, memory deficits, unipolar depression, dysthymia, bipolar depression, treatment-resistant depression, depression in the medically ill, panic disorder, obsessive-compulsive disorder, eating disorders, social phobia, premenstrual dysphoric disorder, mood disorders, such as depression or more particularly depressive 5 disorders, for example, single episodic or recurrent major depressive disorders and dysthymic disorders, or bipolar disorders, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, e.g., specific animal phobias, social phobias, stress disorders including post-traumatic stress disorder and acute stress 10 disorder, and generalized anxiety disorders; delirium, dementia, and amnestic and other cognitive or neurodegenerative disorders, such as Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple etiologies; Parkinson's disease and other extra 15 pyramidal movement disorders such as medication-induced movement disorders, for example, neuroleptic-induced parkinsonism, neuroleptic malignant syndrome, neuroleptic induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremor; substance-related disorders arising from the use of alcohol, amphetamines (or amphetamine-like substances) caffeine, cannabis, 20 cocaine, hallucinogens, inhalants and aerosol propellants, nicotine, opioids, phenylglycidine derivatives, sedatives, hypnotics, and anxiolytics, which substance-related disorders include dependence and abuse, intoxication, withdrawal, intoxication delirium, withdrawal delirium, persisting dementia, psychotic disorders, mood disorders, anxiety disorders, sexual dysfunction and sleep disorders; epilepsy; Down's syndrome; demyelinating diseases such as 25 MS and ALS and other neuropathological disorders such as peripheral neuropathy, for example diabetic and chemotherapy-induced neuropathy, and postherpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia and other neuralgias; and cerebral vascular disorders due to acute or chronic cerebrovascular damage such as cerebral infarction, subarachnoid hemorrhage or cerebral edema. -35- WO 2006/034511 PCT/US2005/034862 Compounds of the invention may be used for the treatment of the above conditions, as well as for vasodilation, smooth muscle contraction, bronchoconstriction, brain disorders such as vascular disorders, e.g., blood flow disorders caused by vasodilation and vasospastic diseases such as angina, vascular headache, migraine and Reynaud's disease; pulmonary 5 hypertension and systemic hypertension; and neuropathological disorders including Parkinson's disease and Alzheimer's disease; modulation of the cardiovascular system; prophylaxis and control of the effects of occurrences of cerebral infarct (Apoplexia cerebri) such as stroke or cerebral ischemia; and for the control of disorders of the intestinal tract which are characterized by disturbances of the serotoninergic system and also by disturbances 10 of the carbohydrate metabolism. The compounds may also be useful in treating a variety of other conditions including stress-related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; disorders of bladder function such as cystitis, bladder detrusor hyper-reflexia and incontinence; and pain or nociception attributable to or associated with any of the foregoing 15 conditions, especially pain transmission in migraine. For treating certain conditions it may be desirable to employ the compounds of the invention in conjunction with another pharmacologically active agent. The compounds of the invention may be presented together with another therapeutic agent as a combined preparation for simultaneous, separate or sequential use. Such combined preparations may be, for 20 example, in the form of a twin pack. A further aspect of the invention comprises compounds of the invention in combination with a or another 5-HT antagonist and/or SSRI, e.g., a 5-HT 3 antagonist such as ondansetron, granisetron, tropisetron or zatisetron. Additionally, the compounds of the invention may be administered in combination with an anti-inflammatory corticosteroid, such 25 as dexamethasone. Furthermore, the compounds of the invention may be administered in combination with a chemotherapeutic agent such as an alkylating agent, anti-metabolite, mitotic inhibitor or cytotoxic antibiotic, as described above. In general, the currently available dosage forms of the known therapeutic agents for use in such combinations will be suitable. -36- WO 2006/034511 PCT/US2005/034862 According to a further or alternative aspect, the invention provides compounds of the invention for use in the manufacture of a medicament for the treatment or prevention of physiological disorders associated with serotonin excess or absence, e.g., serotonergic hypofunction or hyperfunction. 5 The invention also provides methods for treating or preventing physiological disorders associated with serotonin excess or absence, e.g., serotonergic hypofunction or hyperfunction, which method comprises administration to a patient in need thereof of an effective amount of a compound of the invention or a composition comprising a compound of the invention. For treating or preventing migraine, the compounds of the invention may be used in 10 conjunction with other anti-migraine agents, such as ergotamines or 5-HT 1 agonists, especially sumatriptan or rizatriptan. Likewise, for treating behavioral hyperalgesia, the compounds of the invention may be used in conjunction with an antagonist of N-methyl D aspartate (NMDA), such as dizocilpine. It will be further appreciated that for treating or preventing depression and/or anxiety, 15 the compounds of the invention may be used in combination with an antidepressant agent or anti-anxiety agent. Suitable classes of antidepressant agents of use in the invention include: norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, reversible monoamine oxidase inhibitors, serotonin and noradrenaline reuptake inhibitors, corticotropin releasing factor (CRF) antagonists, p-adrenoreceptor 20 antagonists and atypical antidepressants. Another class of antidepressant agent of use in the invention is noradrenergic and specific serotonergic antidepressants, such as mirtazapine. Suitable examples of norepinephrine reuptake inhibitors include amitripdyline, clomipramine, doxepine, imipramine, trimipramine, amoxapine, desipramine, maprotiline, nortriptyline, reboxetine and protriptyline and pharmaceutically acceptable salts thereof. Suitable examples 25 of selective serotonin reuptake inhibitors include fluoxetine, fluvoxamine, paroxetine, and sertraline and pharmaceutically acceptable salts thereof. Suitable examples of monoamine oxidase inhibitors include isocarboxazid, phenelzine, tranylcypromain and selegiline, and pharmaceutically acceptable salts thereof. Suitable examples of reversible monoamine oxidase inhibitors include moclobemide, and pharmaceutically acceptable salts thereof. -37- WO 2006/034511 PCT/US2005/034862 Suitable examples of serotonin and noradrenaline reuptake inhibitors include venlafaxine, and pharmaceutically acceptable salts thereof. Suitable examples of corticotropin releasing factor (CRF) antagonists include those compounds described in International Patent Specification Nos. WO 94/13643, WO 94/13644, WO 94/13661, WO 94/13676 and WO 94/13677. 5 Suitable examples of atypical antidepressants include bupropion, lithium, nefazoedone, sibutramine, trazodone and viloxazine, and pharmaceutically acceptable salts thereof. Other antidepressants of use in the invention include adinozolam, alaproclate, amineptine, amitryptyline/chlordiazepoxide combination, atipamezole, azamianserin, bazinaprine, fefuraline, bifemelane, binodaline, bipenamol, brofaromine, bupropion, caroxazone, 10 cericlamine, cianopramine, cimoxatone, citalopram, clemeprol, clovoxamine, dasepinil, deanol, demexiptiline, dibenzepin, dothiepin, droxidopa, enefexine, setazolam, etoperidone, femoxetine, fengabine, fezolamine, fluotracen, idazoxan, indalpine, indeloxazine, iprindole, levoprotiline, litoxetine, lofepramine, medifoxamine, metapramine, metralindole, mianserin, milnacipran, minaprine, mirtazapine, montirelin, nebracetam, nefopam, nialamide, 15 nomifensine, norfluoxetine, orotirelin, oxaflozane, pinazepam, pirindole, pizotyline, ritaserin, rolipram, sercloremine, setiptiline, sibutramine, sulbutiamine, sulpride, teniloxazine, thozalinone, thymoliberin, tianeptine, tiflucarbine, tofenacin, tofisopam, toloxatone, tomoxetine, veralipride, viqualine, zimelidine, and zometapine, and pharmaceutically acceptable salts thereof, and St. John's wort herb, or Hypericum perforatum, or extracts 20 thereof. Preferred antidepressant agents include selective serotonin reuptake inhibitors, in particular, fluoxetine, fluvoxamine, paroxetine, and sertraline and pharmaceutically acceptable salts thereof. Suitable classes of anti-anxiety agents of use in the invention include benzodiazepines and 5-HT1A agonists or antagonists, especially 5-HTIA partial agonists, and corticotropin 25 releasing factor (CRF) antagonists. In addition to benzodiazepines, other suitable classes of anti-anxiety agents are nonbenzodiazepine sedative-hypnotic drugs such as zolpidem; mood stabilizing drugs such as clobazam, gabapentin, lamotrigine, loreclezole, oxcarbamazepine, stiripentol and vigabatrin; and barbiturates. Suitable benzodiazepines of use in the invention include alprazolam, chlordizepoxide, clonazepam, chlorazepate, diazepam, halazepam, 30 lorezepam, oxazepam and prazepam, and pharmaceutically acceptable salts thereof. Suitable -38- WO 2006/034511 PCT/US2005/034862 examples of 5-HTIA agonists or antagonists of use in the invention include, in particular, the 5-HT1A partial agonists buspirone, flesinoxan, gepirone, ipsapirone and pindolol, and pharmaceutically acceptable salts thereof. Another class of anti-anxiety agent of use in the invention are compounds having muscarinic cholinergic activity. Suitable compounds in this 5 class include ml muscarinic cholinergic receptor antagonists such as those compounds described in European Patent Specification Nos. 0 709 093, 0 709 094 and 0 773 021 and International Patent Specification No. WO 96/12711. Another class of anti-anxiety agent of use in the invention are compounds acting on ion channels. Suitable compounds in this class include carbamazepine, lamotrigine and valproate, and pharmaceutically acceptable salts 10 thereof. Therefore, in a further aspect of the invention, a pharmaceutical composition is provided comprising a compound of the invention and an antidepressant or an anti-anxiety agent, together with at least one pharmaceutically acceptable carrier or excipient. Suitable antipsychotic agents of use in combination with the compounds of the 15 invention include phenothiazines, e.g., chlorpromazine, mesoridazine, thioridazine, acetophenazine, fluphenazine, perphenazine and trifluoperazine; thioxanthenes, e.g., chlorprothixene or thiothixene; heterocyclic dibenzazepines, e.g., clozapine or olanzapine; butyrophenones, e.g., haloperidol; diphenylbutylpiperidines, e.g., pimozide; and indolones, e.g., molindolene. Other antipsychotic agents include loxapine, sulpiride and risperidone. It 20 will be appreciated that the antipsychotic agents when used in combination with the compounds of the invention may be in the form of a pharmaceutically acceptable salt, for example, chlorpromazine hydrochloride, mesoridazine besylate, thioridazine hydrochloride, acetophenazine maleate, fluphenazine hydrochloride, flurphenazine enathate, fluphenazine decanoate, trifluoperazine hydrochloride, thiothixene hydrochloride, haloperidol decanoate, 25 loxapine succinate and molindone hydrochloride. Perphenazine, chlorprothixene, clozapine, olanzapine, haloperidol, pimozide and risperidone are commonly used in a non-salt form. Other classes of antipsychotic agent of use in combination with the compounds of the invention include dopamine receptor antagonists, especially D2, D3 and D4 dopamine receptor antagonists, and muscarinic ml receptor agonists. An example of a D3 dopamine -39- WO 2006/034511 PCT/US2005/034862 receptor antagonist is the compound PNU-99194A. An example of a D4 dopamine receptor antagonist is PNU-101387. An example of a muscarinic ml receptor agonist is xanomeline. Another class of antipsychotic agent of use in combination with the compounds of the invention is the 5-HT2A receptor antagonists, examples of which include MDL100907 and 5 fananserin. Also of use in combination with the compound of the invention are the serotonin dopamine antagonists (SDAs) which are believed to combine 5-HT2A and dopamine receptor antagonist activity, examples of which include olanzapine and ziperasidone. Therefore, in a further aspect of the invention, a pharmaceutical composition is provided comprising a compound of the invention and an antipsychotic agent, together with at 10 least one pharmaceutically acceptable carrier or excipient. The compounds of the invention and another other pharmacologically active agent may be administered to a patient simultaneously, sequentially or in combination. It will be appreciated that when using a combination of the invention, the compound of the invention and the other pharmacologically active agent may be in the same pharmaceutically acceptable 15 carrier and therefore administered simultaneously. They may be in separate pharmaceutical carriers such as conventional oral dosage forms which are taken simultaneously. The term "combination" further refers to the case where the compounds are provided in separate dosage forms and are administered sequentially. The compounds of the invention may be administered to patients (animals and 20 humans) in need of such treatment in dosages that will provide optimal pharmaceutical efficacy. It will be appreciated that the dose required for use in any particular application will vary from patient to patient, not only with the particular compound or composition selected, but also with the route of administration, the nature of the condition being treated, the age and condition of the patient, concurrent medication or special diets then being followed by the 25 patient, and other factors which those skilled in the art will recognize, with the appropriate dosage ultimately being at the discretion of the attendant physician. In the treatment of a condition associated with a serotonin excess or absence, e.g., serotonergic hypofunction or hyperfunction, an appropriate dosage level will generally be about 0.001 to 50 mg per kg patient body weight per day, which may be administered in -40- WO 2006/034511 PCT/US2005/034862 single or multiple doses. Preferably, the dosage level will be about 0.01 to about 25 mg/kg per day; more preferably about 0.05 to about 10 mg/kg per day. For example, in the treatment or prevention of a disorder of the central nervous system, a suitable dosage level is about 0.001 to 10 mg/kg per day, preferably about 0.005 to 5 mg/kg per day, and especially about 5 0.01 to 1 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day. It will be appreciated that the amount of the compound of the invention required for use in any treatment will vary not only with the particular compounds or composition selected but also with the route of administration, the nature of the condition being treated, and the age 10 and condition of the patient, and will ultimately be at the discretion of the attendant physician. The compositions and combination therapies of the invention may be administered in combination with a variety of pharmaceutical excipients, including stabilizing agents, carriers and/or encapsulation formulations as described herein. Aqueous compositions of the present invention comprise an effective amount of the 15 peptides of the invention, dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium. "Pharmaceutically or pharmacologically acceptable" include molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate. "Pharmaceutically acceptable carrier" 20 includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated 25 into the compositions. For human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologics standards. -41- WO 2006/034511 PCT/US2005/034862 The compositions and combination therapies of the invention will then generally be formulated for parenteral administration, e.g., formulated for injection via the intravenous, intramuscular, subcutaneous, intralesional, or even intraperitoneal routes. The preparation of an aqueous composition that contains a composition of the invention or an active component 5 or ingredient will be known to those of skill in the art in light of the present disclosure. Typically, such compositions can be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for using to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and the preparations can also be emulsified. 10 The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and 15 must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. Solutions of active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures 20 thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. Therapeutic or pharmacological compositions of the present invention will generally comprise an effective amount of the component(s) of the combination therapy, dissolved or dispersed in a pharmaceutically acceptable medium. Pharmaceutically acceptable media or 25 carriers include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Supplementary active ingredients can also be incorporated into the therapeutic compositions of the present invention. - 42 - WO 2006/034511 PCT/US2005/034862 The preparation of pharmaceutical or pharmacological compositions will be known to those of skill in the art in light of the present disclosure. Typically, such compositions may be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection; as tablets or other solids for oral 5 administration; as time release capsules; or in any other form currently used, including cremes, lotions, mouthwashes, inhalants and the like. Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by 10 incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously 15 sterile-filtered solution thereof. The preparation of more, or highly, concentrated solutions for intramuscular injection is also contemplated. In this regard, the use of DMSO as solvent is preferred as this will result in extremely rapid penetration, delivering high concentrations of the active compound(s) or agent(s) to a small area. 20 The use of sterile formulations, such as saline-based washes, by surgeons, physicians or health care workers to cleanse a particular area in the operating field may also be particularly useful. Therapeutic formulations in accordance with the present invention may also be reconstituted in the form of mouthwashes, or in conjunction with antifungal reagents. Inhalant forms are also envisioned. The therapeutic formulations of the invention may also 25 be prepared in forms suitable for topical administration, such as in cremes and lotions. Suitable preservatives for use in such a solution include benzalkonium chloride, benzethonium chloride, chlorobutanol, thimerosal and the like. Suitable buffers include boric acid, sodium and potassium bicarbonate, sodium and potassium borates, sodium and potassium carbonate, sodium acetate, sodium biphosphate and the like, in amounts sufficient -43 - WO 2006/034511 PCT/US2005/034862 to maintain the pH at between about pH 6 and pH 8, and preferably, between about pH 7 and pH 7.5. Suitable tonicity agents are dextran 40, dextran 70, dextrose, glycerin, potassium chloride, propylene glycol, sodium chloride, and the like, such that the sodium chloride equivalent of the ophthalmic solution is in the range 0.9 plus or minus 0.2%. Suitable 5 antioxidants and stabilizers include sodium bisulfite, sodium metabisulfite, sodium thiosulfite, thiourea and the like. Suitable wetting and clarifying agents include polysorbate 80, polysorbate 20, poloxamer 282 and tyloxapol. Suitable viscosity-increasing agents include dextran 40, dextran 70, gelatin, glycerin, hydroxyethylcellulose, hydroxmethylpropylcellulose, lanolin, methylcellulose, petrolatum, polyethylene glycol, 10 polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose and the like. Upon formulation, therapeutics will be administered in a manner compatible with the dosage formulation, and in such amount as is pharmacologically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like can also be employed. 15 In this context, the quantity of active ingredient and volume of composition to be administered depends on the host animal to be treated. Precise amounts of active compound required for administration depend on the judgment of the practitioner and are peculiar to each individual. A minimal volume of a composition required to disperse the active compounds is 20 typically utilized. Suitable regimes for administration are also variable, but would be typified by initially administering the compound and monitoring the results and then giving further controlled doses at further intervals. For example, for parenteral administration, a suitably buffered, and if necessary, isotonic aqueous solution would be prepared and used for intravenous, intramuscular, subcutaneous or even intraperitoneal administration. One dosage 25 could be dissolved in 1 ml of isotonic NaC1 solution and either added to 1000 ml of hypodermolysis fluid or injected at the proposed site of infusion, (see for example, Remington's Pharmaceutical Sciences 15th Edition, pages 1035-1038 and 1570-1580). In certain embodiments, active compounds may be administered orally. This is contemplated for agents which are generally resistant, or have been rendered resistant, to - 44 - WO 2006/034511 PCT/US2005/034862 proteolysis by digestive enzymes. Such compounds are contemplated to include chemically designed or modified agents; dextrorotatory peptides; and peptide and liposomal formulations in time release capsules to avoid peptidase and lipase degradation. Pharmaceutically acceptable salts include acid addition salts and which are formed 5 with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. 10 The carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the 15 action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and 20 gelatin. Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the 25 basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile filtered solution thereof. -45- WO 2006/034511 PCT/US2005/034862 The preparation of more, or highly, concentrated solutions for direct injection is also contemplated, where the use of DMSO as solvent is envisioned to result in extremely rapid penetration, delivering high concentrations of the active agents to a small area. Upon formulation, solutions will be administered in a manner compatible with the 5 dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like can also be employed. For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient 10 saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure. In addition to the compounds formulated for parenteral administration, such as 15 intravenous or intramuscular injection, other pharmaceutically acceptable forms include, e.g., tablets or other solids for oral administration; liposomal formulations; time-release capsules; and any other form currently used, including cremes. Additional formulations suitable for other modes of administration include suppositories. For suppositories, traditional binders and carriers may include, for example, 20 polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1%-2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and the like. These compositions take the form of solutions, 25 suspensions, tablets, pills, capsules, sustained release formulations or powders. Oral formulations of compounds of the invention, e.g., compounds of formula III, may desirably be formulated for once or twice-daily administration. -46- WO 2006/034511 PCT/US2005/034862 In certain defined embodiments, oral pharmaceutical compositions will comprise an inert diluent or assimilable edible carrier, or they may be enclosed in hard or soft shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compounds may be 5 incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 75% of the weight of the unit, or preferably between 25-60%. The amount 10 of active compounds in such therapeutically useful compositions is such that a suitable dosage will be obtained. The tablets, troches, pills, capsules and the like may also contain the following: a binder, as gum tragacanth, acacia, cornstarch, or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid and the like; 15 a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose or saccharin may be added or a flavoring agent, such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules 20 may be coated with shellac, sugar or both. A syrup of elixir may contain the active compounds sucrose as a sweetening agent methyl and propylparabensas preservatives, a dye and flavoring, such as cherry or orange flavor. The pharmaceutical compositions of this invention may be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains 25 one or more of the compound of the invention, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral applications. The active ingredient may be compounded, for example, with the usual non toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The carriers which -47 - WO 2006/034511 PCT/US2005/034862 can be used are water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form, and in addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used. 5 The active object compound is included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or condition of the disease. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate 10 or gums, and other pharmaceutical diluents, e.g., water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the invention, or a non toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally 15 effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an 20 inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of 25 polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate. The liquid forms in which the compositions of the invention may be incorporated for administration orally or by injection include aqueous solution, suitably flavored syrups, aqueous or oil suspensions, and emulsions with acceptable oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, or with a solubilizing or emulsifying agent suitable for -48- WO 2006/034511 PCT/US2005/034862 intravenous use, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin. 5 Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as set out above. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably sterile pharmaceutically 10 acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device may be attached to a face mask, tent or intermittent positive pressure breathing machine. Solution, suspension or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner. 15 For treating clinical conditions and diseases noted above, the compound of this invention may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. 20 Methods for preparing compounds of the invention are illustrated below and in the following Examples. The following examples are given for the purpose of illustrating the invention, but not for limiting the scope or spirit of the invention. -49 - WO 2006/034511 PCT/US2005/034862 General Scheme 1 OH Cl R COEt HCO 2
NH
4 R SOC 2 /DMF(cat.) R2 N /2 )-...ONHD6 refluxl4-6h R S N 2
HCN
2 S N R 8S N 5R 3 reflux/10-12h 3 (80-95%) 2 (70-90%) 3 R 3 = H 4 0 NaBH(OAc)3, R5 R NH R 5
R
6 AcOH, DCM 25% TFA-DCM/2h 6 (R = H) MN-p R 6 or 2M HCI-Et 2 0/16h N R R4-HNI o1 6 or R 4 -N n (85-95%) H2N n 4 Boc n1 DIEA, MeCN, 10-16 h 8 9 R 5 Rr, 7 (Y = CI, Br, OMs)
R
5
R
5 R6 R1 mN R RI HN n R HN N) R 6 - N H 2 N n N 2M HCI -Et 2 O/O OC 1[HC OH o N __________ / A or RCOOH, ROH R RO~ S N R 3 DIEA/MeCN/ S N R S N R 3 reflux (70-94%) 4 (55-70%) 10 1a k=1,2,3or4 lb I=1/2,1,2,3or4 5 Preparation 1: R, COOEt R OH
HCO
2
NH
4 R1 / R2 ZS NH 2
HCONHR
3 s NR;SI reflux/1 0-1 2h 3 2 (70-90%) 3 10 A mixture of amino ester derivative 2 (1 mmol) and ammonium formate (1.5 mmol) in formamide (4 mL) was heated at reflux for 12 h. Completion of reaction was monitored via TLC. The reaction mixture was allowed to cool to room temperature and then poured into ice (50 g) to afford a creamy precipitate. The precipitate was collected by filtration, and 15 recrystallized from acetone/water to give 3 in 70-90 % yields. -50- WO 2006/034511 PCT/US2005/034862 Preparation 2:
R
1 OH Sr
SOC
2 /DMF(cat.) R R3 IY refluxl4-6h / N R N;R3 (80-95%) 3 4 A mixture of thieno[2,3-d]pyrimidin -4-ol derivative 3 (3.7 mmol), thionyl chloride (5.5 mL) and dry DMF (0.5 mL) was heated at reflux for 4 h. The reaction mixture was cooled to room 5 temperature and the excess thionyl chloride was removed by vacuum distillation. To the resulting residue 200 g of ice was added and extracted with dichloromethane (3 x 100 mL). The combined organic layers were dried (Na 2
SO
4 ) and concentrated. The product was purified by silica chromatography (100 % DCM) to afford 4-chloro-thieno[2,3-d]-pyrimidine 4 in 80-95 % yields. 10 Preparation 3: 0 R5 M NH R5 R 6
(R
5 = H)
R
4 -HN NaBH(OAc) 3 / CM R 4 N n m 0 or 2; n = 1 AcOH/16h (90-95%) R4= Boc 8 5 To a mixture of 4-N-Boc-amino piperidine derivative 5 (10 mmol) and aromatic aldehyde 6 15 (10 mmol) in 40mL of DCM or DCE (1,2-dichloroethane) was added sodium triacetoxyborohydride (15 mmol) followed by acetic acid (20 mmol) under N 2 atmosphere. The resulting cloudy mixture was stirred at room temperature for 16h and quenched with aq.NaHCO 3 solution. The product was extracted with EtOAc, dried (Na 2
SO
4 ) and the solvent was evaporated to get the product 8 in 90-95 % yields. 20 -51- WO 2006/034511 PCT/US2005/034862 Preparation 4: Y R5 M NH R5 R 6
R
4 -HN MeCN/DIEA/reflux
R
4 -N ne m = 0 or 2; n = 1 6-12h (80-94%)
R
4 =Boc (Y = CI, Br, OMs) 8 5
(R
5 = Me, i-Bu) To a mixture of 4-N-Boc-amino piperidine 5 (10 mmol) and N,N-diisopropylethylamine (30 mmol) in 30 mL of CH 3 CN under N 2 atmosphere was added intermediate 7 (10 mmol) at 5 room temperature. The resulting mixture was heated at 80"C for 16h. The reaction mixture was quenched with aq. NaHCO 3 and the product was extracted with EtOAc. The organic extract was dried (Na 2
SO
4 ) and the solvent was evaporated under reduced pressure to get the product 8 in 80-94% yields. 10 Preparation 5:
R
5 N R6 25% TFA-DCM/2h or 2M HCI-Et 2 o/16h
R
4 -N (85-95%)
H
2 N n 8 R 4 = Boc The N-Boc-protection of crude 4-N-Boc-aminobenzyl piperidine derivative 8 was removed by either treating with 25% TFA-DCM at room temperature for 2h or with 2M HCl in Et 2 O solution at room temperature for 16-20h. In both cases, the solvent was evaporated followed 15 by addition of dry Et 2 O. The resulting precipitate was filtered, washed several times with dry Et 2 O and dried under vacuum to afford the corresponding salts of 4-amino-1-benzyl piperidine derivative 9. The free base was either isolated or generated in situ during the next coupling step. 20 Preparation 6:
R
5 R5 R R3H2N NCN R R2 N 3 DIEAIMeCN/ N reflux S N-) R 3 (55-70%) 10 -52- WO 2006/034511 PCT/US2005/034862 To a solution of 4-amino-piperidines 9 (1 mmol) in acetonitrile (5mL) under N 2 was added NN-diisopropylethylamine (4 mmol) followed by chloro-thienopyrimidine 4 (1 mmol). The resulting solution was heated at reflux for 24-48 h (monitored by TLC). The solvent was evaporated and the resulting solid was dissolved in EtOAc (20mL) and washed with aq. 5 NaHCO 3 (lOmL) and brine solution (1OmL). The organic layer was dried (Na 2
SO
4 ), concentrated and purified by silica chromatography (1% MeOH in DCM) to afford 10 in 55 60% yields. Preparation 7:
R
5 R5 R HN N RHNN R 6
R
2 R3 2M HcI -Et 2 0 "c [Hel] S N R 3 (90-94%) S N R 10 10 Ia k=1,2,3or4 To a solution of 10 (1mmol) in dry DCM (1 mL) was added 2 M HC1 in ether (10 mL) at 0 0 C and stirred at the same temperature for 1 h. The precipitated product was filtered, washed with dry Et 2 O and dried under vacuum to afford pure compounds la in 90-94 % yields. 15 Preparation 8:
R
5 R 5 HN n R / R3y RCOOH,ROH R
[RCOOH]
1 S NIR 3 (70-94%) R 10 lb I=1/21,2,3or4 To a solution of 10 (1 mmol) in dry EtOH / DCM (2 mL) was added maleic acid (1 mmol) in 20 EtOH (5 mL) at room temperature and stirred for 1 h. The reaction mixture was diluted with diethyl ether (5 mL) and cooled to 0*C for 6-8 h. The precipitated product was filtered, washed with dry Et 2 O and dried under vacuum to afford pure compounds lb in 70-94 % yields. -53 - WO 2006/034511 PCT/US2005/034862 General Scheme 2
R
1 CI N-R 4
CH
3 CN, EtN HN R2 R3 + 0 o 2n reflux, 16 h R R
R
3 m=or;n (80-85%) R 2 S NR R4= Boc 3 4 11 12 O R (R 5 = H) R m ,jjNH R 5 6 R TFA/DCM, rt, 2 h HN n NaBH(OAc) 3 , CH 2 CI2 R6 or R1 n AcOH, 16 h (90-95 %) R HNi!nI 2 M HC-Et 2 O, R 2 N or
CH
2
C
2 ,0 OC, 16 h N<R 3 R2 (95-97%) 13 R 5
R
6 S N R 3 7 10 MeCN, DIEA, reflux 6-12 h (80-94 %) Preparation 9: CI H2N N-R4 CH 3 CN, DIEA or Et 3 N HN
R
2 / N~: + H 2 N-N(4i reflux, 16h R N R 3 m=0or2;n 1 (55-70%) R 2 /
R
4 =Boc S N R 3 4 11 12 To a solution of 1-Boc-4-amino-piperidine 11 (2 mmol) in acetonitrile (5 mL) was added N,N-diisopropyl ethylamine (4 mmol) and stirred for 5 min. at room temperature under N 2 . Chloro-thienopyrimidine 4 was added to the mixture and the contents were heated at reflux for 16 h (monitored by TLC). The solvent was evaporated and to the residue EtOAc (20mL) 10 and water (1OmL) were added. The organic layer was dried (MgS04) and concentrated to yield crude product. It was purified by silica chromatography (1% MeOH in DCM) to afforded the pure products 12 in 55-70% yields. - 54 - WO 2006/034511 PCT/US2005/034862 Preparation 10: N-R4 m NH , R HN n 25% TFA-CH 2 Cl 2 , 2h R HN n N or N R2S N R 3 2M HCI-Et 2 O, 16h R2 8 N R 3 m = 0 or 2; n= 1; R 4 = Boc 12 13 The Boc-protection of 12 was removed by either treating with 25 % TFA-DCM at room temperature for 2 h or with 2 M HC1 in Et 2 O solution at room temperature for 16-20h. In 5 both cases, the solvent was evaporated followed by addition of dry Et 2 O. The resulting precipitate was filtered, washed several times with dry Et 2 O and dried under vacuum to afford the salts 13 in 95-97% yields. The corresponding free base was either isolated or generated in situ during the next coupling step. 10 Preparation 11:
R
5 R1 HN n R 5
R
6 HN>N R 6 / N NaBH(OAc) 3 , cHaCl2 R N S N R 3 AcOH, 4-16 h (90-95 %) R 2 m = 0 or2; n = 1 S N R3 13 10 To a mixture of 13 (10 mmol) and aldehyde 6 (10 mmol) in 40 mL of DCM or DCE (1,2 dichloroethane) under N 2 atmosphere was added sodium triacetoxyborohydride (15 mmol) 15 followed by acetic acid (20 mmol) at room temperature. The resulting cloudy mixture was stirred at room temperature for 16 h. The reaction mixture was quenched by adding aq. NaHCO 3 , and the product was extracted with EtOAc. The EtOAc extract was dried (MgSO 4 ) and the solvent was evaporated to give the crude product. Purification by silica gel or crystallization afforded the pure products 10 in 90-95 % yields. 20 -55 - WO 2006/034511 PCT/US2005/034862 Preparation 12: R5 R1 H N - H R s (Y = C I, Br, O M s) H R N n R 5
R
6 'T~-N R 6 Z HNK0n R2 DIEA, MeCN N reflux, 6-12 S R 3 (80-94%) R2 m =0 or2; n 1 S N R 3 13 10 To a mixture of 13 (10 mmol) and NN-diisopropylethylamine (30 mmol) in 30 mL of
CH
3 CN was added intermediate 7 (10 mmol) at room temperature under N 2 atmosphere. The 5 resulting mixture was stirred at reflux for 16 h. The reaction mixture was quenched with aq.NaHCO 3 and the product was extracted with EtOAc. The organic extract was dried (Na 2
SO
4 ) and the solvent was evaporated to give the product 10 in 80-94 % yields. Non-limiting examples of reaction conditions for various compositions encompassed 10 within the invention are provided below. Example 1 N-(1-(3,5-Difluorobenzyl)piperidin-4-yl)-6-isopropylthieno[2,3-d]pyrimidin-4-amine, monomaleate. F F N HOOO cOOH NH 15N The title compound was prepared (36 mg, 75 %) from N-(l-(3,5-difluorobenzyl)piperidin-4 yl)-6-isopropylthieno[2,3-d]pyrimidin-4-amine (38 mg, 0.095 mmol) by following the procedure described for preparation 8. 1H NMR (400 MHz, DMSO-d 6 ): 5 8.25 (s, 1H), 7.65 20 (bs, 1H),7.35 (m, 2H), 7.25 (d, 2H), 6.05 (s, 2H), 4.20 (m, 3H), 3.30 (m, 2H), 3.00 (m, 2H), 2.10 (m, 2H), 1.80 (m, 2H), 1.30 (d, 6H); MS (ESI) m/z: Calculated: 402.5; Observed: 403.2 (M+I). - 56 - WO 2006/034511 PCT/US2005/034862 Example 2 N-(1-(3,5-Difluorobenzyl)piperidin-4-yl)-6-chlorothieno[2,3-d]pyrimidin-4-amine, monomaleate. F F N - HO 2 C CO 2 H NH S N 5 The title compound was prepared (10 mg, 64 %) from N-(1-(3,5-difluorobenzyl)piperidin-4 yl)-6-chlorothieno[2,3-d]pyrimidin-4-amine (12 mg, 0.03 mmol) by following the procedure described for Preparation 8. 'H NMR (400 MHz, CD 3 0D) 8 8.33 (s, 1H), 7.46 (s, 1H), 7.18 (m, 3H), 6.23 (s, 2H, maleate), 4.38 (m, 1H), 4.30 (s, 2H), 3.51 (m, 2H), 3.16 (m, 2H), 2.31 (m, 2H), 1.93 (m, 2H); MS (ESI) m/z: Calculated for C 18 Hi 8 C1F 2
N
4 S, 395.09; Observed: 10 395.0 (M++1). Example 3 N-(1-(3-Fluorobenzyl)piperidin-4-yl)-6-chlorothieno[2,3-dlpyrimidin-4-amine, monomaleate F N - HO 2
CCO
2 H NH 15 S N The title compound was prepared (35 mg, 79 %) from N-(1-(3-fluorobenzyl)piperidin-4-yl)-6 chlorothieno[2,3-d]pyrimidin-4-amine (34 mg, 0.09 mmol) by following the procedure described for Preparation 8. 1H NMR (400 MHz, CD 3 0D) 6 8.34 (s, 1H), 7.53 (m, 111), 7.47 20 (s, 1H), 7.36-7.24 (m, 3H), 6.26 (s, 2H, maleate), 4.40 (m, 1H), 4.33 (s, 2H), 3.53 (m, 2H), 3.19 (m, 2H), 2.32 (m, 2H), 1.93 (m, 2H); MS (ESI) m/z: Calculated for C 18
H
19 C1FN 4 S, 377.1; Observed: 377.2 (M*+1). -57 - WO 2006/034511 PCT/US2005/034862 Example 4 N-(1-(2-Fluorobenzyl)piperidin-4-yl)-6-chlorothieno[2,3-d]pyrimidin-4-amine, monomaleate Fpo N HO2CO C 2 H NH 5 SN The title compound was prepared (80 mg, 96 %) from N-(1-(2-fluorobenzyl)piperidin-4-yl)-6 chlorothieno[2,3-d]pyrimidin-4-amine (64 mg, 0.17 mmol) by following the procedure described for Preparation 8. 'H NMR (400 MHz, CD 3 OD) 8 8.33 (s, 1H), 7.57 (m, 2H), 7.47 (s, 1H), 7.32 (m, 2H), 6.25 (s, 2H, maleate), 4.41 (m, 3H), 3.59 (d, 2H), 3.29 (m, 2H), 2.32 (d, 10 2H), 1.95 (m, 2H); MS (ESI) m/z: Calculated for Ci 8 H1 9 ClFN 4 S, 377.1; Observed: 377.2 (M*+1). Example 5 3-((4-(6-Chlorothieno[2,3-djpyrimidin-4-ylamino)piperidin-1-yl)methy)benzoic acid 15 monomaleate C0 2 H N P /H 2 C 2 H NH C, The title compound was prepared (45 mg, 85 %) from 3-((4-(6-chlorothieno[2,3-d]pyrimidin 4-ylamino)piperidin-1-yl)methyl)benzoic acid (41 mg, 0.10 mmol) by following the 20 procedure described for Preparation 8. 1H NMR (400 MHz, CD 3 0D) 6 8.27 (s, 1H), 7.92 (s, 1H), 7.86 (d, 1H), 7.50 (s, 1H), 7.42 (d, 1H), 7.33 (t, 1H), 6.02 (s, 2H, maleate), 4.11 (m, 1H), 3.60 (s, 2H), 2.98 (d, 2H), 2.21 (t, 2H), 2.01 (d, 2H), 1.69 (m, 2H); MS (ESI) m/z: Calculated for C19H 20 ClN 4 0 2 S, 403.1; Observed: 403.2 (M*+1). - 58 - WO 2006/034511 PCT/US2005/034862 Example 6 3-((4-(6-Chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)benzamide, monomaleate
CONH
2 N H0 2 C 0 2 H NH 5 SN The title compound was prepared (17 mg, 94 %) from 3-((4-(6-chlorothieno[2,3-d]pyrimidin 4-ylamino)piperidin-1-yl)methyl)benzamide (14 mg, 0.04 mmol) by following the procedure described for Preparation 8. 1H NMR (400 MHz, CD 3 0D) 8 8.33 (s, 1H), 8.09 (s, 1H), 8.00 10 (d, 1H), 7.78 (d, 111), 7.61 (t, 1H), 7.50 (s, 111), 6.27 (s, 211, maleate), 4.44 (m, 3H), 3.60 (d, 211), 3.27 (t, 211), 2.32 (d, 2H), 1.99 (m, 2H); MS (ESI) m/z: Calculated for C 19
H
2 1 C1N 5 0S, 402.1; Observed: 402.2 (M+l). Example 7 15 3-((4-(6-Chlorothieno[2,3-dlpyrimidin-4-ylamino)piperidin-1-yl)methyl)benzonitrile monomaleate CN N - HO 2
CCO
2 H NH C,1 S N 1 The title compound was prepared (25 mg, 94 %) from 3-((4-(6-chlorothieno[2,3-d]pyrimidin 20 4-ylamino)piperidin-1-yl)methyl)benzonitrile (20 mg, 0.05 mmol) by following the procedure described for Preparation 8. 1H NMR (400 MHz, CD 3 0D) 5 8.33 (s, 1H), 7.92 (s, 111), 7.86 (m, 211), 7.69 (t, 1H), 7.47 (s, 111), 6.26 (s, 2H, maleate), 4.39 (m, 1H), 4.36 (s, 2H), 3.52 (m, 2H), 3.17 (m, 2H), 2.31 (m, 2H), 1.93 (m, 211); MS (ESI) m/z: Calculated for C 1 9
H
19 C1N 5 S, 384.1; Observed: 384.2 (M*+1). -59 - WO 2006/034511 PCT/US2005/034862 Example 8 5-((4-(6-Chlorothieno[2,3-dlpyrimidin-4-ylamino)piperidin-1-yl)methyl)-2-fluoro 5 benzonitrile, monomaleate CN F N Ho 2 C Co 2 H NH C N The title compound was prepared (86 mg, 99 %) from 5-((4-(6-chlorothieno[2,3-d] pyrimidin 4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile (67 mg, 0.17 mmol) by following the 10 procedure described for Preparation 8. 'H NMR (400 MHz, CD 3 0D) 5 8.34 (s, 1H), 7.95 (m, 1H), 7.86 (m, 1H), 7.50 (t, 1H), 7.46 (s, 1H), 6.26 (s, 1H), 4.38 (m, 1H), 4.30 (s, 2H), 3.47(m, 2H), 3.13 (m, 2H), 2.31 (m, 2H), 1.90 (m, 2H); ); MS (ESI) m/z: Calculated for
C
1 9
H
1 8 C1FN 5 S, 402.1; Observed: 402.2 (M*+1). 15 Example 9 6-Chloro-N-(1-((pyridin-3-yl)methyl)piperidin-4-yl)thieno[2,3-dlpyrimidin-4-amine, monomaleate N N Y- HO2C CO2H S N 20 The title compound was prepared (117 mg, 91 %) from 6-chloro-N-(l-((pyridin-3 yl)methyl)piperidin-4-yl)thieno[2,3-d]pyrimidin-4-amine (100 mg, 0.27 mmol) by following the procedure described for preparation 8. 'H NMR (400 MHz, DMSO-d 6 ): 5 8.64 (brs, 1H), -60- WO 2006/034511 PCT/US2005/034862 8.60 (d, 1H), 8.43 (s, 1H), 7.88 (d, 1H), 7.66 (s, 1H), 7.47-7.44 (m, 1H), 6.02 (s, 2H), 4.22 4.18 (m, 1H), 3.59-3.29 (m, 2H), 3.15 (s, 2H), 2.50-2.47 (m, 2H), 2.11-2.07 (m, 211), 1.79 1.66 (i, 2H); MS (ESI) m/z: Calculated: 475.95; Observed: 360.2 (M*+1). 5 Example 10 N-(1-(3,5-Difluorobenzyl)piperidin-4-yl)-6-chloro-5-(4-fluorophenyl)thieno[2,3-dI pyrimidin-4-amine, monomaleate. F F F N NH HOOC COOH SN C1 1o The title compound was prepared (66 mg, 39 %) from N-(1-(3,5-difluorobenzyl)piperidin-4 y1)-6-chloro-5-(4-fluorophenyl)thieno[2,3-d] pyrimidin-4-amine (140 mg, 0.28 mmol) by following the procedure described for Preparation 8. '1H NMR (400 MHz, CD 3 0D): 5 8.40 (s, 1H), 7.55 (m, 2H), 7.40 (t, 2H), 7.10 (m, 3H), 6.25 (s, 2H), 4.20 (m, 3H), 3.30 (m, 2H), 3.00 (m, 2H), 2.15 (m, 2H), 1.40 (m, 2H). MS (ESI) m/z: Calculated: 488.1; Observed: 489.2 15 (M*+l). Example 11 6-Chloro-N-(1-((pyrimidin-5-yl)methyl)piperidin-4-yl)thieno[2,3-d]pyrimidin-4-amine, monomaleate. N N NH ' HOOC COOH c N 20 N The title compound was prepared (100 mg, 64 %) from 6-chloro-N-(1-((pyrimidin-5 yl)methyl)piperidin-4-yl)thieno[2,3-d]pyrimidin-4-amine (119 mg, 0.33 mmol) by following -61- WO 2006/034511 PCT/US2005/034862 the procedure described for preparation 8. 1H NMR (400 MHz, CD 3 0D): 3 9.25 (s, 1H), 8.95 (s, 2H), 8.35 (s, 1H), 7.45 (s, 1H), 6.25 (s, 2H), 4.35 (m, 3H), 3.55 (m, 2H), 3.15 (m, 2H), 2.30 (m, 2H), 1.90 (m, 2H). MS (ESI) m/z: Calculated: 360.09; Observed: 361.1 (M*+1). 5 Example 12 3-((4-(6-Chlorothieno[2,3-dipyrimidin-4-ylamino)piperidin-1-yl)methyl)- 4 -fluoro benzonitrile, monomaleate. CN N F HOOC COOH NH 0 CI- /7 , S N 10 The title compound was prepared (100 mg, 64 %) from 3-((4-(6-chlorothieno[2,3-d] pyrimidin-4-ylamino)piperidin-1-yl)methyl)-4-fluorobenzonitrile (119 mg, 0.33 mmol) by following the procedure described for Preparation 8. 1H NMR (400 MHz, CD 3 0D): 5 8.35 (s, 1H), 8.05 (m, 1H), 7.95 (m, 1H), 7.50 (m, 2H), 6.25 (s, 2H), 4.40 (m, 3H), 3.55 (m, 2H), 3.20 (m, 2H), 2.30 (m, 2H), 1.95 (m, 2H). MS (ESI) m/z: Calculated: 401.09; Observed: 402.1 15 (M*+1). Example 13 N-(1-(3-Chlorobenzyl)piperidin-4-yl)-6-chlorothieno[2,3-d]pyrimidin-4-amine, monomaleate. CI N NH-HOOC COOH 20 S N The title compound was prepared (62 mg, 69 %) from N-(l-(3-chlorobenzyl)piperidin-4-yl) 6-chlorothieno[2,3-d]pyrimidin-4-amine (70 mg, 0.18 mmol) by following the procedure -62- WO 2006/034511 PCT/US2005/034862 described for preparation 8. 'H NMR (400 MHz, CD 3 0D): 8 8.40 (s, 1H), 7.60 (s, 1H), 7.45 (m, 4H), 6.25 (s, 2H), 4.30 (m, 3H), 3.50 (m, 2H), 3.20 (m, 2H), 2.30 (m, 2H), 1.90 (m, 2H). MS (ESI) m/z: Calculated: 392.06; Observed: 393.2 (M*+l). 5 Example 14 3-((4-(6-Chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)-N-methyl benzamide, monomaleate oNH N
HO
2 C CO 2 H NH CI_ N S N The title compound was prepared (71 mg, 96 %) from N-(1-(3,5-difluorobenzyl)piperidin-4 10 yl)-6-chlorothieno[2,3-d]pyrimidin-4-amine (58 mg, 0.14 mmol) by following the procedure described for Preparation 8. 'H NMR (400 MHz, CD 3 0D) 8 'H NMR (400 MHz, CD 3 0D): 8 8.34 (s, 1H), 7.98 (s, 1H), 7.91 (d, 1H), 7.69 (d, 1H), 7.60 (t, 1H), 7.47 (s, 1H), 6.26 (s, 2H, maleate), 4.40 (m, 3H), 3.55 (d, 2H), 3.28 (t, 2H), 2.94 (s, 3H), 2.34 (d, 2H), 1.91 (m, 2H); MS (ESI) m/z: Calculated for C 20
H
23 C1N 5 OS, 416.13; Observed: 416.2 (M*+l). 15 - 63 - WO 2006/034511 PCT/US2005/034862 Example 15 3-((4-(6-Chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)-N,N dimethylbenzamide, monomaleate o NN N HO2C CO 2 H NH CI S N) 5 The title compound was prepared (82 mg, 97 %) from 3-((4-(6-chlorothieno[2,3-d]pyrimidin 4-ylamino)piperidin- 1 -yl)methyl)-N,N-dimethylbenzamide (67 mg, 0.16 mmol) by following the procedure described for Preparation 8. 1H NMR (400 MHz, CD 3 0D) 8 8.34 (s, 1H), 7.58 (m, 4H), 7.47 (s, 1H), 6.26 (s, 2H, maleate), 4.37 (m, 3H), 3.55 (d, 2H), 3.26 (t, 2H), 3.13 (s, 3H), 3.01 (s, 3H), 2.33 (d, 2H), 1.91 (m, 2H); MS (ESI) m/z: Calculated for C 2 1
H
25 C1N 5 0S, 10 430.15; Observed: 430.3 (M++1). Example 16 N-(1-(3-(Methylsulfonyl)benzyl)piperidin-4-yl)-6-chlorothieno[2,3-djpyrimidin-4-amine, monomaleate
SO
2 Me N N NH - HOOC COOH 15 S N The title compound was prepared (50 mg, 76 %) from N-(l-(3 (methylsulfonyl)benzyl)piperidin-4-yl)-6-chlorothieno[2,3-d]pyrimidin-4-amine (53 mg, 0.12 mmol) by following the procedure described for Preparation 8. 'H NMR (400 MHz, CD 3 0D): 20 5 8.35 (s, 1H), 8.15 (s, 1H), 8.10 (d, 1H), 7.85 (d, 1H), 7.75 (t, 1H), 7.45 (s, 1H), 6.25 (s, 2H), -64 - WO 2006/034511 PCT/US2005/034862 4.40 (m, 3H), 3.55 (m, 2H), 3.10-3.25 (m, 5H), 2.30 (m, 2H), 1.90 (m, 2H). MS (ESI) m/z: Calculated: 436.98; Observed: 437.2 (M+l). Example 17 5 N-(1-(3-Trifluoromethyl)benzyl)piperidin-4-yl)-6-chlorothieno[2,3-djpyrimidin-4-amine, monomaleate
CF
3 N
HO
2 C CO 2 H NH CI S N) The title compound was prepared (25 mg, 79 %) from N-(l -(3 10 trifluoromethyl)benzyl)piperidin-4-yl)-6-chlorothieno[2,3-d]pyrimidin-4-amine (25 mg, 0.06 mmol) by following the procedure described for Preparation 8. 1H NMR (400 MHz, CDC1 3 ): 5 8.37 (s, 1H), 7.85 (s, 1H) 7.81 (m, 2H), 7.74 (m, 1H), 7.42 (s, 1H), 6.26 (s, 2H), 4.96 (bs, 3H), 4.41 (m, 2H), 3.53 (m, 3H), 3.24 (m, 2H), 2.25 (m, 2H), 1.87 (m, 2H). MS (ESI) m/z: Calculated: 426. 2; Observed: 427.2 (M*+l). 15 Example 18 N-(1-(3-Trifluoromethylsulfonyl)benzyl)piperidin-4-yl)-6-chlorothieno[2,3-d] pyrimidin 4-amine, monomaleate 0 % CF 3 N H0 2
CCO
2 H NH SN 20 -65- WO 2006/034511 PCT/US2005/034862 The title compound was prepared (150 mg, 81 %) from N-(1-(3-trifluoromethylsulfonyl) benzyl) piperidin-4-yl)-6-chlorothieno[2,3-d]pyrimidin-4-amine (153 mg, 0.31 mmol) by following the procedure described for Preparation 8. 'H NMR (400 MHz, CDC1 3 ): S 8.38 (s, 211), 8.21 (s, 1H) 8.16 (d, 111), 7.93 (t, 1H), 7.43 (s, 1H), 6.26 (s, 2H), 4.95 (bs, 311), 4.44 (s, 5 211), 4.38 (m, 1H), 3.59 (m, 2H), 3.28 (m, 2H), 2.23 (m, 2H), 1.91 (m, 2H). MS (ESI) m/z: Calculated: 490. 2; Observed: 491.2 (M*+1). Example 19 N-(1-(3,5-Difluorobenzyl)piperidin-4-yl)-6-isopropylthieno[2,3-dipyrimidin-4-amine, 10 dihydrochloride. F r- -F N - 2HCI NH The title compound was prepared (110 mg, 93 %) from N-(1-(3,5-difluorobenzyl)piperidin-4 yl)-6-isopropylthieno[2,3-d]pyrimidin-4-amine (100 mg, 0.25 mmol) by following the 15 procedure described for preparation 7. '11 NMR (400 MHz, CD 3 0D): 8 8.50 (s,1H), 7.60 (s,1H), 7.30 (m, 2H), 7.15 (m, 111), 4.65 (m, 1H), 4.40 (s, 2H), 3.65 (m, 211), 3.30 (m, 3H), 2.35 (m, 2H), 2.15 (m, 2H), 1.40 (d, 6H). MS (ESI) m/z: Calculated: 402.5; Observed: 403.1 (M*+1). -66 - WO 2006/034511 PCT/US2005/034862 Example 20 N-(1-(3,5-Difluorobenzyl)piperidin-4-yl)-6-chlorothieno[2,3-d]pyrimidin-4-amine, dihydrochloride F r F N Y - 2HCI NH C I N 5 SN The title compound was prepared (39 mg, 66 %) from N-(l-(3,5-difluorobenzyl)piperidin-4 yl)-6-chlorothieno[2,3-d]pyrimidin-4-amine (50 mg, 0.13 mmol) by following the procedure described for Preparation 7. 'H NMR (400 MHz, CD 3 0D) 8 8.63 (s, 1H), 7.70 (s, 1H), 7.27 10 (d, 2H), 7.17 (s, 1H), 4.56 (s, 1H), 4.40 (s, 2H), 3.62 (d, 2H), 3.29 (d, 2H), 2.35 (d, 2H), 2.05 (m, 2H); MS (ESI) m/z: Calculated for C 18 HisClF 2
N
4 S, 395.09; Observed: 395.0 (M*+1). Example 21 N-(1-(3-Fluorobenzyl)piperidin-4-yl)-6-chlorothieno[2,3-dlpyrimidin-4-amine, 15 dihydrochloride F N Y - 2HCI NH CI N S N The title compound was prepared (62 mg, 90 %) from N-(1-(3-fluorobenzyl)piperidin-4-yl)-6 chlorothieno[2,3-d]pyrimidin-4-amine (58 mg, 0.15 mmol) by following the procedure 20 described for Preparation 7. 'H NMR (400 MHz, CD 3 0D) 8 8.63 (s, 1H), 7.70 (s, 1H), 7.55 (dt, 1H), 7.39 (m, 2H), 7.28 (t, 2H), 4.56 (m, 1H), 4.39 (s, 2H), 3.62 (d, 2H), 3.29 (d, 2H), - 67 - WO 2006/034511 PCT/US2005/034862 2.35 (d, 2H), 2.04 (m, 2H); MS (ESI) m/z: Calculated for C 1 8
H
19 C1FN 4 S, 377.1; Observed: 377.2 (M*+l). Example 22 5 N-(1-(1-(3-Fluorophenyl)ethyl)piperidin-4-yl)-6-isobutylthieno[2,3-dipyrimidin-4 amine, dihydrochloride F N - 2HCI NH The title compound was prepared (66 mg, 73 %) from N-(1-(1-(3 10 fluorophenyl)ethyl)piperidin-4-yl)-6-isobutylthieno[2,3-d]pyrimidin- 4 -amine (77 mg, 0.186 mmol) by following the general procedure described for Preparation 7. 1H NMR (400 MHz,
CD
3 0D): 8 8.65 (s, 1H), 7.40-7.60 (m, 5H), 4.55 (m, 2H), 3.95 (d, 1H), 3.40 (d, 1H), 3.20 (m, 1H), 3.10 (m, 1H), 2.85 (d, 2H), 2.25-2.45 (m, 3H), 2.15 (m, 1H), 2.00 (m, 1H), 1.85 (d, 3H), 1.00 (d, 6H). MS (ESI) m/z: Calculated: 412.57; Observed: 413.1 (M*+1). 15 - 68 - WO 2006/034511 PCT/US2005/034862 Example 23 N-(1-(1-(3,5-Difluorophenyl)ethyl)piperidin-4-yl)-6-isobutylthieno[2,3-dlpyrimidin-4 amine, dihydrochloride F F N . 2HCI NH 5 The title compound was prepared (77 mg, 53 %) from N-(1-(1-(3,5-difluorophenyl)ethyl) piperidin-4-yl)-6-isobutylthieno[2,3-d]pyrimidin-4-amine (125 mg, 0.29 mmol) by following the general procedure described for Preparation 7. 'H NMR (400 MHz, CD 3 OD): 8 8.65 9s, 1H), 7.55 (s, 1H), 7.35 (m, 2H), 7.15 (m, 1H), 4.60 (m, 2H), 3.95 (d, 1H), 3.45 (d, 1H), 3.05 10 3.25 (m, 2H), 2.85 (d, 2H), 2.40 (m, 1H), 2.30 (m, 2H), 2.00 (m, 1H), 1.80 (d, 3H), 1.00 (d, 6H). MS (ESI) m/z: Calculated: 430.56; Observed: 431.1 (M*+1). Example 24 4-N-(3-(1-(3-Fluorophenyl)ethylamino) propylamino)-5,6,7,8-tetrahydro-benzo[4,5] 15 thieno[2,3-d]pyrimidine, dihydrochloride. F HN - 2HCI NH The title compound was prepared (186 mg, 54 %) from 4-N-(3-(1-(3 fluorophenyl)ethylamino) propylamino)-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d] 20 pyrimidine (262 mg, 0.76 mmol) by following the general procedure described for Preparation 7. 1H NMR (400 MHz, CD 3 0D): 8 8.60 (s, 1H), 7.45 (m, 1H), 7.35 (m, 2H), 7.15 - 69 - WO 2006/034511 PCT/US2005/034862 (m, 1H), 4.45 9(q, 1H), 3.80 (m, 2H), 2.80-3.10 (m, 6H), 2.15 (m, 2H), 1.95 (m, 2H), 1.65 (d, 3H); MS (ESI) m/z: Calculated: 384.51; Observed: 385.1 (M*+1). Example 25 5 4-N-(3-(3-Fluorobenzyl amino) propylamino)-5,6,7,8-tetrahydro-benzo[4,5]thieno [2,3 dipyrimidine, dihydrochloride. F HN 2HCI NH The title compound was prepared (105 mg, 61 %) from 4-N-(3-(3-fluorobenzyl amino) 10 propylamino)-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine (145 mg, 0.39 mmol) by following the general procedure described for Preparation 7. 'H NMR (400 MHz, CD 3 0D): 3 8.65 (s, 1H), 7.50 (m, 1H), 7.35 (m, 2H), 7.10 (m, 1H), 4.25 (s, 2H), 3.90 (t, 2H), 3.20 (t, 2H), 3.05 (m, 2H), 2.90 (m, 2H), 2.10 (m, 2H), 1.95 (m, 4H); MS (ESI) m/z: Calculated: 370.49; Observed: 371.1 (M*+1). 15 Example 26 N-(3-(1-(3-Fluorophenyl)ethylamino)propyl)-6-isobutylthieno[2,3-djpyrimidin-4-amine, dihydrochloride F HN 2HCI NH 20 The title compound was prepared (142 mg, 76 %) from N-(3-(1-(3-fluorophenyl)ethylamino) propyl)-6-isobutylthieno[2,3-d]pyrimidin-4-amine (157 mg, 0.4 mmol) by following the - 70 - WO 2006/034511 PCT/US2005/034862 general procedure described for Preparation 7. 1 H NMR (400 MHz, CD 3 0D): 6 8.60 (s, 1H), 7.45 (m, 2H), 7.35 (m, 2H), 7.15 (m, 1H), 4.45 (m, 1H), 3.80 (m, 2H), 3.10 (m, 1H), 2.95 (m, 1H), 2.85 (d, 2H), 2.15 (m, 2H), 2.00 (m, 1H), 1.70 (d, 3H), 1.00 (d, 6H); MS (ESI) m/z: Calculated: 386.53; Observed: 387.1 (M*+l). 5 Example 27 N-(1-(1-(2,4,6-Trifluorophenyl)ethyl)piperidin-4-yl)-6-isobutylthieno[2,3-dI pyrimidin 4-amine, dihydrochloride F F N F - 2HCI NH 10 The title compound was prepared (90 mg, 71 %) from N-(1-(1-(2,4,6-trifluorophenyl) ethyl)piperidin-4-yl)-6-isobutylthieno[2,3-d]pyrimidin- 4 -amine (110 mg, 0.25 mmol) by following the general procedure described for Preparation 7. 1H NMR (400 MHz, CD 3 0D): S 8.05 (s, 1H), 7.60 (s, 1H), 7.15 9m, 2H), 5.00 (m, 1H), 4.60 (m, 1H), 3.65-3.90 (m, 2H), 3.10 15 3.35 (m, 2H), 2.85 (d, 2H), 2.10-2.45 (m, 4H), 2.00 (m, 1H), 1.90 (d, 3H), 1.05 (d, 6H). MS (ESI) m/z: Calculated: 448.55; Observed: 449.1 (M*+1). -71- WO 2006/034511 PCT/US2005/034862 Example 28 N-(1-(1-(2,6-Difluorophenyl)ethyl)piperidin-4-yl)-6-isobutylthieno[2,3-d]pyrimidin-4 amine, dihydrochloride F N F . 2HCI NH 5 The title compound was prepared (105 mg, 87 %) from N-(1-(1-(2,6 difluorophenyl)ethyl)piperidin-4-y)-6-isobutylthieno[2,3-d]pyrimidin-4-amine (104 mg, 0.24 mmol) by following the general procedure described for Preparation 7. 1H NMR (400 MHz,
CD
3 0D): 8 8.65 (s, 1H), 7.65 (m, 1H), 7.60 (s, 1H), 7.20 (t, 2H), 5.00 (m, 1H), 4.60 (m, 1H), 10 3.90 (d, 1H), 3.70 (d, 1H), 3.30 (m, 1H), 3.15 (m, 1H), 2.85 (d, 2H), 2.10-2.45 (m, 4H), 2.00 (m, 1H), 1.90 (d, 3H), 1.00 (d, 6H). MS (ESI) m/z: Calculated: 430.56; Observed: 431.2 (M+ 1). Example 29 15 N-(1-(Cyclohexylmethyl)piperidin-4-yl)-5,6-dimethylthieno[2,3-dlpyrimidin-4-amine, dihydrochloride N Y .2HcI NH SN The title compound was prepared (83 mg, 85 %) from N-(1-(cyclohexylmethyl)piperidin-4 20 yl)-5,6-dimethylthieno[2,3-d]pyrimidin-4-amine (81 mg, 0.23 mmol) by following the procedure described for Preparation 7. 1H NMR (400 MHz, CD 3 0D) 5 8.68 (s, 1H), 4.70 (m, 1H), 3.71 (d, 2H), 3.20 (m, 2H), 3.01 (d, 2H), 2.61 (s, 3H), 2.53 (s, 3H), 2.40-2.20 (m, 4H), -72 - WO 2006/034511 PCT/US2005/034862 1.88-1.71 (m, 6H), 1.39-1.26 (m, 3H), 1.09 (m, 2H); MS (ESI) m/z: Calculated for
C
20
H
31
N
4 S, 359.23; Observed: 359.2 (M*+1). Example 30 5 N-(1-(3-Fluorobenzyl)piperidin-4-yl)-6-chloro-5-methylthieno[2,3-d]pyrimidin-4-amine, dihydrochloride. F N - 2HCI NH C1 The title compound was prepared (98 mg, 70 %) from N-(1-(3-fluorobenzyl)piperidin-4-yl)-6 10 chloro-5-methylthieno[2,3-d]pyrimidin-4-amine (119 mg, 0.3 mmol) by following the general procedure described for Preparation 7. 'H NMR (400 MHz, CD 3 0D): 3 8.05 (s, 1H), 7.55 (m, 1H), 7.40 (m, 2H), 7.25 (m, 1H), 4.65 (m, 1H), 4.40 (s, 2H), 3.65 (m, 2H), 3.25 (m, 2H), 2.65 (s, 3H), 2.35 (m, 2H), 2.15 (m, 2H). MS (ESI) m/z: Calculated: 390.91; Observed: 391.2 (M+1). 15 -73 - WO 2006/034511 PCT/US2005/034862 Example 31 2-((4-(6-Chloro-5-methylthieno[2,3-dlpyrimidin-4-ylamino)piperidin-1-yl)methyl) benzonitrile, dihydrochloride NC N - 2HCI NH CI 5 The title compound was prepared (94 mg, 80 %) from 2-((4-(6-chloro-5-methylthieno[2,3 d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)benzonitrile (100 mg, 0.25 mmol) by following the general procedure described for Preparation 7. 'H NMR (400 MHz, CD 3 OD): 5 8.70 (s, 1H), 7.95 (m, 2H), 7.85 (t, 1H), 7.75 (t, 1H), 4.70 (m, 1H), 4.60 (s, 2H), 3.70 (d, 2H), 3.45 10 (m, 2H), 2.65 (s, 3H), 2.15-2.45 (m, 4H). MS (ESI) m/z: Calculated: 397.92; Observed: 398.1 (M*+1). Example 32 N-(1-(2-Methoxybenzyl)piperidin-4-yl)-6-chloro-5-methylthieno[2,3-dlpyrimidin -4 15 amine, dihydrochloride MeO N - 2HCI NH CI The title compound was prepared (129 mg, 95 %) from N-(1-(2-methoxybenzyl)piperidin-4 yl)-6-chloro-5-methylthieno[2,3-d]pyrimidin-4-amine (115 mg, 0.29 mmol) by following the 20 general procedure described for Preparation 7. 'H NMR (400 MHz, CD 3 OD): 6 8.90 (s, 1H), 7.50 (m, 2H), 7.15 (m, 111), 7.05 (t, 1H), 4.65 (m, 1H), 4.40 (s, 2H), 3.95 (s, 3H), 3.65 (m, - 74 - WO 2006/034511 PCT/US2005/034862 2H), 3.30 (m, 2H), 2.65 (s, 3H), 2.35 (m, 2H), 2.20 (m, 2H). MS (ESI) m/z: Calculated: 402.94; Observed: 403.3 (M*+l). Example 33 5 N-(1-(3-Fluorobenzyl)piperidin-4-yl)5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d] pyrimidin-4-amine, dihydrochloride F N - 2HCI NH The title compound was prepared (427 mg, 91 %) from N-(1-(3-fluorobenzyl)piperidin-4 10 yl)5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d] pyrimidin-4-amine (396 mg, 1 mmol) by following the procedure described for Preparation 7. 1H NMR (400 MHz, CD 3 0D): 6 8.75 (s, 1H), 7.58-7.49 (m, 1H), 7.48-7.40 (m, 2H), 7.60 (t, 1H), 4.70 (m, 1H), 4.39 (s, 2H), 3.61 (m, 2H), 3.30 (t, 2H), 3.24-3.12 (m, 2H), 2.99-2.81 (m, 2H), 2.41-2.29 (m, 4H), 2.02-1.91 (m, 4H); MS (ESI) m/z: Calculated: 396.5; Observed: 397.5 (M*+1). 15 Example 34 N-(1-(1-(3-Fluorophenyl)ethyl)piperidin-4-yl)5,6,7,8-tetrahydro-benzo[4,5]thieno [2,3 dlpyrimidin-4-amine, dihydrochloride F N - 2HCI NH 20 The title compound was prepared (213 mg, 91 %) from N-(1-(1-(3-fluorophenyl)ethyl) piperidin-4-yl)5,6,7,8-tetrahydro-benzo[4,5]thieno [2,3-d]pyrimidin-4-amine (200 mg, 0.47 - 75 - WO 2006/034511 PCT/US2005/034862 mmol) by following the procedure described for Preparation 7. 1H NMR (400 MHz,
CD
3 0D) 8 8.67 (s, 1H), 7.57-7.43 (m, 3H), 7.26 (t, 1H), 4.62 (m, 1H), 4.53 (q, 1H), 3.18-3.01 (m, 2H), 2.91 (t, 2H), 2.56-2.39 (m, 4H), 1.96-1.95 (m, 4H), 1.83 (d, 3H); MS (ESI) m/z: Calculated: 410. 5; Observed: 411.2 (M++1). 5 Example 35 N-(1-(1-(3-Fluorophenyl)ethyl)piperidin-4-yl)-5,6-dimethylthieno[2,3-dlpyrimidin-4 amine, dihydrochloride F N - 2HCI NH S Ny 10 The title compound was prepared (149 mg, 84 %) from N-(1-(1-(3 fluorophenyl)ethyl)piperidin-4-yl)-5,6-dimethylthieno[2,3-d]pyrimidin- 4 - amine (150 mg, 0.39 mmol) by following the procedure described for Preparation 7. 'H NMR (400 MHz,
CD
3 0D) 8 8.66 (s, 1H), 7.37-7.22 (m, 1H), 7.17-7.03 (m, 3H), 4.51-4.37 (m, iH), 4.20 (q, 15 1H), 3.70-3.56 (m, 4H), 2.64 (s, 3H), 2.62 (s, 3H), 2.54-2.49 (m, 2H), 2.02-1.89(m, 2H), 1.82 (d, 3H); MS (ESI) m/z: Calculated: 384.5; Observed: 385.2 (M*+l). -76- WO 2006/034511 PCT/US2005/034862 Example 36 N-(1-(1-(3,5-Difluorophenyl)ethyl)piperidin-4-yl)5,6,7,8-tetrahydro-benzo[4,5]thieno [2,3-d]pyrimidin-4-amine, dihydrochloride F
--
bF N - 2HCI NH 5 The title compound was prepared (93 mg, 89 %) from N-(l-(l-(3,5 difluorophenyl)ethyl)piperidin-4-y)5,6,7,8-tetrahydro-benzo[4,5]thieno [2,3-d]pyrimidin -4 amine (90 mg, 0.21 mmol) by following the procedure described for Preparation 7. 'H NMR (400 MHz, CD 3 0D) 6 8.61 (s, 1H), 7.34 (m, 2H), 7.16 (m, 1H), 4.83 (bs, 3H), 4.63 (m, 1H), 10 4.56 (m, 1H), 3.91 (m, 1H), 3.51-2.87 (m, 4H), 2.39-1.85 (m, 11H), 1.81 (d, 3H); MS (ESI) m/z: Calculated: 428. 5; Observed: 429.1 (M*+1). Example 37 N-(1-(2-Fluorobenzyl)piperidin-4-yl)5,6,7,8-tetrahydro-benzo [4,5jthieno[2,3-d] 15 pyrimidin-4-amine, dihydrochloride F N - 2HCI NH The title compound was prepared (208 mg, 88 %) from N-(1-(2-fluorobenzyl)piperidin-4 yl)5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d] pyrimidin-4-amine (200 mg, 0.50 mmol) by 20 following the procedure described for Preparation 7. 1H NMR (400 MHz, CD 3 0D): 3 8.72 (s, 1H), 7.58-7.49 (m, 1H), 7.48-7.40 (m, 2H), 7.60 (t, 1H), 4.70 (m, 1H), 4.39 (s, 2H), 3.61 (m, -77 - WO 2006/034511 PCT/US2005/034862 2H), 3.30 (t, 2H), 3.04-3.12 (m, 2H), 2.89-2.91 (m, 2H), 2.21-2.39 (m, 4H), 1.91-2.02 (m, 4H); MS (ESI) m/z: Calculated: 396.5; Observed: 397.5 (M*+1). Example 38 5 N-(1-(4-Fluorobenzyl)piperidin-4-yl)5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d] pyrimidin-4-amine, dihydrochloride F N NH -2HCI NH The title compound was prepared (132 mg, 89 %) from N-(1-(4-fluorobenzyl)piperidin-4 10 yl)5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d] pyrimidin-4-amine (125 mg, 0.31 mmol) by following the procedure described for Preparation 7. 1H NMR (400 MHz, CD 3 OD) 6 8.71 (s, 1H), 7.54-7.40 (m, 2H), 7.22-7.14 (m, 2H), 4.64 (m, 1H), 4.32 (s, 2H), 3.78-3.65 (m, 2H), 3.59-3.41 (m, 4H), 2.95-2.87 (m, 4H), 2.45-2.31 (m, 4H), 2.15-2.01 (m, 4H); MS (ESI) m/z: Calculated: 396.5; Observed: 397.5 (M*+1). 15 Example 39 3-((4-(5,6,7,8-Tetrahydro-benzo[4,5]thieno[2,3-djpyrimidin-4-ylamino)piperidin-1 yl)methyl)benzonitrile, dihydrochloride CN N - 2HCI NH 20 The title compound was prepared (194 mg, 91 %) from 3-((4-(5,6,7,8-Tetrahydro benzo[4,5]thieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)benzonitrile (180 mg, -78- WO 2006/034511 PCT/US2005/034862 0.44 mmol) by following the procedure described for Preparation 7. 'H NMR (400 MHz,
CD
3 0D) 8 8.70 (s, 1H), 8.02 (s, IH), 7.96 (d, 1H), 7.90 (d, 1H), 7.70(t, 1H), 4.71 (m, 1H), 4.45 (s, 2H), 3.62-3.59 (m, 2H), 3.07 (t, 2H), 2.90 (t, 2H), 2.34-2.15 (m, 4H), 1.98-1.92 (m, 6H); MS (ESI) m/z: Calculated: 403.5; Observed: 404.3 (M*+l). 5 Example 40 N-(1-(1-(3-Fluorophenyl)ethyl)piperidin-4-yl)thieno[2,3-dlpyrimidin-4-amine, dihydrochloride F N - 2HCI NH 10 The title compound was prepared (246 mg, 82 %) from N-(l-(l-(3 fluorophenyl)ethyl)piperidin-4-yl)thieno[2,3-d]pyrimidin- 4 -amine (250 mg, 0.70 mmol) by following the procedure described for Preparation 7. 1H NMR (400 MHz, CD 3 0D): 5 8.70 (s, 1H), 7.64 (d, 1H), 7.59 (d, 1H), 7.22-7.14 (m, 3H), 4.69-4.50 (m, 1H), 4.52 (q, 1H), 3.50-3.37 15 (m, 4H), 2.39-1.85 (d, 2H), 1.80 (d, 3H); MS (ESI) m/z: Calculated: 356.4; Observed: 357.2 (M+1). -79 - WO 2006/034511 PCT/US2005/034862 Example 41 2-(3-Fluorophenyl)-2-(4-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-djpyrimidin-4 ylamino)piperidin-1-yl)propanenitrile, dihydrochloride F NC N - 2HCI NH 5 The title compound was prepared (533 mg, 92 %) from 2-(3-fluorophenyl)-2-[4-((5,6,7,8 tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-ylamino]piperidin-1-yl)propane- nitrile (500 mg, 1.14 mmol) by following the general procedure described for Preparation 7. 'H NMR (400 MHz, CD 3 0D): 8 8.11 (s, 1H), 7.46-7.31 (m, 2H), 7.07 (t, 111), 6.92 (t, 1H), 4.01-3.91 10 (m, 1H), 3.26-3.10 (m, 411), 2.57-2.42 (m, 4H), 2.06-1.99 (m, 4H), 1.44 (s, 3H). MS (ESI) m/z: Calculated: 508.48; Observed: 436.1 (M*+1, free base). Example 42 N-(1-(2-(3-Fluorophenyl)propan-2-yl)piperidin-4-yl)5,6,7,8-tetrahydro-benzo[4,5] 15 thieno[2,3-dJpyrimidin-4-amine, dihydrochloride F N - 2HCI NH The title compound was prepared (109 mg, 91 %) from N-(1-(2-(3-Fluorophenyl)propan-2 yl)piperidin-4-yl)5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d] pyrimidin-4-amine (100 mg, 20 0.235 m. mol) by following the general procedure described for Preparation 7. 1H NMR (400 MHz, CD 3 0D): 8 8.55 (s, 1H), 7.43-7.29 (m, 3H), 7.22 (t, 1H), 4.42 (m, 1H), 3.18-3.01 (m, - 80 - WO 2006/034511 PCT/US2005/034862 2H), 2.91 (t, 2H), 2.56-2.39 (m, 4H), 1.96-1.95 (m, 4H), 1,46 (s, 3H), 1.44 (s, 3H); MS (ESI) m/z: Calculated: 424. 5; Observed: 425.1 (M*+1). Example 43 5 N-(1-(3,5-Difluorobenzyl)piperidin-4-yl)thieno[2,3-d]pyrimidin-4-amine, dihydrochloride F N . 2HCI NH The title compound was prepared (177mg, 82 %) from N-(1-(3,5-Difluorobenzyl)piperidin-4 10 yl)thieno[2,3-d]pyrimidin-4-amine (180mg, 0.5 mmol) following the procedure described in Preparation 7. 'H NMR (400 MHz, CD 3 0D) 5 8.70 (s, 1H), 7.64 (d, 1H), 7.59 (d, 1H), 7.22 7.14 (m, 3H), 4.66 (m, 1H), 3.91 (s, 2H), 3.50-3.37 (m, 4H), 2.39-1.85 (d, 2H); MS (ESI) m/z: Calculated: 360.42; Observed: 361.1 (M*+1). 15 Example 44 N-(1-(3,5-Difluorobenzyl)piperidin-4-yl)-6-isopropylthieno[2,3-dlpyrimidin-4-amine F r&F N NH The title compound was prepared (264 mg, 56 %) from 4-chloro-6-isopropylthieno[2,3 20 d]pyrimidine (0.25 g, 1.18 mmol) and 1-(3,5-difluorobenzyl)piperidin-4-amine (0.4 g, 1.77 mmol) by following the general procedure described for Preparation 6. '1H NMR (400 MHz, -81- WO 2006/034511 PCT/US2005/034862
CDC
3 ): 6 8.40 (s, 1H), 6.90 (m, 211), 6.80 (s, 1H), 6.70 (im, 1H), 4.95 (d, 1H), 4.20 (m, 1H), 3.50 (s, 2H), 3.20-(m, 1H), 2.85 (m, 211), 2.25 (m, 2H), 2.10 (m, 2H), 1.60 (m, 2H), 1.40 (d, 6H). MS (ESI) m/z: Calculated: 402.5; Observed: 403.1 (M*+l). 5 Example 45 N-(1-(3,5-Difluorobenzyl)piperidin-4-yl)-6-chlorothieno[2,3-d]pyrimidin-4-amine F N NH 'S N The title compound was prepared (0.80 g, 51 %) from 6-chloro-N-(piperidin-4-yl)thieno[2,3 10 d]pyrimidin-4-amine dihydrochloride (1.38 g, 4.05 mmol) and 1-(bromomethyl)-3,5 difluorobenzene (0.84 g, 4.05 mmol) by following the general procedure described for Preparation 12. 1H NMR (400 MHz, CDCl 3 ) 6 8.44 (s, 1H), 6.99 (s, 1H), 6.89 (d, 2H), 6.70 (t, 1H), 4.89 (d, 1H), 4.19 (m, 111), 3.50 (s, 2H), 2.86 (d, 211), 2.24 (t, 2H), 2.01 (d, 2H), 1.59 (m, 2H); MS (ESI) m/z: Calculated for C 1 8 HsClF 2
N
4 S, 395.09; Observed: 395.0 (M*+1). 15 Example 46 3-((4-(6-Chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)benzonitrile CN r6 N ci 20 The title compound was prepared (282 mg, 75 %) from 6-chloro-N-(piperidin-4 yl)thieno[2,3-d]pyrimidin-4-amine dihydrochloride (333 mg, 0.98 mmol) and 3 -82- WO 2006/034511 PCT/US2005/034862 (bromomethyl)benzonitrile (191 mg, 0.98 mmol) by following the general procedure described for Preparation 12. 'H NMR (400 MHz, CDC1 3 ) 5 8.44 (s, 1H), 7.68 (s, 1H), 7.57 (d, 211), 7.43 (t, 1H), 7.00 (s, 1H), 4.88 (d, 1H), 4.20 (m, 111), 3.56 (s, 2H), 2.85 (d, 2H), 2.25 (dt, 2H), 2.12 (d, 211), 1.59 (m, 2H); MS (ESI) m/z: Calculated for C 19
H
19 C1N 5 S, 384.1; 5 Observed: 384.2 (M*+l). Example 47 5-((4-(6-Chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)- 2 -fluoro benzonitrile CN F N NH 10 C1 The title compound was prepared (392 mg, 41 %) from 6-chloro-N-(piperidin-4-yl)thieno[2,3 d]pyrimidin-4-amine dihydrochloride (655 mg, 2.4 mmol) and 2-fluoro-5-formylbenzonitrile (399 mg, 2.7 mmol) by following the general procedure described for Preparation 11. 1H 15 NMR (400 MHz, CDC1 3 ) 6 8.43 (s, 1H), 7.63 (m, 1H), 7.55 (m, 1H), 7.16 (m, 111), 7.00 (s, 1H), 4.93 (d, 111), 4.19 (m, 1H), 3.50 (s, 211), 2.83 (d, 2H), 2.23 (dt, 211), 2.10 (d, 211), 1.59 (m, 2H); MS (ESI) m/z: Calculated for C 1 9
H
18 C1FN 5 S, 402.1; Observed: 402.2 (M*+l). - 83 - WO 2006/034511 PCT/US2005/034862 Example 48 N-(1-(3-Fluorobenzyl)piperidin-4-yl)-6-chloro-5-methylthieno[2,3-dpyrimidin-4-amine F N NH cI 5 The title compound was prepared (119 mg, 91 %) from 6-chloro-5-methyl-N-(piperidin-4 yl)thieno[2,3-d]pyrimidin-4-amine (95 mg, 0.336 mmol) and 1-(bromomethyl)-3 fluorobenzene (70 mg, 0.37 mmol) by following the general procedure described for Preparation 12. 'H NMR (400 MHz, CDC1 3 ): 8 8.40 (s, 1H), 7.30 (m, 1H), 7.10 (m, 2H), 6.95 (m, 1H), 5.30 (d, 1H), 4.05 (m, 1H), 3.55 (s, 2H), 2.95 (m, 2H), 2.50 (s, 3H), 2.25 (m, 2H), 10 2.15 (m, 2H), 1.60 (m, 2H). MS (ESI) m/z: Calculated: 390.91; Observed: 391.2 (M*+1). Example 49 2-((4-(6-Chloro-5-methylthieno[2,3-djpyrimidin-4-ylamino)piperidin-1-yl)methyl) benzonitrile Nc N NH 15 cl The title compound was prepared (100 mg, 75 %) from 6-chloro-5-methyl-N-(piperidin-4 yl)thieno[2,3-d]pyrimidin-4-amine (95 mg, 0.336 mmol) and 2-(bromomethyl) benzonitrile (73 mg, 0.37 mmol) by following the general procedure described for Preparation 12. 1H -84 - WO 2006/034511 PCT/US2005/034862 NMR (400 MHz, CDC1 3 ): 6 8.40 (s, 1H), 7.65 (d, 1H), 7.55 (m, 2H), 7. 35 (m, 1H), 5.30 (d, 1H), 4.25 (m, 1H), 3.7 (s, 2H), 2.85 (m, 2H), 2.50 (s, 3H), 2.40 (m, 2H), 2.10 (m, 2H), 1.40 (m, 2H). MS (ESI) m/z: Calculated: 397.92; Observed: 398.2 (M*+1). 5 Example 50 N-(1-(2-Methoxybenzyl)piperidin-4-yl)-6-chloro-5-methylthieno[2,3-dlpyrimidin-4 amine MeO N NH ci N 10 The title compound was prepared (115 mg, 85 %) from 6-chloro-5-methyl-N-(piperidin-4 yl)thieno[2,3-d]pyrimidin-4-amine (95 mg, 0.336 mmol) and 1-(chloromethyl)-2 methoxybenzene (58 mg, 0.37 mmol) by following the general procedure described for Preparation 12. 'H NMR (400 MHz, CDC1 3 ): 5 8.40 (s, 1H), 7.35 (m, 1H), 7.25 (m, 1H), 6.95 (m, 1H), 6.85 (d, 1H), 5.35 (d, 1H), 4.25 (m, 1H), 3.85 (s, 3H), 3.60 (s, 2H), 2.90 (m, 2H), 15 2.50 (s, 3H), 2.35 (m, 2H), 2.10 (m, 2H), 1.40 (m, 2H). MS (ESI) m/z: Calculated: 402.94; Observed: 403.2 (M*+1). -85 - WO 2006/034511 PCT/US2005/034862 Example 51 N-(1-(3-Fluorobenzyl)piperidin-4-yl)-6-chlorothieno[2,3-dlpyrimidin-4-amine F N N NH ci 5 The title compound was prepared (58 mg, 53 %) from 6-chloro-N-(piperidin-4-yl)thieno[2,3 d]pyrimidin-4-amine dihydrochloride (100 mg, 0.29 mmol) and 1-(bromomethyl)-3 fluorobenzene (55 mg, 0.29 mmol) by following the general procedure described for Preparation 12. 1 H NMR (400 MHz, CDCl 3 ) 6 8.44 (s, 1H), 7.28 (dd, 1H), 7.09 (d, 1H), 7.08 (d, 1H), 6.98 (s, 1H), 6.95 (dt, 1H), 4.85 (d, 1H), 4.19 (m, 1H), 3.49 (s, 2H), 2.87 (d, 2H), 10 2.23 (dt, 2H), 2.09 (d, 2H), 1.60 (m, 2H); MS (ESI) m/z: Calculated for C 18
H
19 C1FN 4 S, 377.1; Observed: 377.2 (M*+l). Example 52 N-(1-(2-Fluorobenzyl)piperidin-4-yl)-6-chlorothieno[2,3-djpyrimidin-4-amine N N N 15 cl The title compound was prepared (65 mg, 37 %) from 6-chloro-N-(piperidin-4-yl)thieno[2,3 d]pyrimidin-4-amine dihydrochloride (160 mg, 0.47 mmol) and 2-fluorobenzaldehyde (58 mg, 0.47 mmol) by following the general procedure described for Preparation 11. 'H NMR (400 MHz, CDCl 3 ) 8 8.43 (s, 1H), 7.37 (t, 1H), 7.25 (m, 1H), 7.13 (t, 1H), 7.07 (t, 1H), 6.97 -86- WO 2006/034511 PCT/US2005/034862 (s, 1H), 4.85 (d, 1H), 4.16 (m, 1H), 3.63 (s, 2H), 2.92 (d, 2H), 2.29 (t, 2H), 2.08 (d, 2H), 1.61 (m, 2H); MS (ESI) m/z: Calculated for CiH1 9 C1FN 4 S, 377.1; Observed: 377.2 (M*+1). Example 53 5 Methyl 3-((4-(6-chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl) benzoate
CO
2 CHa N
NH
The title compound was prepared (430 mg, 33 %) from 6-chloro-N-(piperidin-4-yl)thieno[2,3 d]pyrimidin-4-amine (848 mg, 3.15 mmol) and methyl 3-(bromomethyl)benzoate (867 mg, 10 3.76 mmol) by following the general procedure described for Preparation 12. 'H NMR (400 MHz, CDC13) 8 8.44 (s, 1H), 8.00 (s, 1H), 7.95 (d, 1H), 7.54 (d, 1H), 7.41 (t, 1H), 6.98 (s, 1H), 4.83 (d, 1H), 4.18 (m, 1H), 3.93 (s, 3H), 3.58 (s, 2H), 2.87 (d, 2H), 2.24 (dt, 2H), 2.11 (d, 2H), 1.59 (m, 2H); MS (ESI) m/z: Calculated for C 20
H
22 C1N 4 0 2 S, 417.1; Observed: 417.2 (M*+1). 15 Example 54 3-((4-(6-Chlorothieno(2,3-dlpyrimidin-4-ylamino)piperidin-1-yl)methyl)benzoic acid
CO
2 H NH CI Methyl 3-((4-(6-chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)benzoate (127 20 mg, 0.3 mmol) was heated in a 25 % MeOH-H 2 0 solution at 90 *C for 3 h in the presence of LiOH-H 2 O (12.7 mg, 0.3 mmol). The solvent was removed under reduced pressure; the -87 - WO 2006/034511 PCT/US2005/034862 residue was dissolved in MeOH and filtered. The filtrate was evaporated to collect product in 79 % yield (97 mg). 'H NMR (400 MHz, CD 3 0D) 8 8.27 (s, 1H), 7.92 (s, 1H), 7.85 (d, 111), 7.50 (s, 1H), 7.42 (d, 1H), 7.33 (t, 1H), 4.11 (m, 1H), 3.59 (s, 2H), 2.98 (d, 2H), 2.20 (t, 2H), 2.00 (d, 2H), 1.68 (m, 2H); MS (ESI) m/z: Calculated for C1 9
H
20 C1N 4 0 2 S, 403.1; Observed: 5 403.2 (M*+l). Example 55 3-((4-(6-Chlorothieno[2,3-dlpyrimidin-4-ylamino)piperidin-1-yl)methyl)benzamide cONH 2 N NH CI 10 3-((4-(6-Chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)benzoic acid (60 mg, 0.15 mmol) was heated in 5 mL of thionylchloride at 80 'C for 3h. The reaction was cooled to room temperature and thionylchloride was removed by rotary evaporation; the residue was dissolved in 10 mL of DCM and NH 3 (g) was bubbled through at 0 "C for lh. After removal of solvent the crude product was purified by silica chromatography in 5 % MeOH-DCM to 15 obtain the title product (14 mg, 23 %). 'H NMR (400 MHz, CD 3 0D) 8 8.30 (s, 1H), 7.98 (s, 1H), 7.86 (m, 1H), 7.66 (d, 1H), 754 (m, 2H), 4.26 (m, 1H), 3.97 (s, 2H), 3.22 (d, 2H), 2.64 (m, 2H), 2.13 (d, 2H), 1.85 (m, 211); MS (ESI) m/z: Calculated for C1 9
H
21 C1N 5 0S, 402.1; Observed: 402.2 (M*+l). -88- WO 2006/034511 PCT/US2005/034862 Example 56 N-(1-(1-(3-Fluorophenyl)ethyl)piperidin-4-yl)-6-isobutylthieno(2,3-d]pyrimidin-4-amine F N NH The title compound was prepared (291 mg, 64 %) from 4-chloro-6-isobutylthieno[2,3 5 d]pyrimidine (250 mg, 1.1 mmol) and 1-(1-(3-fluorophenyl)ethyl)piperidin-4-amine (0.49 mg, 2.2 mmol) by following the general procedure described for Preparation 6. 1H NMR (400 MHz, CDC1 3 ): 8 8.40 (s, 1H), 7.25 (m, 1H), 7.05 (in, 2H), 6.95 (m, 1H), 6.75 (s, 111), 5.00 (m, 1H), 4.10 (m, 111), 3.45 (m, 1H), 3.00 (d, 1H), 2.80 (d, 1H), 2.70 (d, 2H), 1.85-2.25 (m, 5H), 1.45-1.65 (m, 2H), 1.35 (d, 3H), 0.95 (d, 6H). MS (ESI) m/z: Calculated: 412.57; 10 Observed: 413.3 (M*+1). Example 57 N-(1-(1-(3,5-Difluorophenyl)ethyl)piperidin-4-yl)-6-isobutylthieno[2,3-djpyrimidin-4 amine F Y&F N 15 SNy The title compound was prepared (127 mg, 69 %) from 6-isobutyl-N-(piperidin-4 yl)thieno[2,3-d]pyrimidin-4-amine (125 mg, 0.43 mmol) and 1-(3,5-difluorophenyl)ethyl methanesulfonate (243 mg, 1.03 mmol) by following the general procedure described for Preparation 12. 'H NMR (400 MHz, CDC1 3 ): S 8.40 (s, 1H), 6.90 (m, 2H), 6.75 (s, 1H), 6.70 - 89 - WO 2006/034511 PCT/US2005/034862 (m, 1H), 4.95 (d, 1H), 4.15 (m, 1H), 3.45 (m, 1H), 2.95 (m, 1H), 2.80 (m, 1H), 2.70 (d, 2H), 2.20 (m, 4H), 1.95 (m, 1H), 1.55 (m, 2H), 1.35 (d, 3H), 0.95 (d, 6H). MS (ESI) m/z: Calculated: 430.56; Observed: 431.1 (M*+1). 5 Example 58 2-(3-Fluorophenyl)-2-(4-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl amino)piperidin-1-yl)propanenitrile F NC+Jb N NH / N S N 10 To a mixture of N-(piperidin-4-yl)-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d] pyrimidin-4 amine (2.86 g, 10 mmol) and 3-fluorophenylacetophenone (1.38 g, 10 mmol) in dry DCM (25 mL) was added titanium isopropoxide (2.85 g, 10 m.mol) at room temperature and stirred for 24 h. 1 M solution of diethylaluminumcyanide in toluene (1.2 mL, 10mmol) was added to the above solution and the mixture was allowed to stir for 24h. The reaction was quenched by the 15 addition of saturated aq. NaHCO 3 solution (15 mL) and the organic layer was separated, dried and concentrated under reduced pressure to get the title compound (4.3 g, 100 %) as pale yellow powder. 'H NMR (400 MHz, CDC1 3 ): 8 8.01 (s, 1H), 7.35-7.24 (m, 2H), 6.99 (t, 1H), 6.78 (t, 1H), 4.21 (brs, 1H, NH), 3.91-3.86 (m, 1H), 3.11-3.03 (m, 2H), 2.91 (t, 2H), 2.49 2.27 (m, 4H), 2.00-1.92 (m, 4H), 1.42 (s, 3H). MS (ESI) m/z: Calculated: 435.56; Observed: 20 436.2 (M*+1). - 90 - WO 2006/034511 PCT/US2005/034862 Example 59 N-(1-(2-(3-Fluorophenyl)propan-2-yl)piperidin-4-yl)-5,6,7,8-tetrahydro-benzo[4,5] thieno[2,3-dpyrimidin-4-amine F N NH S N 5 2-(3-Fluorophenyl)-2-(4-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-y1 amino)piperidin-1-yl)propanenitrile (435 mg, 1 mmol) was dissolved in dry THF (20 mL) and was added 1 M solution of MeMgBr in butyl ether (1.7 mL, 12 mmol) at 0* C The reaction was stirred at room temperature for 3 h. The mixture was poured into a cold saturated NIH 4 C1 solution (10 mL) and extracted with DCM (2x25 mL). The organic layer was washed with 10 brine (20 mL), dried over Na 2
SO
4 and evaporated under reduced pressure. Purification by silica chromatography (2 % MeOH-DCM) afforded the title compound (331 mg, 78 %). 'H NMR (400 MHz, CDC1 3 ): 8 7.94 (s, 1H), 7.29-7.21 (m, 3H), 6.83 (t, 1H), 3.81-3.72 (m, 1H), 3.08-3.01 (m, 2H), 2.81 (t, 2H), 2.36-2.20 (m, 4H), 1.96-1.95 (m, 4H), 1,31 (s, 3H), 1.30 (s, 3H). MS (ESI) m/z: Calculated: 424. 5; Observed: 425.1 (M*+1). 15 Example 60 6-Chloro-N-(1-((pyridin-3-yl)methyl)piperidin-4-yl)thieno[2,3-d]pyrimidin-4-amine N N NH ci N The title compound was prepared (338 mg, 94 %) from 6-chloro-N-(piperidin-4 20 yl)thieno[2,3-d]pyrimidin-4-amine (341 mg, 1.0 mmol) and 3-pyridinecarboxaldehyde (107 -91- WO 2006/034511 PCT/US2005/034862 mg, 1.0 mmol) by following the general procedure described for Preparation 11. 1H NMR (400 MHz, CDC1 3 ): 8.57 (d, 1H), 8.52 (dd, 1H), 8.43 (s, 1H), 7.68-7.65 (m, 1H), 7.29 (d, 1H), 7.02 (s, 1H), 5.14 (d, 1H), 4.21-4.17 (m, 1H), 3.54 (s, 2H), 2.88 (d, 2H), 2.43 (t, 2H), 2.10 2.07 (m, 2H), 1.62-1.52 (m, 2H); MS (ESI) m/z: Calculated: 359.88; Observed: 360.2 5 (M*+1). Example 61 N-(1-(3,5-Difluorobenzyl)piperidin-4-yl)-6-chloro-5-(4-fluorophenyl)thieno[2,3-d] pyrimidin-4-amine F F F N F F NH 10 c The title compound was prepared (140 mg, 49 %) from 4,6-dichloro-5-(4 fluorophenyl)thieno[2,3-d]pyrimidine (175 Ing, 0.59 mmol) and 1-(3,5 difluorobenzyl)piperidin-4-amine (170 mg, 0.7 mmol) by following the general procedure 15 described for Preparation 6. 1H NMR (400 MHz, CDC1 3 ): 5 8.45 (s, 1H), 7.45 (m, 2H), 7.30 (m, 2H), 6.85 (m, 2H), 6.65 (m, 1H), 4.65 (m, 1H), 4.05 (bs, 1H), 3.40 (s, 2H), 2.40 (m, 2H), 2.15 (m, 2H), 1.85 (m, 2H), 1.15 (m, 1H). MS (ESI) m/z: Calculated: 488.1; Observed: 489.2 (M*+1). - 92 - WO 2006/034511 PCT/US2005/034862 Example 62 6-Chloro-N-(1-((pyrimidin-5-yl)methyl)piperidin-4-yl)thieno[2,3-d]pyrimidin-4-amine N N NH ci N The title compound was prepared (119 mg, 45 %) from 6-chloro-N-(piperidin-4 5 yl)thieno[2,3-d]pyrimidin-4-amine (200 mg, 0.74 mmol) and pyrimidine-5-carbaldehyde (80 mg, 0.74 mmol) by following the general procedure described for Preparation 11. IH NMR (400 MHz, CDC1 3 ): 6 9.05 (s, 1H), 8.65 (s, 2H), 8.35 (s, 1H), 7.00 (s, 1H), 5.50 (bs, 1H), 4.10 (m, 1H), 3.45 (s, 2H), 2.80 (m, 2H), 2.20 (m, 2H), 2.00 (m, 2H), 1.50 (m, 2H). MS (ESI) m/z: Calculated: 360.09; Observed: 361.1 (M*+1). 10 Example 63 3-((4-(6-Chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)- 4 fluorobenzonitrile ON N F NH 15 The title compound was prepared (119 mg, 45 %) from 6-chloro-N-(piperidin-4 yl)thieno[2,3-d]pyrimidin-4-amine (150 mg, 0.56 mmol) and 4-fluoro-3-formylbenzonitrile (83 mg, 0.56 mmol) by following the general procedure described for Preparation 11. 1H NMR (400 MHz, CDC1 3 ): S 8.45 (s, 1H), 7.85 (m, 1H), 7.60 (m, 1H), 7.15 (t, 1H), 7.00 (s, 1H), 5.00 (d, 1H), 4.20 (m, 1H), 3.60 (s, 2H), 2.90 (m, 2H), 2.35 (m, 2H), 2.15 (m, 2H), 1.60 20 (i, 2H). MS (ESI) m/z: Calculated: 401.09; Observed: 402.1 (M*+1). - 93 - WO 2006/034511 PCT/US2005/034862 Example 64 N-(1-(3-Chlorobenzyl)piperidin-4-yl)-6-chlorothieno[2,3-d]pyrimidin-4-amine CI N NH 5 The title compound was prepared (70 mg, 43 %) from 6-chloro-N-(piperidin-4-yl)thieno[2,3 d]pyrimidin-4-amine (110 mg, 0.41 mmol) and 1-(bromomethyl)-3-chlorobenzene (93 mg, 0.45 mmol) by following the general procedure described for Preparation 12. 1H NMR (400 MHz, CDC1 3 ): 8 8.45 (s, 1H), 7.35 (s, 1H), 7.10 (m, 4H), 5.25 (d, 1H), 4.20 (m, 1H), 3.50 (s, 2H), 2.90 (m, 2H), 2.35 (m, 2H), 2.10 (m, 2H), 1.60 (m, 2H). MS (ESI) m/z: Calculated: 10 392.06; Observed: 393.2 (M*+l). Example 65 4-N-(3-(1-(3-Fluorophenyl)ethylamino) propylamino)-5,6,7,8-tetrahydro-benzo[4,51 thieno[2,3-dipyrimidine. F HN NH 15 The title compound was prepared (291 mg, 100 %) from 5,6,7,8-tetrahydro-benzo[4,5] thieno[2,3-d]pyrimidine (172 mg, 0.76 mmol) and N-1-(1-(3-fluorophenyl)ethyl)propane-1,3 diamine (150 mg, 0.76 mmol) by following the general procedure described for Preparation 6. 'H NMR (400 MHz, CDC1 3 ): 8 8.35 (s, 1H), 7.25 (m, 1H), 7.05 (m, 2H), 6.95 (m, 1H), 20 5.90 (bs, 1H), 3.60-3.80 (m, 3H), 2.85 (m, 2H), 2.80 (m, 2H), 2.70 (m, 1H), 2.55 (m, 1H), -94- WO 2006/034511 PCT/US2005/034862 1.75- 1.95 (m, 6H), 1.40 (d, 3H). MS (ESI) m/z: Calculated: 384.51; Observed: 385.1 (M*+1). Example 66 5 4-N-(3-(3-Fluorobenzyl amino) propylamino)-5,6,7,8-tetrahydro-benzo[4,5]thieno [2,3 djpyrimidine F N HN NH The title compound was prepared (145 mg, 69 %) from 3-N-(5,6,7,8-tetrahydro benzo[4,5]thieno[2,3-d]pyrimidine-4-y)-1,3-diaminopropane (150 mg, 0.57 mmol) and 3 10 fluorobenzaldehyde (70 mg, 0.57 mmol) by following the general procedure described for Preparation 3. 'H NMR (400 MHz, CDC1 3 ): 5 8.40 (s, 1H), 7.30 (m, 1H), 7.05 (m, 2H), 6.95 (m, 1H), 6.20 (bs, 1H), 3.80 (s, 211), 3.70 (m, 2H), 2.80 (m, 6H), 1.80 (m, 6H), 1.70 (bs, 1H). MS (ESI) m/z: Calculated: 370.49; Observed: 371.1 (M+1). 15 Example 67 N-(3-(1-(3-Fluorophenyl)ethylamino)propyl)-6-isobutylthieno[2,3-djpyrimidin-4-amine F N HN NH S N The title compound was prepared (157 mg, 62 %) from 4-chloro-6-isobutylthieno[2,3 d]pyrimidine (150 mg, 0.662 mmol) and N-1-(1-(3-fluorophenyl)ethyl)propane-1,3-diamine - 95 - WO 2006/034511 PCT/US2005/034862 (130 mg, 0.662 mmol) by following the general procedure described for Preparation 6. 1H NMR (400 MHz, CDC1 3 ): 8 8.40 (s, 1H), 7.40 (m, 1H), 7.05 (m, 2H), 6.95 (m, 1H), 6.75 (bs, 1H), 6.70 (s, 1H), 3.85 (m, 1H), 3.70 (m, 2H), 2.80 (m, 1H), 2.70 (d, 2H), 2.65 (m, 1H), 1.95 (m, 1H), 1.85 (m, 2H), 1.45 (d, 3H), 0.95 (d, 6H). MS (ESI) m/z: Calculated: 386.53; 5 Observed: 387.1 (M*+1). Example 68 N-(1-(1-(2,4,6-Trifluorophenyl)ethyl)piperidin-4-yl)-6-isobutylthieno[2,3-dI pyrimidin 4-amine F F F N F NH 10 The title compound was prepared (110 mg, 55 %) from 6-isobutyl-N-(piperidin-4 yl)thieno[2,3-d]pyrimidin-4-amine (130 mg, 0.45 mmol) and 1-(2,4,6-trifluorophenyl)ethyl methanesulfonate (228 mg, 0.9 mmol) by following the general procedure described for Preparation 12. 'H NMR (400 MHz, CDC1 3 ): 6 8.40 (s, 1H), 6.75 (s, 1H), 6.65 (m, 2H), 4.95 15 (d, 1H), 4.15 9q, 1H), 4.05 (m, 1H), 3.00 (m, 2H), 2.70 (d, 2H), 2.20 (m, 1H), 2.10 (m, 2H), 1.90 (m, 1H), 1.55 (d, 3H), 1.25-1.65 (m, 2H), 0.95 (d, 6H). MS (ESI) m/z: Calculated: 448.55; Observed: 449.2 (M*+1). -96- WO 2006/034511 PCT/US2005/034862 Example 69 N-(1-(1-(2,6-Difluorophenyl)ethyl)piperidin-4-yl)-6-isobutylthieno[2,3-d]pyrimidin-4 amine F N F NH 5 The title compound was prepared (104 mg, 54 %) from 6-isobutyl-N-(piperidin-4 yl)thieno[2,3-d]pyrimidin-4-amine (130 mg, 0.45 mmol) and 1-(2,6-difluorophenyl)ethyl methanesulfonate (211 mg, 0.9 mmol) by following the general procedure described for Preparation 12. IH NMR (400 MHz, CDC1 3 ): 8 8.40 (s, 1H), 7.10 (m, 1H), 6.90 (m,2H), 6.75 (s, 1H), 4.90 (d, 1H), 4.25 (q, 1H), 4.05 (m, 1H), 3.05 (m, 2H), 2.70 (d, 2H), 2.15 (m, 1H), 10 2.10 (m, 3H), 1.95 (m, 1H), 1.40 (d, 3H), 1.45-1.65 (m, 2H), 0.95 (d, 6H). MS (ESI) m/z: Calculated: 430.56; Observed: 431.2 (M*+l). Example 70 N-(1-(Cyclohexylmethyl)piperidin-4-yl)-5,6-dimethylthieno[2,3-dIpyrimidin-4-amine N NH 15 The title compound was prepared (81 mg, 28 %) from 4-chloro-5,6-dimethylthieno[2,3 d]pyrimidine (325 mg, 1.21 mmol) and 1-(cyclohexylmethyl)piperidin-4-amine dihydrochloride (160 mg, 0.81 mmol) by following the general procedure described for Preparation 6. 1H NMR (400 MHz, CDC1 3 ) 8 8.36 (s, 1H), 5.36 (d, 1H), 4.22 (m, 1H), 2.80 20 (d, 2H), 2.44 (s, 3H), 2.41 (s, 3H), 2.21-2.09 (m, 7H), 1.79-1.45 (m, 6H), 1.20 (m, 4H), 0.88 (m, 2H); MS (ESI) m/z: Calculated for C 20
H
31
N
4 S, 359.23; Observed: 359.2 (M*+1). -97 - WO 2006/034511 PCT/US2005/034862 Example 71 3-((4-(6-Chlorothieno[2,3-djpyrimidin-4-ylamino)piperidin-1-yl)methyl)-N-methyl benzamide NH N NH ci N 5 3-((4-(6-Chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)benzoic acid (118 mg, 0.29 mmol) was heated in 3 mL of thionylchloride at 80 *C for 3h. The reaction was cooled to room temperature and the thionylchloride was removed under reduced pressure. The residue obtained was dissolved in 25 mL of DCM followed by addition of methylamine hydrochloride (60 mg, 0.88 mmol) and DIEA (227 mg, 1.76 mmol). The reaction was 10 allowed to stir at room temperature for 16 h and washed with 25 mL of water. The DCM layer was dried over Na 2
SO
4 and evaporated under reduced pressure; the crude product was purified by silica chromatography in 5 % MeOH-DCM to obtain 58 mg of product in 48 % yield. 1H NMR (400 MHz, CDCl 3 ) 8 8.43 (s, 1H), 7.76 (s, 1H), 7.65 (d, 1H), 7.45 (d, lH), 7.39 (t, 1H), 7.02 (s, 1H), 6.22 (bs, 1H), 4.96 (bs, 1H), 4.18 (m, 1H), 3.57 (s, 2H), 3.03 (d, 15 3H), 2.87 (d, 2H), 2.23 (t, 2H), 2.08 (d, 2H), 1.59 (m, 2H); MS (ESI) m/z: Calculated for
C
20
H
23
CN
5 OS, 416.13; Observed: 416.2 (M*+1). - 98 - WO 2006/034511 PCT/US2005/034862 Example 72 3-((4-(6-Chlorothieno[2,3-djpyrimidin-4-ylamino)piperidin-1-yl)methyl)-N,N dimethylbenzamide o N, N NH CI 5 3-((4-(6-Chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)benzoic acid (104 mg, 0.26 mmol) was heated in 3 mL of thionylchloride at 80 *C for 3h. The reaction was cooled to room temperature and the thionylchloride was removed under reduced pressure. The residue obtained was dissolved in 25 mL of DCM followed by addition of dimethylamine hydrochloride (63 mg, 0.77 mmol) and DIEA (200 mg, 1.55 mmol). The reaction was 10 allowed to stir at room temperature for 16 h and extracted with 25 mL of water. The DCM layer was dried over Na 2
SO
4 and evaporated under reduced pressure; the crude product was purified by silica chromatography in 5 % MeOH-DCM to obtain 67 mg of product in 60 % yield. 1H NMR (400 MHz, CDCl 3 ) 3 8.43 (s, 1H), 7.33 (m, 4H), 7.03 (s, 1H), 5.03 (d, lH), 4.17 (m, 1H), 3.55 (s, 2H), 3.13 (s, 3H), 2.99 (s, 3H), 2.86 (d, 2H), 2.22 (t, 2H), 2.19 (d, 2H), 15 1.55 (dq, 2H); MS (ESI) m/z: Calculated for C 21
H
2 5 ClN 5 0S, 430.15; Observed: 430.2 (M+1). - 99 - WO 2006/034511 PCT/US2005/034862 Example 73 N-(1-(3-(Methylsulfonyl)benzyl)piperidin-4-yl)-6-chlorothieno[2,3-d]pyrimidin-4-amine
SO
2 Me N N NH The title compound was prepared (70 mg, 43%) from 6-chloro-N-(piperidin-4-y)thieno[2,3 5 d]pyrimidin-4-amine (100 mg, 0.37 mmol) and 1-(bromomethyl)-3-(methylsulfonyl)benzene (139 mg, 0.55 mmol) by following the general procedure described for Preparation 12. IH NMR (400 MHz, CDC13): S 8.40 (s, 1H), 7.95 (s, 1H), 7.80 (d, 1H), 7.60 (d, 1H), 7.50 (t, 1H), 7.05 (s, 1H), 5.25 (d, 1H), 4.20 (m, 1H), 3.60 (s, 2H), 3.05 (s, 3H), 2.80 (m, 2H), 2.20 (m, 2H), 2.05 (m, 2H), 1.60 (m, 2H). MS (ESI) m/z: Calculated: 436.98; Observed: 437.2 10 (M*+l). Example 74 N-(1-(3-Trifluoromethyl)benzyl)piperidin-4-yl)-6-chlorothieno[2,3-dpyrimidin-4-amine
CF
3 N cl 15 The title compound was prepared (25 mg, 49 %) from 6-chloro-N-(piperidin-4-y)thieno[2,3 d]pyrimidin-4-amine dihydrochloride (32 mg, 0.12 mmol) and 3 (trifluoromethyl)benzylbromide (34 mg, 0.14 mmol) by following the general procedure -100- WO 2006/034511 PCT/US2005/034862 described for Preparation 12. '1H NMR (400 MHz, CDC1 3 ): 6 8.43 (s, 1H), 7.65 (s, 1H) 7.57 (m, 2H), 7.44 (m, 1H), 6.97 (s, 1H), 4.96 (d, 1H), 4.22 (m, 1H), 3.61 (s, 2H), 2.89 (m, 2H), 2.36-2.11 (m, 4H), 1.62 (m, 2H). MS (ESI) m/z: Calculated: 426. 2; Observed: 427.2 (M*+1). 5 Example 75 N-(1-(3-Trifluoromethylsulfonyl)benzyl)piperidin-4-yl)-6-chlorothieno[2,3-d] pyrimidin 4-amine 0- .CF3 NH cl 10 The title compound was prepared (153 mg, 60 %) from 6-chloro-N-(piperidin-4-yl)thieno[2,3 d]pyrimidin-4-amine dihydrochloride (140 mg, 0.52 mmol) and 1-(bromomethyl)-3 (trifluoromethylsulfonyl)benzene (190 mg, 0.63 mmol) by following the general procedure described for Preparation 12. 1H NMR (400 MHz, CDC1 3 ): 6 8.41 (s, 1H), 8.06 (s, 1H) 7.94 (d, 1H), 7.81 (d, 1H), 7.63 (t, 1H), 7.02 (s, 1H), 5.09 (d, 1H), 4.22 (m, 1H), 3.61 (s, 2H), 2.82 15 (m, 2H), 2.33 (m, 2H), 2.16 (m, 2H), 1.61 (m, 2H). MS (ESI) m/z: Calculated: 490. 2; Observed: 491.2 (M*+1). - 101 - WO 2006/034511 PCT/US2005/034862 Example 76 {1-[1-(3-Fluoro-phenyl)-ethyl]-4-methyl-piperidin-4-yl}-(5,6,7,8-tetrahydro-benzo [4,5]thieno[2,3-dlpyrimidin-4-yl)-amine F N 5 The title compound was prepared (97 mg, 81 %) from (4-methyl-piperidin-4-yl)-(5,6,7,8 tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine (150 mg, 0.28 mmol) and methanesulfonic acid 1-(3-fluoro-phenyl)-ethyl ester (61.1mg, 0.28 mmol) by following the procedure described for preparation 12. 1H NMR (400 MHz, CDCl 3 ): 3 (ppm) 8.38 (s, 1H), 7.20 (s, 1H), 6.89-6.79 (m, 3H), 3.91 (q, 1H), 2.80-2.74(m, 4H), 2.20-2.09(M, 2H), 1.90 (m, 10 2H), 1.89-1.85 (m, 4H), 1.55 (m, 4H), 1.31 (s, 3H); MS (SEI): m/z: Calculated: 424.2; Observed: 425.2 (M*+1). Example 77 4-(4-(3-(4-Fluorophenyl)propyl)piperazine-1-yl)(5,6,7,8-tetrahydro-benzo[4,5]thieno 15 [2,3-djpyrimidine F N HN F S N) The title compound was prepared (150 mg, 49 %) from N-(piperidine-4-yl)(5,6,7,8 Tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidine bis(trifluoroacetic acid) (370 mg, 0.72 mmol) and 1-(2,6-difluorophenyl)ethyl methanesulfonate (190 mg, 0.79 mmol) by following the 20 general procedure described for Preparation 12. 1 H NMR (400 MHz, CDCl 3 ): 8 8.30 (s, 1H), 7.26-7.18 (m, 1H), 6.80 (t, 2H), 5.17 (d, 1H), 4.24 (q, 1H), 4.15-4.11 (m, 1H), 2.90 (t, 2H), -102- WO 2006/034511 PCT/US2005/034862 2.70 (t, 2H), 2.36-2.11 (m, 4H), 2.09-1.87 (m, 4H), 1.59 (d, 3H). MS (ESI) m/z: Calculated: 428. 5; Observed: 429.1 (M+l). Example 78 5 6-Chloro-5-methyl-N-(piperidin-4-yl)thieno[2,3-djpyrimidin-4-amine H N NH C'S N3 The title compound was prepared (289 mg, 64 %) from tert-butyl 4-(6-chloro-5 methylthieno[2,3-d]pyrimidin-4-ylamino)piperidine-l-carboxylate (611 mg, 1.6 mmol) by following the general procedure described for Preparation 10. 'H NMR (400 MHz, CDC1 3 ): 8 10 8.40 (s, 1H), 5.30 (d, 1H), 4.25 (m, 1H), 3.15 (m, 2H), 2.85 (m, 2H), 2.55 (s, 3H), 2.15 (m, 2H), 1.95 (bs, 1H), 1.45 (m, 2H). Example 79 3-(5,6,7,8-Tetrahydro-benzo[4,5]thieno [2,3-d]pyrimidine-4-yl)-1,3-diaminopropane
H
2 N NH 15 N A solution of 4-chloro-5,6,7,8-tetrahydro-benzo[4,5]thieno [2,3-d]pyrimidine (0.5 g, 2.43 m. mol) in 1,3-diaminepropane (5 ml) was heated at 80 'C for 1 day. It was cooled to room temperature and then diluted with water (50 mL). The clear solution was cooled at 0 *C for overnight. The resulting solid was filtered and dried to get the title compound (0.3 g, 52 %) as 20 a brown color solid. 'H NMR (400 MHz, CD 3 0D): 8 8.20 (s, 1H), 3.65 (t, 2H), 2.95 (m, 2H), 2.80 (m, 4H), 1.80-2.00 (m, 6H). MS (ESI) m/z: Calculated: 262.37; Observed: 263.1 (M*+1). -103 - WO 2006/034511 PCT/US2005/034862 Example 80 6-Isobutyl-N-(piperidin-4-yl)thieno[2,3-d]pyrimidin-4-amine H N N3 The title compound was prepared (628 mg, 94 %) from tert-butyl 4-(6-isobutylthieno[2,3 5 d]pyrimidin-4-ylamino)piperidine-1 -carboxylate (900 mg, 2.3 mmol) by following the general procedure described for Preparation 10. IH NMR (400 MHz, CDC1 3 ): 6 8.45 (s, 1H), 6.80 (s, 1H), 4.95 (d, 1H), 4.30 (m, 1H), 3.20 (m, 2H), 2.85 (m, 2H), 2.75 (d, 2H), 2.40 (bs, 2H), 2.15 (m, 2H), 1.95 (m, 1H), 1.50 (m, 2H), 1.00 (d, 6H). 10 Example 81 (4-Methyl-piperidin-4-yl)-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-dlpyrimidin-4-yl) amine. H N S N 1 The title compound was prepared (179 mg, 97 %) from 4-methyl-4-(5,6,7,8-tetrahydro 15 benzo[4,5]thieno[2,3-d]pyrimidin-4-yamino)-piperidine-1-carboxylic acid tert-butyl ester (140 mg, 0.35 mmol) by following the procedure described for preparation 10. 1H NMR (400 MHz, CDC1 3 ): 5 8.51 (bs, 2H), 8.27 (s, 1H), 3.15 (m, 2H), 3.03 (m, 4H), 2.77 (m, 2H), 2.68 (m, 2H), 1.82 (m, 6H), 1.51 (s, 3H); MS (ESI): m/z: Calculated:302.2; Observed: 303.1 (M+ 1). 20 -104- WO 2006/034511 PCT/US2005/034862 Example 82 6-Chloro-N-(piperidin-4-yl)thieno[2,3-dlpyrimidin-4-amine dihydrochloride H N HN 2HCI
CI
S N 5 The title compound was prepared (1.2 g, 99 %) from t-butyl 4-(6-chlorothieno[2,3 d]pyrimidin-4-ylamino)piperidine-1-carboxylate (1.4 g, 3.7 mmol) by following the procedure described for Preparation 10. IH NMR (400 MHz, CD 3 0D) 5 8.70 (s, 1H), 7.84 (s, 1H), 4.60 (m, 1H), 3.54 (m, 2H), 3.24 (m, 2H), 2.31 (m, 2H), 2.03 (m, 2H); MS (ESI) m/z: Calculated for CjjH1 4 ClN 4 S, 269.06; Observed: 269.1 (M*+1). 10 Example 83 tert-Butyl-4-(6-chloro-5-methylthieno[2,3-d]pyrimidin-4-ylamino)piperidine-1 carboxylate Boc N NH CI S N 15 The title compound was prepared (611 mg, 82 %) from 4,6-dichloro-5-methylthieno[2,3 d]pyrimidine (425 mg, 1.94 mmol) and tert-butyl 4-aminopiperidine-1-carboxylate (582 mg, 2.9 mmol) by following the general procedure described for Preparation 9. 1H NMR (400 MHz, CDC1 3 ): 5 8.40 (s, 1H), 5.25 (d, 1H), 4.35 (m, 1H), 4.30 (m, 2H), 3.00 (m, 2H), 2.55 (s, 3H), 2.15 (m, 2H), 1.45 (s, 9H), 1.35-1.55 (m, 2H). 20 -105- WO 2006/034511 PCT/US2005/034862 Example 84 tert-Butyl 4-(6-isobutylthieno[2,3-d]pyrimidin-4-ylamino)piperidine-1-carboxylate OC N NH S N The title compound was prepared (337 mg, 65 %) from 4-chloro-6-isobutylthieno[2,3 5 d]pyrimidine (300 mg, 1.32 m. mol) and tert-butyl 4-aminopiperidine-l-carboxylate (400 mg, 1.99 m. mol) by following the general procedure described for Preparation 9. 1H NMR (400 MHz, CDCl 3 ): 5 8.45 (s, 1H), 6.80 (s, 1H), 4.95 (m, 1H), 4.35 (m, 1H), 4.15 (m, 2H), 2.95 (m, 2H), 2.75 9d, 2H), 2.15 (m, 2H), 1.95 (m, 1H), 1.45 (s, 9H), 1.40-1.50 (m, 2H), 0.95 (d, 6H). 10 Example 85 t-Butyl 4-(6-chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidine-1-carboxylate Boc N NH S N) 15 A mixture of t-butyl 4-(thieno[2,3-d]pyrimidin-4-ylamino)piperidine-1-carboxylate (1.00 g, 3.00 mmol) and N-chlorosuccinimide (0.39 g, 3.00 mmol) were heated in 50 mL of acetic acid for 3 h. After cooling to room temperature acetic acid was removed under reduced pressure and the remaining residue was partition in 1 M NaOH and DCM. The DCM layer was dried over Na 2
SO
4 and evaporated under reduced pressure. The crude product was 20 purified by silica chromatography in 5 % MeOH-DCM to collect 0.78 g of product (71 % yield). 1H NMR (400 MHz, CDCl3): 8 8.45 (s, 1H), 7.01 (s, 1H), 4.94 (d, 1H), 4.32 (m, 1H), -106- WO 2006/034511 PCT/US2005/034862 4.15 (m, 2H), 2.94 (m, 2H), 2.11 (m, 2H), 1.48 (s, 9H), 1.44 (m, 2H); MS (ESI) m/z: Calculated for C 16
H
21 C1N 4 0 2 S, 368.11; Observed: 368.8 (M*+1). Example 86 5 4-Methyl-4-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-djpyrimidin-4-ylamino)-piperidine 1-carboxylic acid tert-butyl ester Boc N NH S N The title compound was prepared (373.9 mg, 93 %) from 4-chloro-5,6,7,8-tetrahydro 1o benzo[4,5]thieno[2,3-d]pyrimidine (224 mg, 1 mmol) and 4-amino-4-methyl-piperidine-1 carboxylic acid tert-butyl ester (235.4 mg, 1.1 mmol) by following the procedure described for preparation 9. 'H NMR (400 MHz, CDC1 3 ): 6 (ppm) 8.39 (s, 1H), 3.33 (m, 4H), 3.10 (m, 2H), 2.87 9M, 2H), 1.93 (m, 4H), 1.66 (m, 4H), 1.40 (s, 9H), 1.22 (s, 3H); MS (ESI): m/z: Calculated: 402.6; Observed: 403.2 (M*+1). 15 Example 87 1-(3,5-Difluorobenzyl)piperidin-4-amine F r F N
NH
2 The title compound was prepared (1.92 g, 85 %) from tert-butyl 1-(3,5 20 difluorobenzyl)piperidin-4-ylcarbamate (3.26 g, 10 mmol) by following the general procedure described for Preparation 5. 1H NMR (400 MHz, CD 3 0D): 8 6.90 (m, 2H), 6.75 (m, 1H), 3.50 (s, 2H), 3.15 (m, 1H), 2.85 (m, 2H), 2.10 (m, 2H), 1.85 (m, 2H), 1.50 (m, 2H). MS (ESI) m/z: Calculated: 226.27; Observed: 227.1 (M++1). - 107 - WO 2006/034511 PCT/US2005/034862 Example 88 N-1-(1-(3-fluorophenyl)ethyl)propane-1,3-diamine F HN
NH
2 5 The title compound was prepared (0.66 g, 100 %) from tert-butyl 3-(l-(3 fluorophenyl)ethylamino)propylcarbamate (1 g, 3.38 mmol) by following the general procedure described for Preparation 10. 'H NMR (400 MHz, CD 3 0D): 6 7.35 (m, 1H), 7.15 (m, 2H), 6.95 (m, 1H), 3.75 (q, 1H), 2.85 (m, 2H), 2.55 (m, 1H), 2.45 (m, 1H), 1.75 (m, 2H), 1.35 (d, 3H). MS (ESI) m/z: Calculated: 196.26; Observed: 197.0 (M*+l). 10 Example 89 tert-Butyl 3-(1-(3-fluorophenyl)ethylamino)propylcarbamate F HN NHBoc A solution of tert-butyl 3-aminopropylcarbamate (0.7g, 4.05 mmol) and 1-(3 15 fluorophenyl)ethanone (0.5 g, 3.6 mmol) in titanium(IV) isopropoxide (1.8 mL, 6 mmol) was stirred at room temperature for 3 h. It was diluted with methanol (10 mL) and then sodium borohydride (0.22 g, 5.76 mmol) was added carefully and stirred for 10 minutes. The reaction mixture was quenched with 0.1 N NaOH (10 mL) solution. It was filtered through celite and washed with dichloromethane (2x20 mL). The organic layer was separated, dried over CaC12 20 and evaporated to get the title product (1.07 g, 100 %) as thick liquid. 'H NMR (400 MHz, CDC1 3 ): 5 7.30 (m, 1H), 7.05 (m, 2H), 6.95 (m, 1H), 5.10 (bs, 1H), 3.75 (q, 1H), 3.15 (m, - 108 - WO 2006/034511 PCT/US2005/034862 2H), 2.55 (m, 1H), 2.45 (m, 1H), 1.60 (m, 2H), 1.45 (s, 9H), 1.35 (d, 3H). MS (ESI) m/z: Calculated: 296.38; Observed: 297.0 (M*+1). Example 90 5 1-(Cyclohexylmethyl)piperidin-4-amine, dihydrochloride N -2HCI
NH
2 The title compound was prepared (1.17 g, 71 %) from tert-butyl 1 (cyclohexylmethyl)piperidin-4-ylcarbamate (1.82 g, 6.17 mmol) by following the general procedure described for Preparation 5. 'H NMR (400 MHz, CD 3 0D) 5 3.69 (dt, 2H), 3.49 10 (m, 1H), 3.11 (t, 2H), 2.98 (d, 2H), 2.24 (m, 2H), 2.11 (m, 2H), 1.90-1.70 (m, 4H), 1.43-1.19 (m, 4H), 1.06 (m, 2H); MS (ESI) m/z: Calculated for C 12
H
25
N
2 , 197.2; Observed: 197.2 (M*+1). Example 91 15 t-Butyl 1-(cyclohexylmethyl)piperidin-4-ylcarbamate H'N O The title compound was prepared (1.83 g, 83 %) from tert-butyl piperidin-4-ylcarbamate (1.50 g, 7.48 mmol) and cyclohexanecarbaldehyde (0.84 g, 7.48 mmol) by following the general procedure described for Preparation 3. 'H NMR (400 MHz, CDC 3 ) 6 4.80 (bs, 1H), 20 3.71 (m, 1H), 3.63 (m, 2H), 2.53 (m, 2H), 2.43 (m, 2H), 2.00-1.61 (m, 9H), 1.44 (s, 9H), 1.23 (m, 4H), 0.95 (m, 2H); MS (ESI) m/z: Calculated for C 17
H
33
N
2 0 2 , 297.25; Observed: 297.1 (M*+1). -109- WO 2006/034511 PCT/US2005/034862 Example 92 tert-Butyl 1-(3,5-difluorobenzyl)piperidin-4-ylcarbamate F F N NHBoc The title compound was prepared (3.3 g, 100 %) from tert-butyl piperidin-4-ylcarbamate (2 g, 5 10 m mol) and 3,5-difluorobenzaldehyde (1.42 g, 10 mmol) by following the general procedure described for Preparation 3. 'H NMR (400 MHz, CDC1 3 ): 8 6.85 (m, 2H), 6.65 (m, 1H), 4.45 (bs, 1H), 3.50 (m, 1H), 3.05 (s, 2H), 2.75 (m, 2H), 2.10 (m, 2H), 1.90 (m, 2H), 1.45 (m, 1 1H). MS (ESI) m/z: Calculated: 326.38; Observed: 327.0 (M*+1). 10 Example 93 4-Chloro-6-isopropylthieno[2,3-d]pyrimidine CI >-S IN3 The title compound was prepared (13 g, 80 %) from 6-isopropylthieno[2,3-d] pyrimidin-4-ol (15 g, 0.077 mol) by following the general procedure described for Preparation 2. IH NMR 15 (400 MHz, CDC1 3 ): 8 8.80 (s, 1H), 7.10 (s, 1H), 3.30 (m, 1H), 1.45 (d, 6H). MS (ESI) m/z: Calculated: 212.7; Observed: 213.2 (M++l). Example 94 4-Chloro-6-isobutylthieno[2,3-dipyrimidine CI 20 The title compound was prepared (0.96 g, 88 %) from 6-isobutylthieno[2,3-d] pyrimidin-4-ol (1 g, 4.8 mmol) by following the general procedure described for Preparation 2. 'H NMR -110- WO 2006/034511 PCT/US2005/034862 (400 MHz, CDCl 3 ): 5 8.95 (s, lH), 7.10 (s, IH), 2.80 (d, 2H), 2.05 (m, 1H), 1.05 (d, 6H). MS (ESI) m/z: Calculated: 226.73; Observed: 227.1 (M+l). Example 95 5 4-Chloro-5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-dipyrimidine CI S NI) The title compound was prepared (6.3 g, 90%) from 5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3 d]pyrimidin-4-ol (6.5g, 32 mmol) by following the procedure described for preparation 2. 'H 10 NMR (400 MHz, CDCl 3 ): 6 8.71 (s, 1H), 3.10 (m, 2H), 2.89 (m, 2H), 1.94 (m, 4H); MS (ESI): m/z: Calculated: 224; Observed: 225 (M++1). Example 96 4,6-Dichloro-5-methylthieno[2,3-dlpyrimidine CI 15 C I N) The title compound was prepared (428 mg, 98 %) from 6-chloro-5-methylthieno[2,3 d]pyrimidin-4-ol (400 mg, 2.0 m. mol) by following the general procedure described for Preparation 2. 1H NMR (400 MHz, CDCl 3 ): 8 8.80 (s, 1H), 2.65 (s, 3H). 20 Example 97 4,6-Dichloro-5-(4-fluorophenyl)thieno[2,3-dipyrimidine F CI CI | S N -111 - WO 2006/034511 PCT/US2005/034862 To a solution of 4-chloro-5-(4-fluorophenyl)thieno[2,3-d]pyrimidine (1 g, 4.06 mmol) in acetic acid (15 mL), N-chlorosuccinimide (1.08 g, 8.1 m. mol) was added and the mixture was stirred at 90 'C for 2 h. The solvent was evaporated under reduced pressure and the residue was dissolved in ethyl acetate (30 mL) and washed with sat. NaHCO 3 solution (3 x 20 5 mL). The organic layer was dried over sodium sulfate and evaporated. The crude product was purified by column chromatography to get the title product (200 mg, 16 %) as pale yellow solid. 1H NMR (400 MHz, CDCl 3 and CDC1 3 ): 5 8.85 (s, 1H), 7.35 (m, 2H), 7.20 (m, 2H). MS (ESI) m/z: Calculated: 297.95; Observed: 299.2 (M+l). 10 Example 98 6-Isobutylthieno[2,3-dlpyrimidin-4-o OH S N The title compound was prepared (3.58 g, 82 %) from ethyl 2-amino-5-isobutylthiophene-3 carboxylate (4.68 g, 21 mmol) by following the general procedure described for Preparation 15 1. 'H NMR (400 MHz, CD 3 0D): 6 8.50 (s, 1H), 7.20 (s, 1H), 2.80 (d, 2H), 1.95 (m, 1H), 1.00 (d, 6H). MS (ESI) m/z: Calculated: 208.28; Observed: 209.2 (M*+l). Example 99 6-Isopropylthieno[2,3-dlpyrimidin-4-ol OH 20 S N The title compound was prepared (15 g, 70 %) from ethyl 2-amino-5-isopropylthiophene-3 carboxylate (23.5 g, 0.11 mol) by following the general procedure described for Preparation 1. 'H NMR (400 MHz, CDC1 3 ): 8 8.40 (s, 1H), 7.10 (s, 1H), 3.00 (m, 1H), 1.40 (d, 6H). MS (ESI) m/z: Calculated: 194.25; Observed: 195.3 (M*+1). 25 -112 - WO 2006/034511 PCT/US2005/034862 Example 100 6-Chloro-5-methylthieno[2,3-d]pyrimidin-4-ol OH CI- 1 - N S N) 5 To a solution of 5-methylthieno[2,3-d]pyrimidin-4-ol (2 g, 12 mmol) in acetic acid (30 mL) at room temperature, chlorine gas was bubbled for 3 h. The reaction mixture was stirred at same temperature for 2 days. The solvent was evaporated under reduced pressure at 40"C and the residue was dissolved in ethyl acetate (30 mL) and washed with sat. NaHCO 3 solution (3 x 20 mL). The organic layer was dried over sodium sulfate and evaporated to get the title 10 compound as a pale yellow solid (2 g, 82 %). 1H NMR (400 MHz, CDCl 3 and CD 3 0D): 5 7.90 (s, 1H), 2.55 (s, 3H). MS (ESI) m/z: Calculated: 200.65; Observed: 201.3 (M*+1). Example 101 6-Chloro-5-methylthieno[2,3-dlpyrimidin-4-ol 15 OH The title compound was prepared (3.38 g, 75 %) from ethyl 2-amino-5-chloro-4 methylthiophene-3-carboxylate (5 g, 27 mmol) by following the general procedure described for Preparation 1. 1H NMR (400 MHz, CD 3 0D): 6 8.00 (s, 1H), 7.00 (s, 1H), 2.55 (s, 3H). 20 MS (ESI) m/z: Calculated: 166.2; Observed: 167.1 (M*+1). Example 102 5,6,7,8-Tetrahydro-benzo[4,51-thieno[2,3-djpyrimidin-4-ol HO 25 S N - 113 - WO 2006/034511 PCT/US2005/034862 The title compound was obtained in 92 % following the procedure described in Preparation 1. 1 H NMR (400 MHz, DMSO-d 6 ): 8 12.35 (bs, 1H), 8.0 (s, iH), 2.88 (t, 2H), 2.74 (t, 2H), 1.74 1.82 (m, 4H). MS (ESI) m/z: Calculated: 206.2; Observed: 207.2 (M*+1). 5 Example 103 N-(1-(4-Fluoro-3-methoxybenzyl)piperidin-4-yl)-6-chlorothieno[2,3-d]pyrimidin-4 amine, monomaleate O' F NH ci N The title compound was prepared (40 mg, 49 %) from N-(1-(4-fluoro-3 10 methoxybenzyl)piperidin-4-yl)-6-chlorothieno[2,3-d]pyrimidin-4-amine (64 mg, 0.16 mmol) by following the procedure described for Preparation 8. 1IH NMR (400 MHz, CD 3 0D): 5 8.35 (s, 1H), 7.50 (s, 111), 7.15-7.30 (m, 211), 7.10 (m, 111), 6.25 (s, 2H), 4.40 (m, 1H), 4.30 (s, 2H), 3.95 (s, 3H), 3.55 (m, 211), 3.20 (m, 211), 2.35 (m, 211), 1.90 (m, 2H). MS (ESI) m/z: Calculated: 406.90; Observed: 407.2 (M*+1). 15 -114- WO 2006/034511 PCT/US2005/034862 Example 104 N-(1-(4-Fluoro-3-methoxybenzyl)piperidin-4-yl)-6-chlorothieno[2,3-d]pyrimidin-4 amine 01-1 F N NH ci 5 The title compound was prepared (64 mg, 43%) from 6-chloro-N-(piperidin-4-yl)thieno[2,3 d]pyrimidin-4-amine (100 mg, 0.37 mmol) and 4-fluoro-3-methoxybenzaldehyde (57 mg, 0.37 mmol) by following the general procedure described for Preparation 11. 'H NMR (400 MHz, CDC1 3 ): S 8.45 (s, 1H), 7.00 (m, 3H), 6.85 (m, 111), 5.00 (d, 1H), 4.20 (m, 1H), 3.90 (s, 3H), 3.50 (s, 2H), 2.90 (m, 2H), 2.20 (m, 2H), 2.10 (m, 2H), 1.60 (m, 2H). MS (ESI) m/z: 10 Calculated: 406.90; Observed: 407.2 (M*+1). Example 105 N-(1-((Benzo[d][1,3]dioxol-5-yl)methyl)piperidin-4-yl)-6-chlorothieno[2,3-dI pyrimidin 4-amine, monomaleate Y . HOOC C OOM NH 15 c N The title compound was prepared (42 mg, 48 %) from N-(l-((benzo[d][1,3]dioxol-5 yl)methyl)piperidin-4-yl)-6-chlorothieno[2,3-d] pyrimidin-4-amine (69 mg, 0.17 mmol) by following the procedure described for Preparation 8. 1H NMR (400 MHz, CD 3 0D): 8 8.35 (s, -115- WO 2006/034511 PCT/US2005/034862 1H), 7.50 (s, 1H), 7.05 (m, 2H), 6.95 (d, 1H), 6.25 (s, 2H), 6.00 (s, 2H), 4.40 (m, 1H), 4.25 (s, 2H), 3.60 (m, 2H), 3.15 (in, 2H), 2.35 (m, 2H), 1.90 (m, 2H). MS (ESI) m/z: Calculated: 402.90; Observed: 403.2 (M*+l). 5 Example 106 N-(1-((Benzo[d][1,3]dioxol-5-yl)methyl)piperidin-4-yl)-6-chlorothieno[2,3-dI pyrimidin 4-amine N NH c N The title compound was prepared (69 mg, 47%) from 6-chloro-N-(piperidin-4-yl)thieno[2,3 10 d]pyrimidin-4-amine (100 mg, 0.37 mmol) and 5-(chloromethyl)benzo[d][1,3]dioxole (63 mg, 0.37 mmol) by following the general procedure described for Preparation 12. 1H NMR (400 MHz, CDC1 3 ): 8 8.40 (s, 1H), 7.25 (s, 1H), 6.95 (s, 1H), 6.75-7.05 (m, 2H), 5.95 (s, 2H), 5.85 (d, 1H), 4.25 (m, 1H), 3.65 (s, 2H), 3.10 (m, 2H), 2.40 (m, 2H), 2.15 (m, 2H), 1.90 (m, 2H). MS (ESI) m/z: Calculated: 402.90; Observed: 403.2 (M*+1). 15 -116- WO 2006/034511 PCT/US2005/034862 Example 107 Scheme 2 - General synthesis of piperidinylamino-thieno[2,3-d] pyrimidines HO RI COQEt HCO 2
NH
4 H N SC1RI 1
HCONH
2
R
2 /ca DF R2N HS 94% 90% S N 2 3 4 NHBoc Ar-(CH2)nCHO NHBoc NH 2 6 10% TFA-DCM N NaBH(OAc) 3 N 85-95% N H
CH
2 CI2 Ar Ar 90-95% 5 7 8 Ar O Ar R1
R
1 HN R2 'R2 S N Et 3 N / !PrOH or MeCN S N reflux / 55-70% 4 5 Ethyl 2-amino-3-carboxythiophene 2 is refluxed with ammonium formate and formamide to give the cyclized intermediate 3 which is then treated with thionyl chloride to afford the chloro derivative 4. Boc-protected aminopiperidine 5 is reductively alkylated with a variety of arylaldehydes 6 to provide the corresponding intermediates 7. Deprotection of 7 10 with trifluoroacetic acid treatment yields the free amine intermediate 8. Reflux of a mixture of the key intermediates 4 and 8 in i-propanol or acetonitrile in the presence of triethylamine yields the final compound 1. The following compounds of the invention made by the above synthetic method are expected to also have good activity: -117- WO 2006/034511 PCT/US2005/034862 N -&
CF
3 HN -N 0/S3 N (5,6,7,8-Tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl) [1 -(4-trifluoromethyl-benzyl)-piperidin-4-yl] -amine HN HN -N> (1 -Phenethyl-piperidin-4-yl)-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl) amine HN HN 10 [1 -(3-Phenyl-propyl)-piperidin-4-yl]-(5,6,7,8-tetrahydro benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine -118- WO 2006/034511 PCT/US2005/034862 EXAMPLE 108 Compound Activity Compounds of the invention were made according to the respective syntheses noted above, and their activity and selectivity was determined. These compounds were found to be 5 active (e.g., at concentrations from about 0.1 to about 1 Op.M) and selective 5-HT 2 B modulators. Test data are shown in Tables A and B. The compounds accordingly are expected to be useful as 5-HT2B receptor modulators, e.g., in the treatment of a wide variety of clinical conditions which are characterized by serotonin excess or absence, e.g., serotoninergic hypofunction or hyperfunction. Such conditions include those noted above, 10 and conditions associated with vascular disorders, e.g., allergic asthma, irritable bowel syndrome; hypertonic lower esophageal sphincter; motility disorders or benign prostatic hyperplasia; CNS disorder; attention deficit hyperactivity disorder; obesity; sleeping disorder; Alzheimer's disease; Parkinson; anxiety; depression; schizophrenia; neural injury; stroke; migraine; angina; hypertension including pulmonary arterial hypertension and systemic 15 hypertension; disorders of the gastrointestinal tract; restenosis; asthma; obstructive airway disease; pain including inflammatory pain, neuropathic pain, cancer pain, acute pain or chronic pain; prostatic hyperplasia and priapism. Biological Data Table # Structure Chemical Name Ki HLM Other
T
1 2 Activity Data B1 N N-(1-benzylpiperidin-4- 13 nM (5HT 2 B) <15 min IC 50 [ yl)5,6,7,8-tetrahydro- (Functional): H benzo[4,5]thieno[2,3- 110 nM N d]pyrimidin-4-amine (Antagonist at 0.11uM) Rat pK: TI/ 2 : 60 min (po) B2 F N-(1-(4- 8.2 nM fluorobenzyl)piperidin-4- (5HT 2 B) NH yl)5,6,7,8-tetrahydro N benzo[4,5] thieno[2,3 d]pyrimidin-4-amine -119- WO 2006/034511 PCT/US2005/034862 B3 F N-l(-2.3 nM 4.3 min IC 50 N6 fluorobenzyl)piperidin-4- (5HT 2 B) (Functional): Nyl)5,6,7,8-tetrahydro- 100 nM Y benzo[4,5] thieno[2,3- 240 nM (D2S) (Antagonist at NHd]pyrimidin-4-amine 0.l0uM) y N IC50 (IP 3 ): S 22.46 nM hERG (% Inhibition at luM): 58.5 B4 N-l(-6.3 n1 hERG (% N fluorobenzyl)piperidin-4- (5HT 2 B) Inhbibition at Y yl)5,6,7,8-tetrahydro- luM): 58.5 N'H benzo[4,5] tbieno[2,3 S N' d]pyrimidin-4-am-ine B5 fy N-methyl-N-(1- -2//1 nM methylpiperidin-4- 1 1/io/0 nM / I yl)5,6,7,8-tetrahyclro- 67%/i OOrnM S Nbenzoli4,5] thienoll2,3 d]pyrimidin-4-ainine B6 N-(1-benzylpiperidin-4-yl)- 7.7 nM <15 mnn N5-phenylthieno[2,3- or
K
1 >d]pyrimidin-4-amine 38%/10 nM / NH91%/100 nM N ~1O1%//lOOOnM B7 CF, N. 2-(4-(5-phenylthieno[2,3-d] 3%/10On Npyrinfidin-4- 4%/100 nM y 1 ~ ylamiino)piperidin-1-yl)-5- 30/i lOOOnM N (trifluoromethyl)pyridin-3 B8 N-(1-benzylpiperidin-4- 35 nM N yl)thieno or 9[2,3-d]pyrimnidin-4-amine 13%/10 nM NH6%10Y N 96//OO nM N,/OOn B9 <j N-(l-benzylpiperidin-4-yl)- 38 nM rO5-methylthieno[2,3- or Ndlpyffimidin-4-amine 15%/10 nM 62/o0 nM "N 97%/b OOOnM - 120 - WO 2006/034511 PCT/US2005/034862 B10O Ib N-(1-(1-(3- 4.0 nM <15 min N fluorophenyl)ethyl) (5HT 2 B) Y piperidin-4-yl)-(5,6,7,8 N tetrahydro-benzo[4,5]thieno V/ [2,3-d]pyrirnidin-4-amine, _____dihydrochloride 1311 CN rb 3-((4-(5,6,7,8-tetrahydro- 5HT 2 B: <15 min hERG (% Nbenzo [4,5]thienoli2,3- 35/mlM Ihibition at 09dlpyrimnidin-4- 82%/lOnM luM): 44.9 N ylamino)piperidin-1 -yl) 1010/%/lO0nM N methyl)benzonitrile, s dihydrochioride B12 F YbN-(1-(1-(3-fluorophenyl) 14 nM (5- 11 min IERG (% N ethyl) piperidin-4-yl)thiieno HT2B) Inhibition at 9[2,3-d]pyrimidin-4-amine, luM): 58.5 NH dihydrochioride ! N 250 nM (D2S) B13 F ,I N.-(1-(1-(3-fluorophenyl) 4.6 nM <15 min N ethyl)piperidin-4-yl)-5,6 9 dimethylthieno[2,3-d] B14 F I N-(-(-(3- 0.97 DM <15 min Rat pK: % F N fluorophenyl)ethyl)=4 piperidin-4-yl)-6- T 1
/
2 : 0.5h Y isobutyithieno [2,3-d] (po); 0.5h (iv) / I pyrimidin-4-amine, hERG N dihydrochloride (%Ihibition at luM): 76.1
IC
5 0 (Functional): 5.3 uM WO 2006/034511 PCT/US2005/034862 B15 F IN-(1-(1-(3- 1.2 uM <15 min Nb fluorophenyl)ethyl)-4 N methylpiperidin-4 p yl)5,6,7,8-tetrahydro N ' Hbenzo[4,5]thieno[2,3 /I 'Nd]pyrimidin-4-amnine, 'S N dihydrochioride B16F II-6 N-(1-(1-(3-fluorophenyl)-3- 84 nM < 15 N methylbutyl)piperidin-4-yl) min p 5,6,7,8-tetrahydro NH benzo[4,5]thienol2,3-d] I pyrimidin-4-amine, dihydrochioride B17 F 3.2 nM N-(1-(1-(3,5- <15 min IC 50 Yb F difluorophenyl)ethyl) (Functional): ppiperidin-4-yl)5,6,7,8- 1.3 uM NH tetrahydro-benzo N [4,5]ieno[2,3-dpyriniidin B18 F C I N-(1-(1-(3,5- 4.2 nM 7 min IC 50 N difluorophenyl) (Functional): 9ethyl)piperidin-4-yl)-6- 5.7 uM NHisobutyithieno, [2,3- Rat pK: % F L"I d]pyrimidin-4-amine,=3 SN) dihydrochioride
T
1 1 2 : 0.4h (po); 0.2h (iv) hERG (%Jnibition at luM): 31 % Protein Binding 93.8% - 122 - WO 2006/034511 PCT/US2005/034862 B19 F N-(1-(l-(2,4,6- 7OnM4 <15 min hERG NtFinfluorophenyl) (%hihibition ethyl)piperidin-4-yl)-6- at luM): 50.2 NH isobutyithieno [2,3 / I d]pyrimidin-4-am-ine, S N dihydrochioride B20F -pN-(1-{1-(2,6- 20OnM <15 min hERG N F difluoroplienyl)ethyl) (%Ihibition Ppiperidin-4-yl)-6- at luM): 73.4 N isobutylthieno[2,3-d] pyrimidin-4-amine, dihydrochioride B21 y Y N-(1-(1-(2,6- 52 nM < 15 N F difluorophenyl)ethyl) min 9 piperidin-4-yl) 5,6,7,8 NH tetrahydro / I benzo[4,5]thieno[2,3 S N) d]pyrimidin-4-amine, dihydrochloride B2F FN-(1-(1-(2,4,6- 72 nMl N F trifluorophenyl)ethyl) Y piperidin-4-yl) 5,6,7,8 tetrahiydro / benzo[4,5]thieno[2,3 S Nd]pyrimidin-4-amine, dihydrochloride B23 F Nc_ N 2-(3-fluorophenyl)-2-(4- 120 nM4 <15 min N (5,6,7,8-tetrahydro 9 benzo[4,5]thieno[2,3-d] NH pyfimidin-4 K1 1 (ylarnino)piperidin-1-yl) propanenitrile, dihydrochioride B24 F IN-(1-(2-(3- 15 niM <15 min N fluorophenyl)propan-2-yl) piperidin-4-yl) 5,6,7,8 YH tetrahydro benzo[4,5]thieno[2,3 s ~d]pyrimidin-4-amaine, _____ ____________ dihydrochloride __________________ - 123 - WO 2006/034511 PCT/US2005/034862 B25 F rbN-3-3-17 nM <15 min HN fluorobenzylamino)propyl) d 5,6,7,8-tetrahydro NH benzoll4,5] thieno[2,3 / I d]pyrimidin-4-amine, S/ NI dihydrochloride ______ B26 F N-(3-(1-(3-fluorophenyl) 44 nM < 15 min HN ethylamino)propyl) 5,6,7,8 tetrahydro NH benzo[4,5]thieno[2,3-d] s le)pyrimidin-4-amine, dihydrochioride ______ B27 F _r) N-(3-(1-(3-fluorophenyl) 150 nM <15 min HN ethylamiino)propyl)-6 9 isobutyithieno [2,3 NH d]pyrimidin-4-amine, / I dihydrochioride B28 F
F
3 C rb N-(1-(2,2,2-trifluoro-1-(3- 0.95 uM 11 min N fluorophenyl)ethyl)piperidin -4-yl) 5,6,7,8-tetrahydro YH benzo[4,5] thieno[2,3 / I d]pyrirnidin-4-amine, B29 r N-(3,5-difluorobenzyl)-1-(6- 1.3 uM 18 min HN isobutylthienoi2,3 b djjpyrimiidin-4-yl) piperidin / I 4-amine, dihydrochioride B30 F IN-(1-(3,5- 18 nM 19 min IC 50 r F difluorobenzyl)piperidin-4- (5HT2B) (Functional): N yl)tbieno[2,3-d]pyrimridin-4- 1.6 uM Y amine, dihydrocl'loride Rat pK: % F NH~= 17 % ' N
TI/
2 : 0.8 h S N) (po) hERG (%Inibition at IluM): 62 -124- WO 2006/034511 PCT/US2005/034862 B31 F r I N-(1-(3,5- 0.99 nM (5- 8 min IC 50 N difluorobenzyl)piperidin-4- HT 2 B) (Functional): yl)-6-isopropylthieno[2,3-d] 0.83 uM Ypyrimidin-4-amnine, 230 nM (D2S) Rat pK: % F / I"3dihydrochloride 10 % S N T 1
/
2 : 0.5 h (po0) B32 FN-(1-(3,5- 0.57 nM
IC
50 I difluorobenzyl)piperidin-4- (5H-T2B3) (Functional): Nyl)-6-isopropylthieno[2,3-d] 0.45 uM NH . pyrimidin-4-amine, / I7 monomnaleate
IC
5 0 (ll'3): N 1.53 nM B33 F FI N-(1-(3,5- 1.9 nM 13 min hERG N difluorobenzyl)piperidin-4- (5H-T2B3) (%Inhibition NHyl)-6-chlorothieno[2,3- at luM): 22.8 / d]pyrimidin-4-aniine, __T_ ___IN___) dihydrochloride ______ ___ _____ - 125 - WO 2006/034511 PCT/US2005/034862 B34 F N-(1-(3,5- 0.79 nM (5- Functional F difluorobenzyl)piperidin-4- HT 2 B) Activity: yl)-6-chlorothieno[2,3- 66 nM (D2S) IC 50 : 0.68 uM NH COOH d]pyrimidin-4-amine, (5HT 2 B) N monomaleate 140 nM (D3) IC 50 : 17.2 nM 35 nM (D2L) (5HT1A) IC 5 0 : 63.3 nM 260nM(5HT2
(D
2 s) A) IC 50 :Not 2.4/6.6 nM Active (aYl) (5HT2A) 3.4 nM (D4.4) IC 50 : Not Active (5HTIA)
IC
50 : 0.74 nM (IP3) Rat pK: % F =29.1%
T
1 2: 1.1 h (po); 0.4 h (iv) hERG (%Inhibition at luM): 29.4 % Protein Binding = 99% AMES Test: Negative B35 N N-(1- 7.8 nM (5- <15 min hERG (cyclohexylmethyl)piperidin HT 2 B) (%Inhibition N -4-yl)-5,6- at luM): 91.7 dimethylthieno[2,3 d]pyrimidin-4-amine, dihydrochloride B36N N 2-((4-(5,6- 210 nM (5- hERG dimethylthieno[2,3-d] HT 2 B) (%Inhibition NH pyrimidin-4- at luM): 21.7 N ylamino)piperidin-1 yl)methyl)benzonitrile, dihydrochloride -126- WO 2006/034511 PCT/US2005/034862 B37F N-(l(3-2.5 nM (5- 11min N fluorobenzyl)piperidin-4-
HT
2 B3) C I Nmethylthieno[2,3 s d]pyrimidin-4-amine, dihydrochioride B38 B3 N-(1-(3-fluorobenzyl) 1.8 nM
IC
50 piperidin-4-yl)-6-chloro-5- (5HT 2 B) (Functional): * CICO~ methylthienolj2,3- 560 nM c ~d]pyrimidin-4-amine, 170 nM (D2S) IC50 (IN 3 : monomaleate 2.27 nM Rat pK: % F = 18.2 %
T
112 : 0.9 h (po), 0.4 h (iv) hERG (%Lhibition at luM): 78.1 % Protein Binding= 93.8% B39 NC:o r0 2-((4-(6-chloro-5- 80 nM (5HT 2 B) <15 min q methyithieno [2,3-d] NH pyrimidin-4-ylainino) C1 N piperidin-1 -yl) methyl) s benzonitrile, dihydrochloride B40 B 061n N N-(1-(2-methoxybenzyl) 6. M <15 min Npiperidin-4-yl)-6-chloro-5- (5HT 2 B) NH methylthieno[2,3-d] C1 I ' pyrimidin-4-aniine, N dihydrochioride -127- WO 2006/034511 PCT/US2005/034862 B41F N N-(1-(3-fluorobenzyl) 2.8 nM 10 min piperidin-4-yl)-6- (5HT 2 ) chlorothieno [2,3 d]pyrimidin-4-arnine, dihydrochloride B42 F N-(1-(3-fluorobenzyl) 1.1 nM Functional N piperidin-4-yl)-6- (5HT2B) Activity: NH -COOH chlorothieno [2,3- 170 nM (D2S) IC 50 : 110 nM d]pyrimidin-4-amine, 250 nM (Na (5HT 2 B) monomaleate chan) IC 50 : 162 nM 26 nM (D3) (D 2 L) 6.7 nM (a1) IC 50 : 292 nM 17 nM
(D
2 s) (5HT1A) IC 50 : 340 nM 52 nM (5HT 2 A) (5HT2A) IC 50 : Not 4.7 nM (D4.4) Active (5HTIA)
IC
5 0
(IP
3 ): 1.70 nM AMES Test: Negative Rat pK: % F = 22.4 %
T
1
/
2 : 1.2 h (po); 0.4 h (iv) hERG (%Inhibition at luM): 50.1 % Protein Binding: 98.3% - 128 - WO 2006/034511 PCT/US2005/034862 B43 CN 3-((4-(6-chlorothieno[2,3-d] 0.57 nM 22 min Functional pyrimidin-4-ylamino) (5HT 2 B) Activity: piperidin-1-yl)methyl) 1 uM (D2S) IC 50 : 17.5 nM N benzonitrile, monomaleate 11 nM (al) (5HT 2 B) 25nM(D4.4) EC5 0 NH 280 nM (agonist): 920 CI N (5HTiA) nM (D2) S N 970 nM (Na+) IC 50 : No 1.2 uM (D1) antagonist 1.3 uM (D3) activity (D2) ICs0 (IP3): 1.48 nM AMES Test: Negative Rat pK: % F = 17.2 %
TI/
2 : 1.53 h (po); 0.74 h (iv) Mouse pK: % F=87%
TI
2 : 26 min (iv); 30 min (ip) hERG (%Inhibition at luM): 47.3 % Protein Binding: 98.2% B44 COOH r6 3-((4-(6-chlorothieno[2,3-d] 260 nM N pyrimidin-4-ylamino) (5HT 2 B) piperidin-1 NH yl)methyl)benzoic acid, I N dihydrochloride B45 CONH 2 3-((4-(6-chlorothieno[2,3- 170 nM 86 min N d] pyrimidin-4-ylamino) (5HT 2 B) piperidin-1-yl)methyl) NH benzamide, monomaleate ci N -129- WO 2006/034511 PCT/US2005/034862 B46 F r N-(1-(2-fluorobenzyl) 4.3 nM <15 min hERG (% N piperidin-4-yl)-6- (5HT 2 B) Inhibition at NH chlorothieno [2,3- luM): 39.5 / 'N d]pyrimidin-4-amine, S N monomaleate B47 N 6-chloro-N-(1-((pyridin-3- 51 nM (5HT 2 B) 12 min N' yl) methyl)piperidin-4 (, yl)thieno [2,3-d]pyrimidin- >10 uM (D2S) NH 4-amine, monomaleate S N B48 F N-(1-(3,5-difluorobenzyl) 150 nM < 15 rb F F N piperidin-4-yl)-6-chloro-5- (5HT2B) min (4-fluorophenyl)thieno[2,3- 1.1 uM (D2S) /NH d] pyrimidin-4-amine, 5HT1A: not er NN monomaleate Active B49 N N N 6-chloro-N-(1-((pyrimidin- 170 nM 60 min N 5-yl) methyl)piperidin-4- (5HT 2 B) yl)thieno [2,3-d]pyrimidin NH 4-amnine, monomaleate N
CI
c N B50 CN F 5-((4-(6-chlorothieno[2,3-d] 1.8 nM 28 min IC 50 pyrimidin-4- (5HT 2 B) (Functional): N ylamino)piperidin-1- 2.2 nM 27 nM yl)methyl)-2- (5HT 2 B) Rat pK: % F NH fluorobenzonitrile, 100 nM = 22.57 % c N monomaleate (5HTIA) T 1 1 2 : 0.89 h S N670 nM (D2S) (po); 0.62 h 5.4 nM (D4.4) (iv) hERG (% Inhibition at luM): 23.7 AMES Test: Negative - 130 - WO 2006/034511 PCT/US2005/034862 B51 CN 3-((4-(6-clilorothieno[2,3-d] 0.74 nM 10 min N F pyrimnidin-4- (5HT 2 B) N F ylamino)piperidin-1 Y yl)methyl)-4 fluorobenzonitrile, Ci- monomaleate B52 Ci N-l-3-0.74 nM 11 min r6 chlorobenzyl)piperidin-4- (5HT2B) y yl)-6-chlorothieno[2,3 p ~d]pyrimidin-4-amine, NH monomnaleate B53 F N-l-3-13 nM 8 min r6 fluorobenzyl)piperidin-4- (5HT2B) N yl)-6-chloro-5 d]pyrimidin-4-amine, ci " monomaleate B54
CF
3 IN-(1-(3- 5.7 nM 16min N6 (trifluoromethyl)benzyl) (5HT2B) N piperidin-4-yl)-6 Yll chlorothienoll2,3 / d]pyrimidin-4-amine, ci- I 3N monomnaleate B55
CH
3 B550 NH 3-((4-(6-chlorothieno[2,3-d] 25 nM 34 mm pyrimidin-4- -(5HT2B) N ylaniino)piperidin-1- NA (D2S) yl)methyl)-N- 330 nM (D4) methylbenzam-ide, ~ / "3'monomaleate S N NA: Not Active B56 S2F rbN-I-3-45 nM <15 min N (trifluoromethylsulfonyl) (5HT2B) Ybenzyl) piperidin-4-yl)-6- 3.1 uM (D2S) chlorothieno[2,3-d] 180 nM (D4) Ci / " pyrimidin-4-amine, ____ _______N _ monomnaleate ____________________ - 131 - WO 2006/034511 PCT/US2005/034862 YH3 B70NC 3-((4-(6-clilorothieno[2,3- 50 nM 24 min r ,d]pyridin-4- (5HT2B) N ylam-ino)piperidin-1- NA* (D2S) 9yl)methyl)-NN- 540 nM (D4) / I /dimethylbenzamide, monomaleate *NA: Not _______Active B58
SO
2
CH
3 r-N-l-3 45 nM 27 min N (methylsulfonyl)benzyl) (5HT2B) 9piperidin-4-yl)-6- >lOuM (D2S) NHchlorothieno[2,3- 430 nM (D4) /l- d~yii-4-amine, S dprrii N_______ monomaleate - 132 - WO 2006/034511 PCT/US2005/034862 EQUIVALENTS Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such 5 equivalents are considered to be within the scope of the invention and are covered by the following claims. Various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. Other aspects, advantages, and modifications are within the scope of the invention. The contents of all references, issued patents, and published patent applications cited throughout 10 this application are hereby incorporated by reference. The appropriate components, processes, and methods of those patents, applications and other documents may be selected for the invention and embodiments thereof. - 133 - WO 2006/034511 PCT/US2005/034862 Reference List Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G & Begaud B 1996 Appetite-suppressant drugs and the risk 5 of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N.Engl.J.Med. 335 609-616. Farber HW & Loscalzo J 2004 Pulmonary arterial hypertension. N.Engl.J.Med. 351 1655-1665. Fishman AP 1998 Etiology and pathogenesis of primary pulmonary hypertension: a perspective. Chest 114 242S-247S. 10 Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ & Robertson DW 2000 Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol.Pharmacol. 57 75-81. Kennett GA, Ainsworth K, Trail B & Blackburn TP 1997 BW 723C86, a 5-HT2B receptor 15 agonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology 36 233-239. Kursar JD, Nelson DL, Wainscott DB & Baez M 1994 Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor. Mol.Pharmacol. 46 227-234. Kuryshev YA, Brown AM, Wang L, Benedict CR & Rampe D 2000 Interactions of the 5 20 hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. JPharnacoLExp.Ther. 295 614-620. Launay JM, Herve P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G & Maroteaux L 2002 Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat.Med. 8 1129-1135. 25 MacLean MR 1999 Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action Trends Pharmacol.Sci. 20 490-495. Marcos E, Fadel E, Sanchez 0, Humbert M, Dartevelle P, Simonneau G, Hamon M, Adnot S & Eddahibi S 2004 Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ.Res. 94 1263-1270. 30 Nauser TD & Stites SW 2001 Diagnosis and treatment of pulmonary hypertension. Am.Fam.Physician 63 1789-1798. Nebigil CG, Launay JM, Hickel P, Tournois C & Maroteaux L 2000 5-hydroxytryptamine 2B receptor regulates cell-cycle progression: cross-talk with tyrosine kinase pathways. Proc.Natl.Acad.Sci. U.S.A 97 2591-2596. - 134- WO 2006/034511 PCT/US2005/034862 Poissonnet G, Parmentier JG, Boutin JA & Goldstein S 2004 The emergence of selective 5-HT 2B antagonists structures, activities and potential therapeutic applications. Mini.Rev.Med. Chem. 4 325-330. Rich S, Rubin L, Walker AM, Schneeweiss S & Abenhaim L 2000 Anorexigens and pulmonary 5 hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 117 870-874. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ & Roth BL 2000 Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102 2836-2841. 10 Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB & Roth BL 2003 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol.Pharmacol. 63 1223-1229. Teoh, H., Wang, G. and Ward, M.E. Hypoxia Enhances 5-HT2B 2005 Receptor Response and 15 Expression in the Rat Pulmonary Artery. International Conference of the American Thoracic Society. San Diego Ullmer C, Boddeke HG, Schmuck K & Lubbert H 1996 5-HT2B receptor-mediated calcium release from ryanodine-sensitive intracellular stores in human pulmonary artery endothelial cells. Br.J.Pharmacol. 117 1081-1088. 20 Ullmer C, Schmuck K, Kalkman HO & Lubbert H 1995 Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett. 370 215-221. Witchel HJ, Hancox JC & Nutt DJ 2003 Psychotropic drugs, cardiac arrhythmia, and sudden death. J. Clin.Psychopharmacol. 23 5 8-77. Witchel HJ, Pabbathi VK, Hofinann G, Paul AA & Hancox JC 2002 Inhibitory actions of the 25 selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett. 512 59-66. Yamada J & Sugimoto Y 2000 The 5-HT(2C/2B) receptor agonist, m-chlorophenylpiperazine, increases plasma glucagon levels in rats. Eur.J.Pharmacol. 406 153-157. 30 -135-

权利要求:
Claims (48)
[1] 1. A compound having the formula (R 2 )n N NH n(R1) N S _J N (I') wherein - R 1 is selected from the group consisting of halo, lower alkyl, cyano, and trihalomethyl; = each R 2 is independently hydrogen, halo, cyano, trihalomethyl, lower alkoxy, carboxylate, an amide, or a sulfonyl group; and = n is 1 or 2, provided that when n is 1, R 2 is not hydrogen, and when n is 2, both R 2 groups are not hydrogen; or a pharmaceutically acceptable salt and/or ester thereof. -136- WO 2006/034511 PCT/US2005/034862
[2] 2. A compound having the formula (R3)n N NH N s N N (III) wherein = X is halo; = R 3 is hydrogen, halo, cyano, or trihalomethyl; and = n is 1 or 2, provided that when n is 1, R 3 is not hydrogen, and when n is 2, both R 3 groups are not hydrogen; or a pharmaceutically acceptable salt and/or ester thereof.
[3] 3. A compound having the formula R 5 R 4 1. IQ RR, R 4 N S N R 3 (IV) wherein = R, and R2 are independently hydrogen, halogen, COOH; CN; NH 2 ; NO 2 ; OH; lower alkyl; substituted lower alkyl; substituted or unsubstituted aryl or heteroaryl; R7; COOR 7 ; CONHR 7 ; CON(R 7 ) 2 ; OR7; NHR 7 ; N(R 7 ) 2 ; R 7 -alkoxy; and R 7 -haloalkyl; R 7 -haloalkoxy; or -137- WO 2006/034511 PCT/US2005/034862 - R 1 and R 2 , taken together with their bonded carbons, form a substituted or unsubstituted C 4 -C 7 cycloalkyl or cycloheteroalkyl ring, - wherein a heteroatom in the C 4 -C 7 cycloheteroalkyl ring comprises at least one of 0, N and S, and - wherein the substituted C 4 -C 7 cycloalkyl or cycloheteroalkyl ring comprises at least one substituent selected from hydrogen, halogen, COOH; CN; NH 2 ; NO 2 ; OH; lower alkyl; substituted lower alkyl; substituted or unsubstituted CI-C 6 cycloalkyl or cycloheteroalkyl; substituted or unsubstituted aryl or heteroaryl; R 7 ; COOR 7 ; CONHR 7 ; CON(R 7 ) 2 ; OR 7 ; NHR 7 ; N(R 7 ) 2 ; R 7 -alkoxy; R 7 -haloalkyl; and R 7 -haloalkoxy; - R3 is independently H; halogen; CN; NH 2 ; lower alkyl; R 7 ; OR 7 ; NHR 7 ; N(R 7 ) 2 ; or substituted or unsubstituted aryl or heteroaryl; = R 4 is H, R 7 , or substituted or unsubstituted aryl or heteroaryl; t 1i I I 1' i N N N N HN HN R R 9 -Q is chosen from * , * * 8*, * ,and * wherein Rg is hydrogen, halogen, or lower alkyl and * indicates attachment points; - R5 and R 6 are independently selected from hydrogen, halogen, COOH; CN; NH 2 ; NO 2 ; OH; lower alkyl; substituted lower alkyl; substituted or unsubstituted aryl or heteroaryl; R 7 ; COOR 7 ; CONHR 7 ; CON(R 7 ) 2 ; OR 7 ; NHR 7 ; N(R 7 ) 2 ; R 7 -alkoxy; and R 7 -haloalkyl; R 7 -haloalkoxy; or = Rs and R 6 , taken together with their bonded carbons, form a substituted or unsubstituted unsaturated 5- or 6- membered carbocyclic ring or a substituted or unsubstituted saturated 5-, 6-, or 7-membered carbocyclic ring, wherein - the carbocyclic ring may be a heterocarbocyclic ring comprising at least one hetero atom chosen from 0, N and S, - 138 - WO 2006/034511 PCT/US2005/034862 - wherein the substituted ring comprises at least one hydrogen, halogen, COOH; CN; Nil 2 ; NO 2 ; OH; lower alkyl; substituted lower alkyl; substituted or unsubstituted aryl or heteroaryl; R 7 ; COOR 7 ; CONHR 7 ; CON(R 7 ) 2 ; OR 7 ; NHR 7 ; N(R 7 ) 2 ; R 7 -alkoxy; and R 7 -haloalkyl; R 7 -haloalkoxy; = wherein R 7 is substituted or unsubstituted (C 1 -C 6 ) alkyl or a (C 3 -C 6 ) cycloalkyl or cycloheteroalkyl; and - n is 2, 3, 4 or 5, or is branched; or a pharmaceutically acceptable salt and/or ester thereof.
[4] 4. The compound of claim 3, wherein R 1 and R 2 , taken together, form a C 5 -C7 cycloalkyl or cycloheteroalkyl ring.
[5] 5. The compound of claim 4, wherein R 1 and R 2 , taken together, form a cyclohexyl ring.
[6] 6. The compound of claim 3, wherein n is 2 or 3.
[7] 7. The compound of claim 3, wherein said lower alkyl is C 1 -C 5 alkyl.
[8] 8. The compound of claim 3, wherein R 2 is chlorine or isopropyl.
[9] 9. The compound of claim 3, wherein said compound is a 5-HT receptor antagonist.
[10] 10. The compound of claim 9, wherein said compound is a 5-HT 2 receptor antagonist.
[11] 11. The compound of claim 10, wherein said compound is a 5-HT2A, B or C receptor antagonist.
[12] 12. The compound of claim 10, wherein said compound is a 5-HT2B receptor antagonist.
[13] 13. The compound of claim 3, wherein said compound is selected from the group consisting of: N-(1-(3,5-Difluorobenzyl)piperidin-4-y1)-6-isopropylthieno[2,3-d]pyrimidin-4-amine; N-(1-(3,5-Difluorobenzy1)piperidin-4-y1)-6-chlorothieno[2,3-d]pyrimidin-4-amine; 3-((4-(6-Chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl) benzonitrile; 5-((4-(6-Chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)-2 fluorobenzonitrile; -139- WO 2006/034511 PCT/US2005/034862 N-(1-(3-Fluorobenzyl)piperidin-4-yl)-6-chloro-5-methylthieno[2,3-d] pyrimidin-4 amine; 2-((4-(6-Chloro-5-methylthieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl) methyl) benzonitrile; N-(1-(2-Methoxybenzyl)piperidin-4-yl)-6-chloro-5-methylthieno[2,3-d] pyrimidin-4 amine; N-(1-(3-Fluorobenzyl)piperidin-4-yl)-6-chlorothieno[2,3-d]pyrimidin-4-amine; N-(l-(2-Fluorobenzyl)piperidin-4-yl)-6-chlorothieno[2,3-d]pyrimidin-4-amine; Methyl 3-((4-(6-chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl) methyl) benzoate; 3-((4-(6-Chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl) benzoic acid; 3-((4-(6-Chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl) benzamide; N-(1-(1-(3-Fluorophenyl)ethyl)piperidin-4-yl)-6-isobutylthieno[2,3-d] pyrimidin-4 amine; 4-N-(3-(3-Fluorobenzyl amino) propylamino)-5,6,7,8-tetrahydro-benzo [4,5]thieno [2,3 d]pyrimidine; 2-(3-Fluorophenyl)-2-(4-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d] pyrimidin-4-yl amino)piperidin- 1-yl) propane-nitrile; N-(1-(2-(3-Fluorophenyl)propan-2-yl)piperidin-4-yl)-5,6,7,8-tetrahydro-benzo [4,5] thieno[2,3-d]pyrimidin-4-amine; 6-Chloro-N-(1-(pyridine-3-yl)-(methyl)piperidin-4-yl)thieno[2,3-d]pyrimidin-4-amine; N-(1-(3,5-difluorobenzyl)piperidin-4-yl)-6-chloro-5-(4-fluorophenyl)thieno [2,3-d] pyrimidin-4-amine; 6-Chloro-N-(1-((pyrimidin-5-yl)methyl)piperidin-4-yl)thieno[2,3-d]pyrimidin-4-amine; 3-((4-(6-Chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)-4 fluorobenzonitrile; N-(1-(3-Chlorobenzyl)piperidin-4-yl)-6-chlorothieno[2,3-d]pyrimidin-4-amine; 4-N-(3-(1-(3-Fluorophenyl)ethylamino) propylamino)-5,6,7,8-tetrahydro-benzo[4,5] thieno[2,3-d]pyrimidine; 4-N-(3-(3-Fluorobenzyl amino) propylamino)-5,6,7,8-tetrahydro-benzo [4,5]thieno [2,3 d]pyrimidine; N-(3-(1-(3-Fluorophenyl)ethylamino)propyl)-6-isobutylthieno[2,3-d] pyrimidin-4 amine; N-(1-(1-(2,4,6-Trifluorophenyl)ethyl)piperidin-4-yl)-6-isobutylthieno[2,3-d] pyrimidin 4-amine; N-(1-(1-(2,6-Difluorophenyl)ethyl)piperidin-4-yl)-6-isobutylthieno[2,3-d] pyrimidin-4 amine; -140- WO 2006/034511 PCT/US2005/034862 N-(1-(Cyclohexylmethyl)piperidin-4-yl)-5,6-dimethylthieno[2,3-d]pyrimidin-4-amine; N-(1 -(3-Fluorobenzyl)piperidin-4-yl)5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d] pyrimidin-4-amine; N-(1-(1-(3-Fluorophenyl)ethyl)piperidin-4-yl)thieno [2,3-d]pyrimidin-4-amine; 2-(4-(5-phenylthieno[2,3-d] pyrimidin-4-ylamino)piperidin-1-yl)-5 (trifluoromethyl)pyridin-3-ol; N-(1-(3,5-Difluorobenzyl)piperidin-4-yl)thieno[2,3-d]pyrimidin-4-amine; N-(1-(1-(2,4,6-Trifluorophenyl)ethyl)piperidin-4-yl)5,6,7,8-tetrahydro-benzo[4,5]thieno [2,3-d]pyrimidin-4-amine; N-(1-(4-Fluoro-3-methoxybenzyl)piperidin-4-yl)-6-chlorothieno[2,3-d]pyrimidin-4 amine; and N-(1-((Benzo[d][1,3]dioxol-5-yl)methyl)piperidin-4-yl)-6-chlorothieno[2,3-d] pyrimidin-4-amine.
[14] 14. A compound having the formula R3a Cy N-R6 R 2 N S N (VI) wherein " R 1 and R 2 independently are one or more of hydrogen; halogen, halo-substituted alkyl, lower alkyl, Ci-C 6 cycloalkyl, C 3 -C 6 cycloheteroalkyl, aryl, halo substituted aryl or heteroaryl; or R 1 and R 2 , taken together, form a C 5 -C 7 cycloalkyl or cycloheteroalkyl ring; " R 3 and R 3 ' are independently H, halogen, CN or R 5 ; a Cy is a single or conjugated substituted or unsubstituted lower alkyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl; and m R 4 is hydrogen; halogen, halo-substituted alkyl, lower alkyl, CN, COOH, COOR 5 , OR 5 , CONH 2 , CONHR 5 , CON(Rs) 2 , halo-substituted or unsubstituted NR 5 , halo-substituted or unsubstituted SOORs, aryl, halo-substituted aryl or heteroaryl, CI-C 6 cycloalkyl, or C 3 -C 6 cycloheteroalkyl; -141- WO 2006/034511 PCT/US2005/034862 - wherein R 5 is a substituted or unsubstituted lower alkyl; - R 6 is hydrogen or lower alkyl; and = nisl,2,3,4or5; and pharmaceutically acceptable salts and/or esters thereof
[15] 15. The compound of claim 14, wherein R 1 is hydrogen and R 2 is a halogen.
[16] 16. The compound of claim 15, wherein Cy is pyrimidinyl, pyridinyl, or substituted or unsubstituted benzyl, R 4 is hydrogen; halogen, halo-substituted alkyl, lower alkyl, CN, COOH, COOR 5 , OR 5 , CONH 2 , CONHR 5 , CON(Rs) 2 , halo-substituted or unsubstituted NR 5 , halo-substituted or unsubstituted SOOR 5 , C 1 -C 6 cycloalkyl, C 3 -C 6 cycloheteroalkyl, aryl, halo-substituted aryl or heteroaryl; and R 6 is hydrogen.
[17] 17. The compound of claim 14, wherein R 1 is lower alkyl and R 2 is halogen.
[18] 18. The compound of claim 17, wherein Cy is substituted or unsubstituted benzyl, and R 4 is hydrogen, halogen CN or OR 5 .
[19] 19. The compound of claim 18, wherein R 4 is fluorine, n is 1, 2 or 3, and R 3 and R 3 ' are independently hydrogen or Rs; and R 6 is hydrogen.
[20] 20. The compound of claim 14, wherein R 1 and R 2 are lower alkyl.
[21] 21. The compound of claim 20, wherein Cy is cyclohexyl or benzyl, R4 is hydrogen, halogen, CN or R 5 , R 3 is hydrogen or Rs; and R 6 is hydrogen.
[22] 22. The compound of claim 14, wherein one of R 1 and R 2 is lower alkyl and the other is hydrogen.
[23] 23. The compound of claim 22, wherein Cy is substituted or unsubstituted benzyl; and R4 is hydrogen, halogen CN or OR 5 .
[24] 24. The compound of claim 23, wherein R4 is fluorine; n is 1, 2 or 3; R 3 and R 3 ' are independently hydrogen or R 5 ; and R 6 is hydrogen.
[25] 25. The compound of claim 14, wherein R 1 is substituted or unsubstituted benzyl and R 2 is hydrogen or halogen. -142- WO 2006/034511 PCT/US2005/034862
[26] 26. The compound of claim 25, wherein Cy is substituted or unsubstituted benzyl or pyridinyl, R 4 is hydrogen, halogen hydroxyl or R 5 ; R 3 and R 3 ' are independently hydrogen or R 5 ; and R 6 is hydrogen.
[27] 27. The compound of claim 14, wherein R 1 and R 2 , taken together, form a C 5 -C7 cycloalkyl or cycloheteroalkyl ring.
[28] 28. The compound of claim 27, wherein Cy is lower alkyl or is substituted or unsubstituted benzyl, wherein R 4 is hydrogen, halogen CN or OR 5 ; R 3 and R 3 ' are independently hydrogen or R5, and R 6 is hydrogen or lower alkyl.
[29] 29. The compound of claim 14, wherein R 1 and R 2 are each hydrogen; Cy is substituted or unsubstituted benzyl; R 4 is hydrogen, halogen, hydroxyl or R5; R 3 and R3' are independently hydrogen or R 5 ; and R 6 is hydrogen.
[30] 30. The compound of claim 3 in an amount effective to treat depression further comprising a pharmaceutical carrier.
[31] 31. The compound of claim 3 in an amount effective to treat a CNS disorder further comprising a pharmaceutical carrier.
[32] 32. The compound of claim 3 in an amount effective to treat migraine further comprising a pharmaceutical carrier.
[33] 33. The compound of claim 3 in an amount effective to treat pulmonary hypertension further comprising a pharmaceutical carrier.
[34] 34. The compound of claim 3 in an amount effective to treat erectile dysfunction further comprising a pharmaceutical carrier.
[35] 35. A pharmaceutically acceptable salt of a compound of any one of claims 1, 2, 3, or 14, which is a maleate, hydrochloride or fumarate salt.
[36] 36. A method of treating pulmonary hypertension, comprising administering to a patient in need thereof a composition comprising a compound of any one of claims 1, 2, 3, or 14.
[37] 37. A method of treating erectile dysfunction, comprising administering to a patient in need thereof a composition comprising a compound of any one of claims 1, 2, 3, or 14. - 143 - WO 2006/034511 PCT/US2005/034862
[38] 38. A method of treating systemic hypertension, comprising administering to a patient in need thereof a composition comprising a compound of any one of claims 1, 2, 3, or 14.
[39] 39. A method of treating a disease state that is alleviated by treatment with a 5-HT2B antagonist, comprising administering to a patient in need thereof a composition comprising a compound of any one of claims 1, 2, 3, or 14 or its salt in an amount effective to treat the disease state.
[40] 40. The method of claim 39, wherein the disease state is selected from the diseases pulmonary arterial hypertension, CHF, migraine, hypertension, disorders of the gastrointestinal tract, restenosis, asthma, obstructive airway disease, prostatic hyperplasia, erectile dysfunction and priapism.
[41] 41. The method of claim 39, wherein the disease state comprises inflammatory pain, neuropathic pain, cancer pain, acute pain or chronic pain.
[42] 42. The method of claim 39, wherein the disease state comprises allergic asthma, irritable bowel syndrome, hypertonic lower esophageal sphincter, motility disorders or benign prostatic hyperplasia.
[43] 43. The method of claim 39, wherein the disease state comprises depression, anxiety, attention deficit hyperactivity disorder, obesity, sleeping disorder, Alzheimer's disease, or Parkinson disease.
[44] 44. The method of claim 39, wherein the disease state comprises carcinoid tumors or teratocarcinoma.
[45] 45. The method of claim 39, wherein the disease state comprises hyperprolactinemia or acromegaly.
[46] 46. A method of treating depression, comprising administering to a patient in need thereof a composition comprising the compound of claim 30 in an amount effective to treat the depression.
[47] 47. A method of treating a CNS disorder, comprising administering to a patient in need thereof a composition comprising the compound of claim 31. -144- WO 2006/034511 PCT/US2005/034862
[48] 48. A method of treating migraine, comprising administering to a patient in need thereof a therapy including a composition comprising the compound of claim 32. - 145 -

类似技术:

---

公开号 | 公开日 | 专利标题

---

EP1797099B1|2010-08-11|Piperidinylamino-thieno[2,3-d] pyrimidine compounds

---

AU2004227913B2|2010-12-02|New piperidinylamino-thieno| pyrimidine compounds

---

ES2351110T3|2011-01-31|PIPERIDINYLAMINE-TIENO COMPOUNDS [2,3-D] -PIRIMIDINE.

---

RU2685234C1|2019-04-17|Condensed bicyclic heteroaromatic derivatives as modulators of tnf activity

---

IL277539D0|2020-11-30|Heterocyclic compounds as immunomodulators

---

RU2691629C1|2019-06-17|Imidazopyrimidine derivatives as modulators of tnf activity

---

ES2775535T3|2020-07-27|Benzotriazole derivatives as modulators of TNF activity

---

EP3080128B1|2020-06-24|Imidazopyridazine derivatives as modulators of tnf activity

---

CA2931578C|2021-10-26|Triazolopyridine derivatives as modulators of tnf activity

---

RU2684641C1|2019-04-11|Pyrazolopyridine derivatives as modulators of tnf activity

---

EP3080111A1|2016-10-19|Imidazopyridine derivatives as modulators of tnf activity

---

KR20140040774A|2014-04-03|Imidazopyridine compound

---

NZ554927A|2009-07-31|Thienopyridinone compounds and methods of treatment

同族专利:

---

公开号 | 公开日

---

JP2008514643A|2008-05-08|

---

PL1797099T3|2011-07-29|

---

EP1797099A1|2007-06-20|

---

WO2006034511A1|2006-03-30|

---

HRP20100607T1|2011-03-31|

---

EP1797099B1|2010-08-11|

---

DK1797099T3|2010-11-29|

---

KR20070057970A|2007-06-07|

---

PT1797099E|2010-11-18|

---

DE602005022897D1|2010-09-23|

---

BRPI0515530A|2008-07-29|

---

NZ553886A|2010-11-26|

---

US20100113485A1|2010-05-06|

---

NO20072037L|2007-06-21|

---

IL182099D0|2007-07-24|

---

MX2007003026A|2007-12-04|

---

CN101048412A|2007-10-03|

---

TW200628472A|2006-08-16|

---

US7612078B2|2009-11-03|

---

CA2581175A1|2006-03-30|

---

AR054982A1|2007-08-01|

---

AT477257T|2010-08-15|

---

US20050222176A1|2005-10-06|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

US3069412A|1958-08-15|1962-12-18|Fmc Corp|N-aminoazetidine and preparation thereof|

---

CA933923A|1969-12-19|1973-09-18|Eichenberger Kurt|Process for the manufacture of new thiopyranes|

---

GB1570494A|1975-11-28|1980-07-02|Ici Ltd|Thienopyrimidine derivatives and their use as pesticides|

---

DE2925175A1|1979-06-22|1981-01-08|Basf Ag|METHOD FOR PRODUCING ISATOIC ACID ANHYDRIDES|

---

IT1203323B|1987-02-02|1989-02-15|Hoechst Italia Spa|PHOTO-ACTIVATOR ADDITIVE FOR POLYMERIC COMPOSITIONS CONSTITUTED BY METALLIC SALT OF AN OXIDIZED WAX|

---

US5236917A|1989-05-04|1993-08-17|Sterling Winthrop Inc.|Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof|

---

DE4008726A1|1990-03-19|1991-09-26|Basf Ag|Thieno-pyrimidine derivs. - are plant growth regulators, herbicides and pesticides, esp. insecticides|

---

US5155115A|1991-03-12|1992-10-13|Kyowa Hakko Kogyo Co., Ltd.|Thienopyridine derivatives|

---

US5219864A|1991-03-12|1993-06-15|Kyowa Hakko Kogyo Co., Ltd.|Thienopyridine derivatives|

---

US5227387A|1991-09-03|1993-07-13|Dowelanco|Quinoline nematicidal method|

---

DE4138820A1|1991-11-26|1993-05-27|Basf Ag|CHINOLIN-3-CARBONATEAMIDE, THEIR PREPARATION AND USE|

---

DE4208254A1|1992-03-14|1993-09-16|Hoechst Ag|SUBSTITUTED PYRIMIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A PEST CONTROL AND FUNGICIDE|

---

DE4227747A1|1992-08-21|1994-02-24|Basf Ag|Heteroaromatically condensed hydroxypyridonecarboxamides, their preparation and use|

---

US5409948A|1992-11-23|1995-04-25|The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services|Method for treating cognitive disorders with phenserine|

---

JPH06239858A|1993-02-16|1994-08-30|Otsuka Pharmaceut Co Ltd|Peripheral vasodilator|

---

GB9306460D0|1993-03-29|1993-05-19|Smithkline Beecham Plc|Novel compounds|

---

TW449600B|1994-04-19|2001-08-11|Takeda Chemical Industries Ltd|Condensed-ring thiophene derivatives, their production and use|

---

JP3829879B2|1994-05-18|2006-10-04|大正製薬株式会社|Quinoline carboxylic acid derivatives|

---

GB2295387A|1994-11-23|1996-05-29|Glaxo Inc|Quinazoline antagonists of alpha 1c adrenergic receptors|

---

DE19636769A1|1996-09-10|1998-03-12|Basf Ag|3-Substituted pyrido [4 ', 3': 4,5] thieno [2,3-d] pyrimidine derivatives, their preparation and use|

---

DE19724980A1|1997-06-13|1998-12-17|Basf Ag|3-Substituted 3,4-dihydro-thieno [2,3-d] pyrimidine derivatives, their preparation and use|

---

JPH11130777A|1997-08-13|1999-05-18|Takeda Chem Ind Ltd|Thienopyridine derivative, its intermediate and their production|

---

AT404539T|1997-10-02|2008-08-15|Eisai R&D Man Co Ltd|CONDENSED PYRIDINE DERIVATIVES|

---

AU2879799A|1998-02-26|1999-09-15|Neurogen Corporation|4- substituted heteroaryl fused pyridines: gaba brain receptor ligands|

---

DE19815026A1|1998-04-03|1999-10-07|Hoechst Schering Agrevo Gmbh|Substituted piperidines, processes for their preparation and their use as pesticides and fungicides|

---

US6232320B1|1998-06-04|2001-05-15|Abbott Laboratories|Cell adhesion-inhibiting antiinflammatory compounds|

---

CN1461216A|1999-04-28|2003-12-10|呼吸器有限公司|Compound for use as medicament for treatment of disorders involving bronchocontraction|

---

SE9902987D0|1999-08-24|1999-08-24|Astra Pharma Prod|Novel compounds|

---

WO2001025218A1|1999-10-01|2001-04-12|Japan Energy Corporation|Novel quinazoline derivatives|

---

EP1270568A1|2001-06-19|2003-01-02|Biofrontera Pharmaceuticals AG|1-methyl-4--piperidine and its use as 5-HT2B and/or H1 antagonist|

---

WO2003020728A1|2001-08-30|2003-03-13|Pharmacia & Upjohn Company|4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS|

---

MXPA03000145A|2002-01-07|2003-07-15|Pfizer|Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators.|

---

AU2003298514A1|2002-05-17|2004-05-04|Eisai Co., Ltd.|Methods and compositions using cholinesterase inhibitors|

---

US20040138238A1|2002-08-08|2004-07-15|Dhanoa Dale S.|Substituted aminopyrimidine compounds as neurokinin antagonists|

---

AU2003255845A1|2002-08-22|2004-03-11|Piramed Limited|Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents|

---

AU2003277215A1|2002-10-01|2004-04-23|Predix Pharmaceuticals Holdings, Inc.|Novel neurokinin antagonists and methods of use thereof|

---

US7153858B2|2003-01-31|2006-12-26|Epix Delaware, Inc.|Arylpiperazinyl compounds|

---

US20050222175A1|2004-03-31|2005-10-06|Dhanoa Dale S|New piperidinylamino-thieno[2,3-D] pyrimidine compounds|

---

WO2004089312A2|2003-03-31|2004-10-21|Predix Pharmaceuticals Holdings, Inc.|New piperidinylamino-thieno[2,3-d] pyrimidine compounds|

---

US7119205B2|2003-05-16|2006-10-10|Abbott Laboratories|Thienopyridones as AMPK activators for the treatment of diabetes and obesity|

---

SI1651234T1|2003-07-25|2008-02-29|Hoffmann La Roche|Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders|

---

GB0322140D0|2003-09-22|2003-10-22|Pfizer Ltd|Combinations|

---

US20050137142A1|2003-11-03|2005-06-23|Probiodrug Ag|Combinations useful for the treatment of neuronal disorders|

---

US7598265B2|2004-09-30|2009-10-06|Epix Delaware, Inc.|Compositions and methods for treating CNS disorders|

---

US7576211B2|2004-09-30|2009-08-18|Epix Delaware, Inc.|Synthesis of thienopyridinone compounds and related intermediates|

---

US7488736B2|2004-05-17|2009-02-10|Epix Delaware, Inc.|Thienopyridinone compounds and methods of treatment|

---

US20060084806A1|2004-07-21|2006-04-20|Ramasubramanian Sridharan|Processes for the preparation of imidazo[1,2-a] pyridine derivatives|

---

US7407966B2|2004-10-07|2008-08-05|Epix Delaware, Inc.|Thienopyridinone compounds and methods of treatment|

---

KR20070097590A|2005-01-25|2007-10-04|에픽스 델라웨어, 인코포레이티드|Substituted arylamine compounds and their use as 5-ht6 modulators|

---

AU2006317689B2|2005-11-23|2013-07-25|Epix Delaware, Inc.|S1P receptor modulating compounds and use thereof|US20050222175A1|2004-03-31|2005-10-06|Dhanoa Dale S|New piperidinylamino-thieno[2,3-D] pyrimidine compounds|

---

US7576211B2|2004-09-30|2009-08-18|Epix Delaware, Inc.|Synthesis of thienopyridinone compounds and related intermediates|

---

US7488736B2|2004-05-17|2009-02-10|Epix Delaware, Inc.|Thienopyridinone compounds and methods of treatment|

---

US7598265B2|2004-09-30|2009-10-06|Epix Delaware, Inc.|Compositions and methods for treating CNS disorders|

---

US7407966B2|2004-10-07|2008-08-05|Epix Delaware, Inc.|Thienopyridinone compounds and methods of treatment|

---

US7576080B2|2004-12-23|2009-08-18|Memory Pharmaceuticals Corporation|Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors|

---

KR20070097590A|2005-01-25|2007-10-04|에픽스 델라웨어, 인코포레이티드|Substituted arylamine compounds and their use as 5-ht6 modulators|

---

US20070099877A1|2005-11-02|2007-05-03|Cytovia, Inc.|N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof|

---

US20070099941A1|2005-11-02|2007-05-03|Cytovia, Inc.|N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof|

---

US20070213305A1|2005-11-02|2007-09-13|Cytovia, Inc.|N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof|

---

US7939661B2|2006-09-11|2011-05-10|Hoffman-La Roche Inc.|Pyridine, quinoline and pyrimidine derivatives|

---

WO2008061966A2|2006-11-22|2008-05-29|Boehringer Ingelheim International Gmbh|New use of flibanserin|

---

WO2008061968A1|2006-11-22|2008-05-29|Boehringer Ingelheim International Gmbh|Benzimidazolone derivates in the treatment of pulmonary arterial hypertension|

---

AU2008296308A1|2007-09-04|2009-03-12|Trovis Pharmaceuticals, Llc|Piperidinylamino-thieno pyrimidine compounds for treating fibrosis|

---

WO2010065743A2|2008-12-03|2010-06-10|Nanotherapeutics, Inc.|Bicyclic compounds and methods of making and using same|

---

US8618116B2|2009-08-03|2013-12-31|Daljit Singh Dhanoa|Deuterium-enriched pyrimidine compounds and derivatives|

---

US8933087B2|2010-07-23|2015-01-13|President And Fellows Of Harvard College|Tricyclic proteasome activity enhancing compounds|

---

KR101401496B1|2011-05-12|2014-06-11|한국화학연구원|Thienopyrimidine derivatives, pharmaceutically acceptable salt thereof preparation method thereof and pharmaceutical composition for prevention or treatment of diabetes-related disease containing the same as an active ingredient|

---

WO2013112706A1|2012-01-25|2013-08-01|Proteostasis Therapeutics, Inc.|Proteasome activity modulating compounds|

---

CN103467596A|2012-06-06|2013-12-25|北京大学|Novel target spot for treatment of pulmonary arterial hypertension|

---

US9505781B2|2013-03-13|2016-11-29|The Regents Of The University Of Michigan|Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof|

---

WO2016040330A1|2014-09-09|2016-03-17|The Regents Of The University Of Michigan|Thienopyrimidine and thienopyridine compounds and methods of use thereof|

---

CN104592248A|2014-12-31|2015-05-06|芜湖杨燕制药有限公司|Preparation method of 4-chlorine-6-substituted thieno [2,3-d] pyrimidine compound|

---

EP3302057A4|2015-06-04|2018-11-21|Kura Oncology, Inc.|Methods and compositions for inhibiting the interaction of menin with mll proteins|

---

AR104020A1|2015-06-04|2017-06-21|Kura Oncology Inc|METHODS AND COMPOSITIONS TO INHIBIT THE INTERACTION OF MENINA WITH MILL PROTEINS|

---

US10781218B2|2016-03-16|2020-09-22|Kura Oncology, Inc.|Substituted inhibitors of menin-MLL and methods of use|

---

EP3429585B1|2016-03-16|2021-11-24|Kura Oncology, Inc.|Bridged bicyclic inhibitors of menin-mll and methods of use|

---

MX2019002962A|2016-09-14|2019-07-04|Janssen Pharmaceutica Nv|Spiro bicyclic inhibitors of menin-mll interaction.|

---

CN109715634A|2016-09-14|2019-05-03|詹森药业有限公司|The fused bicyclic inhibitor of MENIN-MLL interaction|

---

CN110075109B|2019-03-28|2021-07-27|中国人民解放军军事科学院军事医学研究院|Compound for promoting synthesis and secretion of stem cell factor and application thereof|

法律状态:
2009-10-08| MK1| Application lapsed section 142(2)(a) - no request for examination in relevant period|

优先权:

---

申请号 | 申请日 | 专利标题

---

US10/947,995|US20050222175A1|2004-03-31|2004-09-23|New piperidinylamino-thieno[2,3-D] pyrimidine compounds|

---

US10/947,995||2004-09-23||

---

US11/075,565||2005-03-08||

---

US11/075,565|US7612078B2|2003-03-31|2005-03-08|Piperidinylamino-thieno[2,3-D] pyrimidine compounds|

---

PCT/US2005/034862|WO2006034511A1|2004-09-23|2005-09-23|Piperidinylamino-thieno[2,3-d] pyrimidine compounds|

---